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Background: Rheumatoid arthritis is a major inflammatory disorder and causes substantial disability.
Treatment goals span minimising disease activity, achieving remission and decreasing disability. In active
rheumatoid arthritis, intensive management achieves these goals. As many patients with established
rheumatoid arthritis have moderate disease activity, the TITRATE (Treatment Intensities and Targets
in Rheumatoid Arthritis ThErapy) programme assessed the benefits of intensive management.
Objectives: To (1) define how to deliver intensive therapy in moderate established rheumatoid arthritis;
(2) establish its clinical effectiveness and cost-effectiveness in a trial; and (3) evaluate evidence
supporting intensive management in observational studies and completed trials.
Design: Observational studies, secondary analyses of completed trials and systematic reviews assessed
existing evidence about intensive management. Qualitative research, patient workshops and systematic
reviews defined how to deliver it. The trial assessed its clinical effectiveness and cost-effectiveness in
moderate established rheumatoid arthritis.
Setting: Observational studies (in three London centres) involved 3167 patients. These were
supplemented by secondary analyses of three previously completed trials (in centres across all English
regions), involving 668 patients. Qualitative studies assessed expectations (nine patients in four London
centres) and experiences of intensive management (15 patients in 10 centres across England). The main
clinical trial enrolled 335 patients with diverse socioeconomic deprivation and ethnicity (in 39 centres
across all English regions).
Participants: Patients with established moderately active rheumatoid arthritis receiving conventional
disease-modifying drugs.
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Interventions: Intensive management used combinations of conventional disease-modifying drugs,
biologics (particularly tumour necrosis factor inhibitors) and depot steroid injections; nurses saw
patients monthly, adjusted treatment and provided supportive person-centred psychoeducation.
Control patients received standard care.
Main outcome measures: Disease Activity Score for 28 joints based on the erythrocyte sedimentation
rate (DAS28-ESR)-categorised patients (active to remission). Remission (DAS28-ESR < 2.60) was the
treatment target. Other outcomes included fatigue (measured on a 100-mm visual analogue scale),
disability (as measured on the Health Assessment Questionnaire), harms and resource use for
economic assessments.
Results: Evaluation of existing evidence for intensive rheumatoid arthritis management showed the
following. First, in observational studies, DAS28-ESR scores decreased over 10–20 years, whereas
remissions and treatment intensities increased. Second, in systematic reviews of published trials, all
intensive management strategies increased remissions. Finally, patients with high disability scores
had fewer remissions. Qualitative studies of rheumatoid arthritis patients, workshops and systematic
reviews helped develop an intensive management pathway. A 2-day training session for rheumatology
practitioners explained its use, including motivational interviewing techniques and patient handbooks.
The trial screened 459 patients and randomised 335 patients (168 patients received intensive
management and 167 patients received standard care). A total of 303 patients provided 12-month
outcome data. Intention-to-treat analysis showed intensive management increased DAS28-ESR
12-month remissions, compared with standard care (32% vs. 18%, odds ratio 2.17, 95% confidence
interval 1.28 to 3.68; p = 0.004), and reduced fatigue [mean difference –18, 95% confidence interval
–24 to –11 (scale 0–100); p < 0.001]. Disability (as measured on the Health Assessment Questionnaire)
decreased when intensive management patients achieved remission (difference –0.40, 95% confidence
interval –0.57 to –0.22) and these differences were considered clinically relevant. However, in all
intensive management patients reductions in the Health Assessment Questionnaire scores were
less marked (difference –0.1, 95% confidence interval –0.2 to 0.0). The numbers of serious adverse
events (intensive management n = 15 vs. standard care n = 11) and other adverse events (intensive
management n = 114 vs. standard care n = 151) were similar. Economic analysis showed that the
base-case incremental cost-effectiveness ratio was £43,972 from NHS and Personal Social Services
cost perspectives. The probability of meeting a willingness-to-pay threshold of £30,000 was 17%. The
incremental cost-effectiveness ratio decreased to £29,363 after including patients’ personal costs and
lost working time, corresponding to a 50% probability that intensive management is cost-effective
at English willingness-to-pay thresholds. Analysing trial baseline predictors showed that remission
predictors comprised baseline DAS28-ESR, disability scores and body mass index. A 6-month extension
study (involving 95 intensive management patients) showed fewer remissions by 18 months, although
more sustained remissions were more likley to persist. Qualitative research in trial completers
showed that intensive management was acceptable and treatment support from specialist nurses
was beneficial.
Limitations: The main limitations comprised (1) using single time point remissions rather than
sustained responses, (2) uncertainty about benefits of different aspects of intensive management and
differences in its delivery across centres, (3) doubts about optimal treatment of patients unresponsive
to intensive management and (4) the lack of formal international definitions of ‘intensive management’.
Conclusion: The benefits of intensive management need to be set against its additional costs. These
were relatively high. Not all patients benefited. Patients with high pretreatment physical disability or
who were substantially overweight usually did not achieve remission.
Future work: Further research should (1) identify the most effective components of the intervention,
(2) consider its most cost-effective delivery and (3) identify alternative strategies for patients not
responding to intensive management.
Trial registration: Current Controlled Trials ISRCTN70160382.
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Funding: This project was funded by the National Institute for Health Research (NIHR) Programme
Grants for Applied Research programme and will be published in full in Programme Grants for Applied
Research; Vol. 9, No. 8. See the NIHR Journals Library website for further project information.
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Plain English summary
Inflamed joints in rheumatoid arthritis are unpleasant and reduce quality of life. Many drugs reducethis inflammation. The ideal treatment goal is remission.When patients with active rheumatoid arthritis
are treated intensively using gradually increasing doses of combinations of drugs they achieve more
remissions. But many patients live with moderately active disease. There is uncertainty as to whether or
not these patients benefit from intensive management. Our research focused on this problem.
Part of the research involved working with patients to identify how best to give intensive management.
Monthly sessions with nurses in rheumatology clinics providing supportive care together with a
handbook for patients were positively received by patients.
The central part of the research was a trial to investigate whether or not intensive management
helped patients with moderately active rheumatoid arthritis. The trial compared intensive management
using drug therapy and supportive non-drug approaches given by specialist nurses with standard care.
Intensive management increased the number of patients in remission after 1 year. With intensive
management, approximately one-third of patients were in remission, compared with about one-sixth of
patients receiving standard care. Intensive management also reduced patients’ fatigue levels. In the
trial, intensive management did not increase harms.
The benefits of intensive management need to be set against its additional costs. These were relatively
high. In addition, not all patients benefited. Patients who had high pretreatment physical disability or
who were substantially overweight usually did not achieve remission.
The final part of the research considered broader perspectives of intensive management. Studying all
trials of this approach showed that many types of intensive management increase remissions. Reviews
of routine care over the last two decades showed that treatment intensities have gradually increased
and more patients now achieve remissions.
Overall, our research shows that intensive management benefits patients with moderately active
rheumatoid arthritis; however, not all patients benefited and the treatment was relatively expensive.
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Rheumatoid arthritis is a major long-term inflammatory disorder that affects nearly 1% of adults in
England. It causes substantial morbidity and impairs quality of life. The TITRATE (Treatment Intensities
and Targets in Rheumatoid Arthritis ThErapy) programme evaluated intensive management in patients
with moderately active rheumatoid arthritis. Key treatment goals were minimising disease activity and
achieving remission, decreasing physical disability and improving health-related quality of life. In active
rheumatoid arthritis, intensive management is known to help achieve these goals. However, many
patients with established rheumatoid arthritis have moderate disease activity between active disease
and remission. The TITRATE programme developed evidence for intensive management in patients with
moderate rheumatoid arthritis.
Objectives
l To define how to deliver intensive therapy to patients with moderate established
rheumatoid arthritis.
l To establish the clinical effectiveness and cost-effectiveness of intensive therapy in treatment of
moderate established rheumatoid arthritis in a clinical trial.
l To evaluate existing evidence supporting such intensive management in observational studies and
completed trials.
Methods
The programme involved observational studies, secondary analyses of completed trials, systematic
reviews, qualitative studies, a 12-month multicentre clinical trial and a health economic analysis with a
6-month follow-up study.
Observational studies comprised four cross-sectional studies of 1323 rheumatoid arthritis patients
at two London specialist outpatient clinics followed for over two decades, one long-term follow-up
study of 1693 rheumatoid arthritis patients followed for over a decade at a single London centre and
152 rheumatoid arthritis patients with stable low disease activity remission followed for 12 months at
three London centres.
The observational studies were supplemented by secondary analyses of three completed clinical trials
in early and established rheumatoid arthritis and involved 668 rheumatoid arthritis patients from many
rheumatology outpatient clinics across all regions of England.
Qualitative studies assessed expectations about intensive management in nine patients and five carers
from four London rheumatology clinics, and perspectives about intensive management in 15 patients
from 10 rheumatology clinics participating in the TITRATE trial.
The TITRATE clinical trial compared intensive management with standard care. A total of 335 rheumatoid
arthritis patients attending rheumatology clinics in 39 centres across all English regions were randomised.
The patients spanned diverse levels of socioeconomic deprivation and ethnicity. The trial evaluated
both clinical and economic outcomes. A 6-month extension study involved 95 patients who had received
intensive management.
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Clinical assessments focused on the Disease Activity Score for 28 joints based on the erythrocyte
sedimentation rate (DAS-ESR). Moderate rheumatoid arthritis scores are 3.2–5.1 and remission
is < 2.6. The Health Assessment Questionnaire evaluated physical disability and the EuroQol-5
Dimensions measured health-related quality of life. Treatments spanned conventional disease-
modifying antirheumatic drugs, biologics and steroids.
Determining how to deliver intensive management involved qualitative research of rheumatoid
arthritis outpatients and workshops involving patients and carers.
The TITRATE trial studied patients with moderately active established rheumatoid arthritis who were
receiving conventional synthetic disease-modifying antirheumatic drugs and were seen in specialist
clinics. The trial tested the hypothesis that intensive management using drug therapy and a treatment
support programme of non-drug approach given by specialist nurses resulted in higher remission rates
than standard care. A comparison group received standard care. The primary outcome was DAS28-ESR
remission at 12 months. Secondary outcomes included other remission criteria, fatigue scores, disability
(measured by the Health Assessment Questionnaire) and adverse events. Resource use of each
participant was determined for health economic assessments. Multivariable logistic and linear
regression compared treatment strategies in intention-to-treat analyses, using multiple imputation
methods for missing data. Total costs and quality-adjusted life-years, measured using the EuroQol-5
Dimensions, were used to assess the incremental cost-effectiveness ratio of intensive management
compared with standard care.
A predefined secondary analysis of the trial evaluated the impact of baseline factors on remissions.
A 6-month extension study from the trial examined the persistence of DAS28-ESR remissions.
Subsequent qualitative research evaluated patients’ and clinicians’ views on intensive treatment.
A fidelity assessment evaluated the delivery of intensive management.
Results
Two observational studies showed substantial reductions in disease activity over the last two decades
and the reductions were associated with increased treatment intensities. Four cross-sectional surveys
between 1996–7 and 2012–14 showed that mean DAS28-ESR scores fell (from 5.2 to 3.7), DAS28-ESR
remissions increased (from 8% to 28%) and biologics prescribing increased (from none to 32% of
patients). A longitudinal study from 2005 to 2015 also showed that mean DAS28-ESR scores fell (from
4.1 to 3.6), DAS28-ESR remissions increased (from 18% to 27%) and more biologics were prescribed
(from 19% to 42% of patients).
A systematic review of intensive management identified 48 superiority trials (intensive management
strategies vs. less intensive strategies), six head-to-head trials comparing combination disease-modifying
antirheumatic drugs with biologics and one trial comparing both. Superiority trials reported remissions
in 3013 of 11,259 intensive management patients and 1211 of 8493 control patients [i.e. intensive
management increased remissions (relative risk 2.23, 95% confidence interval 1.90 to 2.61)]. Head-
to-head trials reported remissions in 317 of 787 patients receiving biologics and 229 of 671 receiving
combination disease-modifying antirheumatic drugs. There was no difference between strategies
(relative risk 1.06, 95% confidence interval 0.93 to 1.21).
The impact of remission in moderately active rheumatoid arthritis was evaluated in a longitudinal cohort
followed for ≥ 3 years and secondary analyses of two completed trials. Patients with moderately active
rheumatoid arthritis were divided into those who subsequently had one or more DAS28-ESR remissions
and those who did not. In patients achieving remissions, disability was reduced with substantially lower
Health Assessment Questionnaire scores.
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Further analyses of the relationships between remission, disability and quality of life were undertaken
in the longitudinal cohort and the completed trials. Sustained remissions were infrequent (5–9% of
patients) and remission at single time points was more common (35–58% of patients). End-point
DAS28-ESR scores post remission showed that 53–61% of patients remained in remission, 9–18%
had low disease activity, 21–22% had moderate disease activity and 4–8% had high disease activity.
Sustained remissions were most specific for patients with low disability (97–98%) and normal quality
of life (93–97%), but lacked sensitivity (low disability 19–29%; normal quality of life 19–36%). Point
remission gave a better balance between sensitivity and specificity (low disability, specificity 50–78%
and sensitivity 68–89%; normal EuroQol-5 Dimensions, specificity 42–72% and sensitivity 70–93%).
A qualitative study on patients’ and carers’ views of intensive management highlighted the importance
of treatment expectations. Patients placed greatest emphasis on improving their physical symptoms,
reducing their pain and increasing their mobility and independence. Patients’ views varied about taking
more medication, depending on the stability and benefits of their current treatments. Most patients
were not receiving drugs that fully controlled their rheumatoid arthritis and they were willing to try
more intensive managements, although they were concerned about side effects. Patients realised that
intensive management involved more frequent clinic appointments, but these were generally welcomed.
A patient handbook about intensive management relevant for moderate disease was developed in a
patient workshop held at a London centre. Patients suggested that it should focus on the aims of
intensive management, its benefits and the importance of patients participating in assessing benefits.
A training manual for nurses delivering intensive management was developed after systematically
reviewing the evidence for psychological support and motivational interviews for rheumatoid arthritis
patients. Psychological support improved disability, pain and fatigue. Motivational interviewing increased
physical activity and treatment concordance. Both were incorporated within the nurses’ training.
The TITRATE trial screened 459 patients (335 patients were randomised, 168 patients had intensive
management and 167 patients received standard care). A total of 303 (90%) patients provided 12-month
outcomes data. With intensive management, 139 (83%) patients attended at least eight separate monthly
sessions, 140 patients started another conventional disease-modifying antirheumatic drug, 67 patients
started a second or third conventional disease-modifying antirheumatic drug, 72 patients had depot steroids
and 45 patients started biologics. With intensive management, patients also received person-centred
psychoeducation provided by their specialist nurses. With standard care, 128 patients started another
conventional disease-modifying antirheumatic drug, 37 patients started a second or third conventional
disease-modifying antirheumatic drug, 50 patients had depot steroids and 24 patients started biologics.
The trial showed that intensive management increased DAS28-ESR 12-month remission rates compared
with standard care (32% vs. 18%; p = 0.004). Intensive management also increased remission rates
using alternative criteria, including the Disease Activity Score for 28 joints based on C-reactive protein
levels (21% vs. 10%; p = 0.008), Clinical Disease Activity Index (18% vs. 10%; p = 0.049) and American
College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) Boolean remissions
(13% vs. 6%; p = 040). Intensive management also increased DAS28-ESR low disease activity states
(48% vs. 32%; p = 0.005) and reduced patient-assessed fatigue (mean difference –15, 95% confidence
interval –21 to –9; p < 0.001) and pain (mean difference –8, 95% CI –15 to –2; p = 0.007). Disability,
assessed by Health Assessment Questionnaire scores, fell when intensive management patients
achieved remission (difference –0.40, 95% confidence interval –0.57 to –0.22). Fourteen patients
receiving intensive management and 11 patients receiving standard care experienced one or more
serious adverse events or died. These differences were not significant.
Economic analysis of the TITRATE trial showed that the base-case incremental cost-effectiveness
ratio was £43,972 (€51,474) from NHS and Personal Social Services perspectives. The probability of
meeting the English willingness-to-pay threshold (i.e. £30,000/€35,000) was 17%. The incremental
DOI: 10.3310/pgfar09080 Programme Grants for Applied Research 2021 Vol. 9 No. 8
Copyright © 2021 Scott et al. This work was produced by Scott et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social
Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution,
reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/. For attribution the
title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
xxxi
cost-effectiveness ratio fell to £29,363 (€24,384) after including patients’ personal costs and
lost working time, and this corresponded to a 50% probability of intensive management being
cost-effective at English willingness-to-pay thresholds.
The predefined secondary analysis of the TITRATE trial evaluated baseline predictors of remission.
Significant predictors were male sex, baseline DAS28-ESR, Health Assessment Questionnaire scores
and body mass index.
The persistence of remission in the 6-month TITRATE extension study showed that in patients receiving
intensive management the frequency of remissions declined at 18 months. This decline was least in
patients achieving two or more remissions during intensive management. DAS28-ESR levels returned
towards low moderate levels and this change was least in patients achieving two or more remissions.
The stability of remission was assessed in a separate observational study of 152 patients with minimal
disease activity undergoing treat-to-target treatment management. Over 12 months, 44 patients had
sustained remissions, 23 patients were disability-free at all visits, 46 patients had fluctuating disease
activity and 51 patients had fluctuating levels of disability.
A qualitative study of the perspectives of patients, nurses and rheumatology practitioners from London
centres involved in intensive management in the TITRATE trial showed that monthly appointments
were acceptable. Their benefits included regular reviews of medication and the ability of practitioners
to establish close relationships with patients. Practitioners felt ‘fairly confident’ using motivational
interviewing techniques. Most patients found optimising their medication based on monthly
assessments helpful and that side effects generally resolved.
Assessments of the fidelity of 10% of intensive management TITRATE trial sessions showed that
health-care practitioners followed some but not all recommended approaches. Health-care practitioners
were good at providing solicited information, using listening skills and asking patients’ open questions.
Affirming patients’ strengths and abilities, evoking and reinforcing change talk and identify patients’
main problems were also used effectively. Other areas, such as helping patients change their behaviour,
were often overlooked.
Conclusions
Intensive management delivered by trained practitioners was clinically effective in moderately active
patients with established RA and its benefits were generalisable across English rheumatology clinics.
It substantially increased remissions at 12 months and also significantly reduced fatigue without
increasing adverse reactions.
Qualitative research showed that patients and nurses found that the intensive management approach
taken in the TITRATE programme was acceptable to patients and could be delivered by the nurses
without major challenges. However, monthly assessments may not be essential. Future research should
identify the optimal frequency of assessments.
The health economic benefits were more complex. Within-trial estimates confirmed patient and
societal value of intensive management; however, the incremental cost-effectiveness ratio from an
NHS and Personal Social Service perspective was above the current willingness-to-pay thresholds for
medical costs in England. Further economic evaluation is needed beyond the 12-month follow-up
period to define overall benefits of intensive management, as within-trial assessments underestimate
the benefits of improved earlier treatment and potentially reduce biologic longer-term drug use.
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Maintaining remissions after intensive management was incomplete in the TITRATE trial and in an
observational study of patients receiving treat-to-target management. Low disease activity may be an
easier target.
The real-world observational studies show that treatment intensity has increased over two decades
with far greater biologic use. Consequently, mean DAS28-ESR scores have decreased and more
patients achieve remissions. These findings suggest that intensive management approaches are
increasingly followed. However, as our observational studies showed, when patients with moderate
rheumatoid arthritis achieve one or more remissions, their outcomes are better and opportunities
remain to increase treatment intensities.
The systematic review of previous trials showed that intensive management increases remissions
in active rheumatoid arthritis. These trials suggest that there is no reason to favour one intensive
management strategy over another. Custom and practice and health economic considerations together
suggest a good case to use combinations of conventional disease-modifying antirheumatic drugs
initially and reserving biologics for patients who do not respond to this approach.
The main limitations of the trial comprised (1) focusing on remissions at single time points rather
than sustained responses, (2) uncertainty about relative benefits of different aspects of intensive
management and (3) doubt about optimal treatment for patients who did not respond to intensive
management.
The balance of evidence suggest that intensive management, no matter how it is delivered, does not
benefit all rheumatoid arthritis patients with established disease. Findings in both previous trials and
the TITRATE trial suggest that current intensive management strategies benefit approximately half
of patients. In the TITRATE trial, patients with high body mass indices, particularly those who also
had high baseline Health Assessment Questionnaire scores, were unlikely to respond to intensive
management. There is growing evidence from observational studies that obesity is associated with
poor outcomes. The implications for management need further investigation.
Although achieving remission reduced disability in the TITRATE trial, many patients still had considerable
disability. Other approaches to minimising disability in patients with established rheumatoid arthritis
are needed in addition to intensive management aimed at optimising drug therapy. The best clinical
approaches to minimising disability needs further research. This research should evaluate a range of
different options, including non-drug treatments.
Trial registration
This trial is registered as ISRCTN70160382.
Funding
This project was funded by the National Institute for Health Research (NIHR) Programme Grants for
Applied Research programme and will be published in full in Programme Grants for Applied Research;
Vol. 9, No. 8. See the NIHR Journals Library website for further project information.
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The synopsis provides a narrative account of the main results from the programme. The results arereported in nine separate sections. They are preceded by this introductory section and followed by
a final section that outlines key conclusions and recommendations for further research, making eleven
sections in total.
The research was undertaken across three workstreams. They were characterised by their dominant
research approaches.Workstream A focused on patients’ perspectives, workstream B was built around the
TITRATE (Treatment Intensities and Targets in Rheumatoid Arthritis ThErapy) clinical trial and workstream
C concentrated on analysing existing evidence from real-world observational studies and published clinical
trials. Each of three workstreams continued throughout the duration of the programme. Labelling these
workstreams A–C was for convenience and it does not imply any particular order.
Each workstream was subdivided into three different work packages. They all comprised one large or
several small studies that formed a distinct cluster. Each of these nine work packages is described in a
separate section. The inter-relationship between the workstreams and work packages is outlined in Figure 1.
The research findings could be ordered in several different ways in this synopsis and none is
necessarily best. We have chosen to present them in a chronological order because we consider such
an approach is most practical. Therefore, we have reported research on longstanding observational
studies and completed trials first, followed by research on developing the intervention used in the
TITRATE trial, then the trial results and, finally, research related to the findings in the trial. This order






































• Secondary analysis trials
• Systematic reviews
Workstream C
FIGURE 1 Research design pathway.
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The nine research sections in the synopsis comprise:
1. the rationale for intensive management
2. treatment targets and predictive factors for intensive management
3. delivering intensive management
4. the TITRATE trial
5. a health economic evaluation of the TITRATE trial
6. response predictors and response persistence in the TITRATE trial
7. stability of disease control and impact on disability
8. patients’ and practitioners’ views
9. implementing intensive management.
Each of these results sections have similar substructures. These consist of aims, methods, key findings,
limitations and relation to overall programme.
For most sections, detailed accounts of the patients and methods are provided in the appendices.
This is because the sections are overviews of published papers and papers about to be submitted.
This approach is the simplest way to make the information available to readers. However, details about
patients and methods for the TITRATE trial itself, the health economic analysis of the TITRATE trial
and secondary analyses of the trial are given in the main text. This is because these parts of the
programme are standalone studies in which the methods and results are best considered together.
Patient and public involvement
The whole programme involved extensive patient and public involvement (PPI) and two patients are
co-authors of the report. Three sections (i.e. Delivering intensive management, Patients’ and practitioners’
views and Implementing intensive management) involved extensive PPI. Patients also contributed to
the trial protocol. The involvement of patients is summarised in the individual sections. The general
approach is given in Patient and public involvement.
SYNOPSIS




The TITRATE programme studied the impact of intensive management for patients with moderately
active rheumatoid arthritis (RA). Current management goals in patients with RA include minimising
disease activity, decreasing physical disability and improving health-related quality of life. There is
considerable evidence that, in patients with active RA, intensive management helps achieve these
goals. However, many patients with RA have moderate disease activity, which falls between active
disease and remission. The TITRATE programme assessed the benefits of intensively managing these
patients with moderate RA disease.
Key features of rheumatoid arthritis
Overview
Rheumatoid arthritis is an immunologically driven long-term condition. Its key features are persistent
synovitis of the joints, systemic inflammation and autoantibodies, such as rheumatoid factor.1–3 RA
affects 0.5–1% of adults in high-income countries, although there is considerable variation between
countries and populations.4–6 It particularly involves women and older adults. Its annual incidence is
5–50 per 100,000 people.6–8 Uncontrolled active RA results in substantial physical disability and poor
quality of life,9,10 which are often associated with loss of work and high medical and social costs.11–13
Management
Rheumatoid arthritis is usually managed in the UK by multidisciplinary teams that comprise
rheumatologists, nurses, physiotherapists, occupational therapists and other health-care professionals.
The multidisciplinary teams provide education, medication, psychological support, exercise and joint
protection. There is substantial variability in the nature of these teams,14 and the evidence supporting
the different approaches they use also varies.15,16 Surgical intervention may be required for end-stage
joint damage.17
Treatment focuses on the control of joint inflammation and the prevention of disease progression using
disease-modifying antirheumatic drugs (DMARDs).18 These reduce synovitis and systemic inflammation
in the short term and physical disability and erosive progression in the long term. DMARDs can be
categorised into several groups. We have classified them as conventional DMARDs, biologics and new
orally acting Janus kinase (JAK) inhibitors. Together with short-term steroids, they are the key drug
treatments for RA.
Methotrexate is the dominant conventional DMARD.19–21 Other currently prescribed conventional
DMARDs include sulfasalazine, leflunomide and hydroxychloroquine. Some patients are treated by
combining two or more conventional DMARDs. Such intensive combination treatment is constrained
by concerns about adverse event risks.22,23
Biologics are used when RA is not controlled by conventional DMARDs.24–28 They include the tumour
necrosis factor inhibitors (TNFis) rituximab, abatacept and tocilizumab. All biologics are highly effective
in reducing joint inflammation. They are usually combined with methotrexate or another conventional
DMARD to increase efficacy and reduce the formation of blocking antibodies that could reduce their
efficacy. Their use is limited by their high costs, although the advent of biosimilars is likely to reduce their
costs.29 Despite often achieving substantial reductions in disease activity, biologics are not curative. New
oral drugs for RA, the JAK inhibitors, have a similar position to biologics in the treatment paradigm.30
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Steroids (glucocorticoids) are used in the short term to reduce joint inflammation. However, their
long-term use is not recommended because of their side effects.31 RA patients also receive various
symptomatic treatments, including non-steroidal anti-inflammatory drugs and analgesics.32,33 These are
not usually given to control the disease process.
Clinical guidelines
There are many clinical guidelines for RA, including English guidelines from the National Institute for
Health and Care Excellence (NICE), which outline its overall management.34 High-cost treatments, such
as the biologics, have specific NICE Health Technology Appraisals that recommend when they should
be used.35 The various guidelines have not resolved how best to manage patients with moderately
active RA.
Treat to target
There is substantial evidence that disease outcomes are optimal when patients with active RA receive
intensive managements to achieve predefined targets, particularly disease remission.36,37 The evidence
supporting treat to target is strongest in early active RA.
NHS importance
Patient load
The long-term management of RA dominates specialist rheumatology services. The 2016 national audit
of early arthritis enrolled > 5000 patients, most of whom had RA. Inflammatory arthritis accounts for
40–60% of rheumatology follow-up visits. English Hospital Episode Statistics data show that there
were more than 1,300,000 rheumatology outpatient follow-ups in 2017/18,38 and it is likely that a
substantial proportion of these would have been for RA, potentially in the region of 300,000–600,000
outpatient follow-ups. The 2009 report from the National Audit Office estimated that 580,000 English
adults had RA, with 26,000 new diagnoses each year.39
Costs
Rheumatoid arthritis has substantial financial impacts for the NHS and the whole UK. The National
Audit Office estimated that NHS costs were £560M per year and work-related disability costs were
another £1800M per year.39 Most costs are incurred by patients with high disability levels. Early
intensive management targeted at remission should reduce future disability and, therefore, decrease
costs. Biologic drug costs, which currently exceed £1B per year, continue to increase.40
Need for research
The 2009 NICE guidance41 identified several unresolved questions that have been directly addressed
in the TITRATE programme. Crucial issues included (1) the optimal management of patients with
moderate disease activity, (2) the impact of enhancing remission rates on reducing future disability and
(3) the role of self-management and the support patients need to use it.
Although more clinical guidelines have been published since 2009, including updated NICE guidance,41
and much new research has been undertaken, these questions remain important and unresolved.
Key prior research
Pathogenic heterogeneity
Rheumatoid arthritis may not be one disease. Instead, it may represent a final common pathway
for several inflammatory joint diseases that vary by antibody profiles and clinical features.42–45
Consequently, individualised management strategies are needed.
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Effective treatments strategies
Both conventional DMARDs and biologics are effective treatments in active RA. However, there are
uncertainties about their benefits and costs. In particular, there is debate about the relative value of
combinations of conventional DMARDs compared with biologics.46–49
Intensive management
Strategy trials have shown that combining treatments, such as conventional DMARDs, short-term
steroids and, in some trials, biologics, optimise clinical outcomes.37,50,51 Such strategy trials justify
adopting treat-to-target approaches. However, there are uncertainties about the impact of intensive
management on established RA patients with moderate disease activity.
Aim and objectives
Aim
The overall aim of the TITRATE programme was to assess the evidence that outcomes improve in
patients with established RA who have moderate disease activity when they receive intensive
management.
Objectives
There were three objectives. These were to:
1. define how to deliver intensive therapy to patients with moderate established RA
2. establish the clinical effectiveness and cost-effectiveness of intensive therapy in treatment of
moderate established RA in a clinical trial
3. evaluate existing evidence supporting such intensive management in observational studies and
completed trials.
Each of these objectives was studied in one of the workstreams. The first, second and third objectives
were studied in workstreams A, B and C, respectively.
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Rationale for intensive managements
The studies in this section place the TITRATE programme into perspective using observationalstudies, secondary analyses of completed trials and systematic reviews. The studies assessed
changes in the outcomes and intensities of RA management in routine clinical care over the last two
decades, the strength of existing evidence for the clinical effectiveness of intensive management in RA
and supportive evidence for using intensive management strategies in moderate RA.
Aims
Research studies with four inter-related aims are included in this section. These aims comprised
analysing temporal changes in treatment, the perspectives in RA management guidelines, the evidence
base for intensive management and observational evidence supporting intensive management for
moderate RA. Four parts of the research have been published.52–55
Changes in rheumatoid arthritis management and outcomes
Rheumatoid arthritis management and outcomes continually evolve, and there is considerable evidence
that RA is becoming better controlled or less severe.56–66 We therefore examined changes in disease
activity, disability and treatment intensities in observational studies in routine practice settings in
recent years. We examined changes in erosive progression in a systematic review of long-term
observational studies52 that measured this outcome. We had to take this approach for erosive
progression because X-ray damage is not quantified in routine practice.
Clinical management guidelines
Expert guidance about managing RA also evolves.67,68 We therefore systematically reviewed published
clinical guidelines on RA management to identify current recommendations on disease assessments
and intensive management (both of which are crucial for the TITRATE strategy).
Trial evidence supporting intensive management
The evidence base for intensive management of RA is also expanding.69 We therefore undertook two
systematic reviews in the area. The first systematic review focused on remissions with all intensive
managements and the second systematic review assessed the clinical effectiveness and cost-effectiveness
of treat-to-target strategies.
Clinical evidence for treating moderately active rheumatoid arthritis intensively
The TITRATE programme reflects two concepts. First, patients with moderate RA and persisting
disease activity are likely to have substantial ongoing disability, and observational evidence supports
this perspective.17 Second, if patients with moderate disease activity subsequently achieve remission,
then they will have less disability, but there is little definitive evidence for this perspective. We
evaluated both assumptions by analysing an observational study and two trials. Our aim was to ensure
that evidence existed in favour of treating moderate RA intensively.
Methods
Observational studies
One observational study combined four cross-sectional surveys undertaken in two adjacent specialist
units from 1996 to 2014 (three surveys had previously been published70–72). The studies each enrolled
189–520 patients (see Appendix 1, Table 27, for details of these patients). Overall, 1324 patients were
studied. The patients in each survey were similar: 76–80% were female, their mean age was 58–60 years
and their mean disease duration was 9–10 years. No particular treatment strategy was followed.
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The other observational study was a longitudinal cohort study established in 2005 at Guy’s Hospital
(London, UK). It involved most of the RA patients who were managed in another specialist centre until
2015. The study enrolled 1693 patients. Seventy-five per cent of the patients were female and their
mean age was 55 years and mean disease duration was 11 years at entry to study (details of these
patients are given in Appendix 1, Table 28). Patients were managed intensively using a treat-to-target
approach. The longitudinal observational study included 752 patients, who were followed over ≥ 3 years.
Clinical trials
The CARDERA (Combination Anti-Rheumatic Drugs in Early Rheumatoid Arthritis) trial, which lasted
24 months, enrolled 467 patients, and complete end-point data were available in 379 patients.73 The
TACIT (Tumour Necrosis Factor Inhibitors Against Combination Intensive Therapy) trial, which lasted
12 months, enrolled 208 patients, and complete end-point data were available in 179 patients.74
Details of these patients are given in Appendix 1, Table 31.
Clinical assessments
We assessed disease activity using the Disease Activity Score for 28 joints based on the erythrocyte
sedimentation rate (DAS28-ESR)75 and disability using the Health Assessment Questionnaire (HAQ).76
Further details are given in Appendix 2.
Systematic reviews
Four systematic reviews assessed:
l erosive progression in long-term observational studies
l clinical guidelines for managing RA
l intensive managements and remission
l the clinical effectiveness and cost-effectiveness of treat-to-target strategies.
Full details of these systematic reviews are given in the supplementary online material, including
PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagrams (see
Report Supplementary Material 1, Figure 1), and details of the included studies (see Report Supplementary
Material 1, Tables 1–5).
Statistical analyses
Data were analysed descriptively using means, standard deviations (SDs) and 95% confidence intervals
(CIs) or medians and interquartile ranges (IQRs). The longitudinal observational study used mixed
models to examine the changes in DAS28-ESR over time.
The systematic review of erosive damage used Larsen77 and Sharp–van der Heijde scores78 to estimate
annual rates of change in a linear regression model. The systematic review of intensive management
and remissions used meta-analysis with RevMan 5.3 (The Cochrane Collaboration, The Nordic
Cochrane Centre, Copenhagen, Denmark) to report relative risks in random-effects models,79 using
Cochrane’s chi-squared test to assess between-study heterogeneity and quantify I2 statistics.80
The other systematic reviews were descriptive and further details are given in Appendix 3.
Key findings
Clinical studies of changes in disease activity and disability
Both observational studies showed that there have been considerable reductions in disease activity
levels and increases in treatment intensities over the last two decades.
The first observational study, involving four cross-sectional surveys between 1996–7 and 2012–14,
showed substantial decreases in mean DAS28-ESR scores (Figure 2). In 1996/7, mean DAS28-ESR scores
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were 5.2 (95% CI 5.0 to 5.4) and they decreased to 3.7 (95% CI 3.6 to 3.8) by 2012/14. DAS28-ESR
remissions increased from 8% to 28%. The main treatment change was increased biologics use. None
was used before 2000, but by 2012/14 biologics were used in 32% patients. Despite reductions in
disease activity and increases in biologics use, disability levels were stable. In 1996/7, mean HAQ
score was 1.30 (95% CI 1.08 to 1.52), and in 2012/14 it was 1.32 (95% CI 1.25 to 1.39).
The second observational study, which comprised a longitudinal cohort study from 2005 to 2015, also
showed that mean DAS28-ESR scores had decreased (see Figure 2). In 2005, the mean DAS28-ESR
score was 4.1 (95% CI 3.9 to 4.3), and by 2015 it was 3.6 (95% CI 3.3 to 3.8). DAS28-ESR remissions
increased from 18% to 27%. The main treatment change was increased biologics use. Biologics were
prescribed for 19% of patients in 2005 and 42% of patients in 2015. The mean HAQ scores fell from
1.38 (95% CI 1.26 to 1.50) in 2005 to 1.19 (95% CI 1.04 to 1.34) in 2015.
Systematic review of changes in the progression of erosive damage
We identified 28 studies reporting RA radiological progression, and 10 studies, reported in nine papers,81–89
had sufficient data for meta-analysis. These 10 studies recruited patients from 1965 to 2000 and followed
them for 5–20 years. Of 1121 patients, 73 had baseline radiological data. Five of the studies recruited
from 1965 to 198981–85 and the other five studies recruited from 1990 to 2000.85–89
Baseline radiographic scores were similar in pre- and post-1990 studies (with a mean maximum
damage of 2.01% and 2.03%, respectively). The annual rate of erosive change was higher in pre-1990
studies (mean 1.50%, 95% CI 1.08% to 1.92%) than in post-1990 studies (mean 0.68%, 95% CI 0.47% to
0.90%) and the difference was significant (p < 0.05) after adjusting for scoring methods. These changes
are summarised in Figure 3.
Systematic review of clinical management guidelines
We identified 22 guidelines36,90–110 (three were for early RA,99,105,107 one for established RA98 and
18 for all disease durations36,90–97,100–104,106,108–110). They were compiled by rheumatologists with variable
patient involvement and contributions from nurses, allied health professionals and other experts.
All guidelines dealt with drug therapies (11 guidelines covered diagnosis and 13 guidelines covered
non-drug treatments).
Twenty guidelines36,90–98,100–105,107–110 recommended remission as the treatment target, and 16 guidelines36,90–97,
102–104,107–110 recommended low disease activity as an alternative.Two guidelines98,106 recommended suppressing
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FIGURE 2 Changes in DAS28-ESR over time. (a) Cross-sectional surveys; and (b) longitudinal study.
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Remission was defined in various ways. DAS28-ESR remission was recommended in 13 guidelines,90,92–95,97,
101,102,104,107–110 Simple Disease Activity Index (SDAI) in nine guidelines,36,92,95–97,102–104,108 Clinical Disease
Activity Index (CDAI) in seven guidelines92,95,97,102,104,108,109 and American College of Rheumatology
(ACR)/European League Against Rheumatism (EULAR) Boolean in seven guidelines.36,92,95,97,103,104,109
Six guidelines did not recommend any specific remission criteria.91,96,98–100,105,106
All guidelines36,90–110 recommend treating active RA. There was less unanimity about treating moderately
active disease. Thirteen guidelines91,92,94–97,100,102–105,107,108 included definite recommendations about
treating moderate disease, four guidelines36,90,101,109 gave implied guidance about treating moderate
disease by indicating what treatment policies were needed until patients achieved remission and
five guidelines93,98,99,106,110 made no recommendations.
Systematic review of trials of remissions with intensive management
We identified 53 trials reporting remissions.74,111–162 Forty-eight trials111–132,134–139,142,143,145–162 were
superiority trials in which an intensive management strategy was compared with a less intensive
strategy, six trials74,128,133,140,141,144 were head-to-head trials comparing combination DMARDs with





























































FIGURE 3 Initial damage and annual rate of damage in pre- and post-1990 cohorts. Means and 95% CIs are shown.
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FIGURE 4 Remission assessments and treatment targets in RA guidelines.
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In superiority studies, 3013 of 11,259 patients achieved remission with intensive management, compared
with 1211 of 8493 control patients. Meta-analysis of the 53 comparisons showed a significant benefit
for intensive management [risk ratio (RR) 2.23, 95% CI 1.90 to 2.61]. Intensive management increased
remissions in early RA (23 comparisons; RR 1.5, 95% CI 1.38 to 1.76) and established RA (29 comparisons;
RR 4.21, 95% CI 2.92 to 6.07). All intensive strategies (i.e. combination DMARDs, biologics, and JAK
inhibitors) increased remissions. These effects are shown in Figure 5.
In the six head-to-head trials,74,128,133,140,141,144 317 of 787 patients achieved remission with biologics,
compared with 229 of 671 patients receiving combination DMARD therapies. There was no difference
between treatment strategies (RR 1.06, 95% CI 0.93 to 1.21). These effects are shown in Figure 5.
Remission frequencies differed in early and established RA. In early RA, 49% of patients had remissions
with intensive management compared with 34% of control patients (RR 1.05, 95% CI 0.88 to 1.24). In
established RA, 19% patients had remissions with intensive management compared with 6% of control
patients (RR 1.21, 95% CI 0.88 to 1.68).
Systematic review of trials supporting using treat to target
We identified 41 papers49,113,128,129,141,148,153,155,163–195 reporting 16 relevant trials. Six trials129,158,171,179,186,190
compared treat to target with usual care, six trials49,113,128,177,183,185 compared different treatment
protocols, two trials141,172 compared different treatment targets and two trials153,160 had other comparisons
of conventional with intensive therapy. As the trials were too heterogeneous for meta-analysis, we
undertook a narrative analysis. Details of the impact of treat-to-target strategies on remission in studies
with controls receiving conventional treatment is shown in Table 1.
Four of six trials comparing treat to target with usual care reported remissions and all found more
remissions with intensive management. Differences were clinically and statistically significant in three
trials,129,179,186 but the differences were considered meaningful in the STREAM (Strategies in Early
Arthritis Management) trial.158 Two trials171,190 comparing treat to target with usual care reported only



































FIGURE 5 Effectiveness in superiority and head-to-head trials assessed by random RRs. (a) Superiority trials; and
(b) head-to-head trials.
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Standard care Intensive management
Relative risk
(95% CI)Treatment Patients, n
Remission,
n (%) Treatment Patients, n
Remission,
n (%)
STREAM158 < 1 year Conventional 40 19 (49) Intensive 42 27 (66) 1.35 (0.88 to 2.01)
T-4 study186 1 year Routine 62 13 (21) DAS28-ESR/MMP3 driven 61 34 (56) 2.66 (1.34 to 4.78)
Optimisation of
adalimumab179
Established Routine care 109 17 (16) DAS28-ESR target 100 38 (38) 2.44 (1.44 to 4.24)
TICORA129 2 years Routine 55 9 (16) Intensive 55 36 (65) 4.00 (2.15 to 8.02)
CAMERA160 < 1 year Conventional 148 55 (37) Intensive 151 76 (50) 1.35 (1.03 to 1.79)
BROSG153 13 years Symptomatic 233 23 (14) Intensive 233 34 (20) 1.48 (0.87 to 2.52)
BeSt128 < 1 year Monotherapy 126 36 (29) Prednisone combination 133 44 (33) 1.16 (0.79 to 1.72)
Infliximab (Remicade®; Centocor Biotech Inc.,
Horsham, PA, USA) combination
128 45 (36) 1.23 (0.84 to 1.92)
FIN-RACo177 < 1 year Single drug 100 18 (18) Combination treatment 99 36 (37) 2.02 (1.21 to 3.47)
U-Act-Early113 < 1 year Methotrexate 108 48 (44) Tocilizumab (Actemra®; Roche, Basel,
Switzerland)/methotrexate
106 91 (86) 1.92 (1.56 to 2.31)
BeSt, Behandel–Strategieën; BROSG, British Rheumatoid Outcome Study Group; CAMERA, Computer Assisted Management in Early Rheumatoid Arthritis; FIN-RACo, Finnish
Rheumatoid Arthritis Combination Therapy Trial; MMP3, matrix metalloproteinase 3; STREAM, Strategies in Early Arthritis Management; T-4, Treating to Twin Targets; TICORA, Tight


















































The six trials49,113,128,177,183,185 that compared treatment protocols all reported remissions. Two trials113,177
included conventionally treated controls and found significantly more remissions with intensive
managements. Five49,128,183,185 of these trials compared different intensive management regimens and
found no significant differences in remissions between regimens. One of these trials [Behandel–Strategieën
(BeSt)128] included a conventionally treated group that had fewer remissions, although the difference
was not significant.
Two trials141,172 compared targets in patients receiving different intensive management regimens.
Both trials141,172 found no significant difference between groups. Finally, two trials153,160 that did not fit
into the previous categories had conventionally treated controls and reported more remissions with
intensive managements. The difference was significant in one trial,160 but not in the other.153
Twelve trials reported harms. Deaths were reported in seven trials.49,113,128,129,141,183,186 There were no
deaths in three trials and 11 deaths in the other four trials (three deaths in two standard care arms
and eight deaths in 10 intensive management arms). Serious adverse events were reported in eight
trials.49,113,128,141,158,177,185,186 Overall, 11% patients had a serious event (12% of patients receiving intensive
management and 9% of patients receiving standard care).
Two studies129,153 reported cost-effectiveness. In one study,129 treat to target dominated usual care and
in the other study153 step-up combination treatments were cost-effective. In 5 of the 16 studies158,172,179,183,185
included in the clinical effectiveness review, no cost-effectiveness conclusion could be reached, and
in one study49 no conclusion could be drawn in the case of patients designated as low risk. In the
remaining 10 studies,113,128,129,141,153,160,171,177,186,190 and among patients identified as high risk in one study,49
cost-effectiveness was inferred. In most cases, treat to target is likely to be cost-effective, except where
biological treatment in early disease is used initially. No conclusions could be drawn for established RA,
as there were too few studies to assess benefit.
Clinical studies of treating moderately active rheumatoid arthritis intensively
The impact of achieving remission on subsequent disease activity and disability, particularly in
moderate disease patients, was studied in 752 patients in a longitudinal observational study followed
for ≥ 3 years and in secondary analyses of early and established RA trials.
The frequency of moderately active disease at baseline in the 752 patients in the observational study
and at 6 months in the 558 patients in the trials was substantial. It varied from 39% to 45% of patients
(Table 2). In all three studies, moderate disease patients were the largest group in terms of disease
activity levels. The mean end-point DAS28-ESR scores in these patients after 1–3 years’ follow-up
varied between 3.5 and 4.2, and their end-point mean HAQ scores varied between 1.3 and 1.5.
Dividing patients with initial/6-month moderate RA into those who subsequently had one or more
DAS28-ESR remissions and those who did not (Figure 6) shows two things. First, those patients who
achieved one or more remissions had lower subsequent mean DAS28-ESR scores than patients who
did not. Second, mean HAQ scores were lower in patients who achieved one or more remissions.
Evaluating these changes in detail (see Table 2) showed that 18–48% of patients with initial/6-month
moderate disease achieved one or more episodes of remission during the period of follow-up. The
patients with one or more remissions had significantly lower end-point mean DAS28-ESR scores in
all studies and significantly lower end-point mean HAQ scores in two studies (i.e. the observational
study and the CARDERA trial73). In the other study (i.e. the TACIT trial74), end-point mean HAQ scores
were lower in patients who achieved one or more remissions, but the difference was not significant.
In patients with initially moderate disease, treatment intensities were comparable in patients with and
without subsequent remissions (Figure 7).
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TABLE 2 Impact of baseline/6-month DAS28-ESR on final DAS28-ESR and HAQ scores and of remission in baseline moderate disease
Activity status














Initial/6 months: all patients
Remission 179 (24) 2.4 (2.3 to 2.6) 0.7 (0.6 to 0.9) 24 (13) 2.6 (1.9 to 3.2) 1.2 (0.8 to 1.5) 74 (20) 2.9 (2.5 to 3.2) 0.6 (0.5 to 0.8)
Low 101 (13) 3.0 (2.8 to 3.3) 1.1 (1.0 to 1.3) 20 (11) 3.3 (2.7 to 3.8) 1.3 (1.0 to 1.7) 37 (10) 3.4 (3.0 to 3.8) 0.9 (0.6 to 1.1)
Moderate 322 (43) 3.5 (3.4 to 3.7) 1.4 (1.3 to 1.5) 69 (39) 3.8 (3.5 to 4.1) 1.5 (1.3 to 1.7) 169 (45) 4.2 (4.0 to 4.4) 1.3 (1.2 to 1.4)
High 150 (20) 4.1 (3.9 to 4.4) 1.7 (1.6 to 1.8) 66 (37) 4.8 (4.4 to 5.2) 1.6 (1.4 to 1.8) 99 (26) 5.2 (5.0 to 5.5) 1.6 (1.5 to 1.8)
Subsequent
Never 167 (52) 4.3 (4.1 to 4.4) 1.7 (1.5 to 1.8) 46 (67) 4.2 (4.0 to 4.5) 1.6 (1.4 to 1.8) 138 (82) 4.6 (4.4 to 4.8) 1.4 (1.3 to 1.5)
Any 155 (48) 2.8 (2.6 to 2.9) 1.1 (1.0 to 1.2) 23 (33) 2.9 (2.3 to 3.4) 1.3 (1.0 to 1.7) 31 (18) 2.7 (2.2 to 3.2) 0.7 (0.5 to 0.9)
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FIGURE 6 Changes in DAS28-ESR and HAQ score in moderate RA patients. Patients divided by none or one or more
remissions. (a) DAS28-ESR – observational; (b) DAS28-ESR – TACIT trial;74 (c) DAS28-ESR – CARDERA trial;73 (d) HAQ –





































FIGURE 7 Changes in DMARD and biologic prescribing in patients with initial moderate disease activity in the
observational study. Patients are divided by whether they had one or more remissions during follow-up. (a) DMARD
monotherapy; (b) DMARD combination; and (c) biologics. (continued )
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Limitations
The studies in this section were limited by the types of patients studied, their assessment of benefits
and risks and the type of intensive management that was used.
Patients studied
It is likely that patient inclusion and follow-up strategies in observational studies have changed over
time. In particular, patients with milder disease may have attended more frequently in recent years.
Such changes in patient care could explain some or all of the reductions in disease activity we
observed. It is also possible that the clinical phenotype of RA has evolved, with milder disease
increasing in frequency. However, a recent analysis of English early RA patients since 1990 does not
suggest that there have been major changes in RA clinical phenotypes.196
Assessing benefits and risks
The assessment of remission and the duration of treatment varied in the trials of intensive management
in the systematic review. This variation created unavoidable complexities when combining data from
studies. When there are many studies, as occurred in the comparison of all intensive managements,
combining heterogeneous data appears reasonable. However, when there are few studies, as occurred
in comparisons of treat-to-target strategies, it is best avoided.
Evidence about the benefits of intensive management are almost entirely based on clinician-defined
outcomes, such as changes in disease activity (e.g. remissions, reductions in disability and erosive
damage). The extent to which patients consider intensive management to be beneficial is largely
unknown. Patients can have different perspectives to clinicians.197–199
One final and important issue is that we did not assess the potential of intensive management to harm
patients in detail. In routine practice settings, it is particularly difficult to assess harms because they
are not reported in any organised way. Nevertheless, we found no evidence of intensive management
substantially increasing adverse events. Published systematic reviews of intensive management,
predominantly using biological treatments, have also not found any substantial increases in adverse
events with more intensive treatment regimens.23,200,201
Treatments
There is no internationally agreed definition of what constitutes intensive management in RA.
The numbers and types of treatments used, the time frames over which they are increased and the
frequencies at which patients are assessed vary across studies. The absence of definite agreement

















FIGURE 7 Changes in DMARD and biologic prescribing in patients with initial moderate disease activity in the
observational study. Patients are divided by whether they had one or more remissions during follow-up. (a) DMARD
monotherapy; (b) DMARD combination; and (c) biologics.
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Relation to overall programme
The intention in this section was to place the TITRATE programme in perspective. The various studies
highlighted what is accepted and where there are continuing uncertainties.
Generally agreed areas
There is extensive evidence that intensive management in RA patients increases the frequency of
remissions. One consequence has been that the use of intensive management is supported in all clinical
guidelines. Another consequence has been that, over the last two decades, the intensity of treatment
has increased in routine practice settings. This change has been reported in other settings.67,202–204
Associated with the increased use of intensive managements have been reductions in overall disease
activity levels and increases in the frequency of remissions. These findings have also been reported by
others.57,60 In addition, erosive progression has lessened substantially for an even longer period, and
this is most likely a consequence of increased treatment intensity together with earlier diagnosis and
treatment, although it remains a relevant outcome measure. This finding has also been identified in
other studies and reviews.59,205
Continuing uncertainties
There is considerable support from expert opinion in clinical guidelines for treating moderate RA
intensively.We also found, in our analysis of observational data and trials, that remissions are associated
with overall reductions in disease activity levels in patients with moderate disease activity. Although
there is some evidence that reducing disease activity improves disability in patients with moderate RA,
our results were not conclusive and further work is needed to resolve this important question.
It is also not possible to be certain that achieving remission in patients with moderate RA in our
observational study and in secondary analyses of completed clinical trials was a result of the intensity
of their treatment. This uncertainty can be resolved only in a prospective clinical trial that directly tests
this hypothesis.
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Treatment targets and predictive factors
The studies in this section evaluated RA treatment targets and simple outcome predictors usingobservational studies and secondary analyses of clinical trials. The studies addressed some aspects
of the complex problem of what to measure when assessing RA patients.
Aims
Research studies with two overarching aims are included in this section. These aims comprised
(1) defining optimal treatment targets and (2) identifying simple response predictors. They addressed
the complex problem of what to measure when assessing RA patients. Optimising treatment targets
and response predictors are important for interpreting the results of the TITRATE programme and
implementing its findings in clinical care. Five parts of the research have been published.206–210
Treatment targets
Targets must balance the ideal with the practical. Stringent targets may deliver optimal outcomes in
some individuals, but achieve fewer overall benefits than more readily achievable targets. The TITRATE
programme adopted DAS28-ESR remission as its primary target because it is the most widely used
composite remission assessment. There is also extensive evidence that achieving DAS28-ESR remission
optimises health-related quality of life and function and minimises radiological damage.211–215 Sustained
remission over time is particularly important because it is associated with better outcomes than
remission at a single time point.216,217 We collected components of other composite measures to
compare their value as targets during intensive management.
In this section, we evaluated four aspects of treatment targets: (1) comparisons of sustained remission
(persistent remission after 6 months’ treatment) and point DAS28-ESR remission and low disease
activity, (2) the impact of lesser improvements in DAS28-ESR, (3) limitations of DAS28-ESR in
comparison to other composite assessments and (4) associations of DAS28-ESR components with
health-related quality of life.
We focused on these aspects of treatment targets, as they are important and we had access to
relevant observational and trial data. We could not examine all indices, as some of the necessary data
are not collected in routine care settings or our published trials. As C-reactive protein (CRP) levels and
physicians’ global assessments are not usually measured in routine practice in England, we could not
study the SDAI.218
Simple baseline outcome predictors
Using baseline measures to predict clinical outcomes may help routine practice. We therefore assessed
the value of simple four-point scores, HAQ scores alone and mental health status.
We selected these areas on the basis of what was practical and likely to be used in clinical practice.
There was a case to assess rheumatoid factor and subtypes and other autoantibodies in predicting RA
outcomes,81,219,220 but these were not used in the observational studies and trials that we could access.
Methods
Observational studies
We further studied the observational longitudinal cohort study established in 2005 at Guy’s Hospital.
The study focused on 752 patients followed over ≥ 3 years. Details of these patients are given in
Appendix 1, Table 28. We also studied 155 early RA patients who completed 12 months’ follow-up with
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clinical data at 0, 6 and 12 months in an observational study [Early Rheumatoid Arthritis Network
(ERAN)]. Details of these patients are given in Appendix 1. We selected these studies because they
involved patients treated in recent years. More historical studies were not used because patients
received far less intensive management.
We also evaluated a compilation of single time point observational studies of outpatients with
RA.72,221–223 The patients included 747 European white RA patients, 197 black African/Caribbean British
patients and 430 Arab patients seen in rheumatology clinics in Saudi Arabia. No specific treatment
policies were followed in these patients. Details of these patients are given in Appendix 1, Table 29.
Clinical trials
We further evaluated the 379 patients completing the 24-month CARDERA trial73 and the 179 patients
completing the TACIT trial.74 We also evaluated patients with established RA in the OPTTIRA (Optimizing
Treatment with Tumour Necrosis Factor Inhibitors In Rheumatoid Arthritis) trial.224 The OPTTIRA trial,
which lasted 6 months, enrolled 103 patients, and complete end-point data were available in 97 patients.
Details of these patients are given in Appendix 1, Table 31.
Clinical assessments
We assessed disease activity using DAS28-ESR, CDAI and Routine Assessment of Patient Index Data 3
(RAPID3), disability using the HAQ, and health-related quality of life using EuroQol-5 Dimensions
(EQ-5D) and the Short Form questionnaire-36 items (SF-36).225–230
Further details are given in Appendix 2.
Statistical analyses
Data were analysed descriptively using means, SDs and 95% CIs or medians and IQRs for non-normally
distributed data. Other tests included chi-squared tests, assessments of sensitivity and specificity, t-tests,
regression analyses, Spearman’s correlations and multiple linear regression methods. Further details are
given in Appendix 3.
Key findings
Treatment targets: DAS28-ESR and disability
The relationships between remission and low disease activity with disability and quality of life were
studied in early and established RA trials and an observational cohort. In these patients, both sustained
remission and sustained low disease activity were relatively uncommon. Between 5% and 9% of patients
had sustained remissions and 9–16% of patients had sustained low disease activity. More patients had
remission and low disease activity at single time points. Between 35% and 58% of patients had an episode
of remission and between 49% and 74% of patients had an episode of low disease activity.
Disease Activity Score for 28 joints based on ESR scores varied substantially after patients had achieved
an episode of remission. End-point DAS28-ESR scores (at 12 and 24 months in TACIT and CARDERA
trials,73,74 and at final assessment in the observational study) in patients achieving an episode of remission
showed that 53–61% of patients were still in remission, 9–18% of patients had low disease activity,
21–22% of patients had moderate disease activity and 4–8% of patients had high disease activity.
These findings are shown in Figure 8.
Individual patients showed marked levels of variation in their subsequent DAS28-ESR scores following
attaining remission. The extent of this within-individual variability was similar across all three cohorts.
Figure 9 shows DAS28-ESR scores for all patients following attaining remission in the longitudinal
observations study in patients with at least five subsequent DAS28-ESR measures.
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Sustained and point remissions had varying impacts on end-point low disability and normal EQ-5D
scores (Table 3). Sustained remissions were most specific for low disability (97–98%) and normal EQ-5D
(93–97%), but lacked sensitivity (low disability: 19–29%; normal EQ-5D: 19–36%). Point remission gave
a better balance between sensitivity and specificity (low disability: specificity 50–78% and sensitivity
68–89%; normal EQ-5D: specificity 42–72% and sensitivity 70–93%).
Attaining sustained low disease activity was also highly specific for low disability (92–96%) and normal
EQ-5D (86–94%), but lacked sensitivity (low disability: 26–41%; normal EQ-5D: 33–41%). Low disease
activity at any point was highly sensitive (low disability: sensitivity 87–97%; normal EQ-5D: sensitivity
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FIGURE 9 Within-individual variability in DAS28-ESR scores after remission for patients in the longitudinal observational
study. DAS28-ESR scores for each individual patient following an episode of remission are plotted, provided there were
at least five subsequent DAS28-ESR measures. Reprinted from Seminars in Arthritis and Rheumatism, Volume 49,
Scott IC, Ibrahim F, Panayi G, Cope AP, Garrood T, Vincent A, et al. The frequency of remission and low disease activity
in patients with rheumatoid arthritis, and their ability to identify people with low disability and normal quality of life,
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FIGURE 8 End-point DAS28-ESR category after attaining point remission.
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TABLE 3 Relationship between remission states and end-point low HAQ scores and normal EQ-5D scores
Group Remission/LDA status Patients
Mean end-point
DAS28 (95% CI)
End-point HAQ End-point EQ-5D
HAQ ≤ 0.5 Specificity Sensitivity Normal EQ-5D Specificity Sensitivity
CARDERA trial73 (n= 379) Sustained remission 26 (7%) 1.80 (1.61 to 1.99) 19/91 98% 21% 16/60 97% 27%
Point remission 132 (35%) 2.81 (2.57 to 3.04) 68/91 78% 75% 42/60 72% 70%
End-point remission 80 (21%) 1.92 (1.80 to 2.03) 48/91 91% 51% 35/60 86% 58%
Sustained LDA/remission 45 (12%) 2.02 (1.84 to 2.19) 33/91 96% 36% 26/60 94% 33%
Point LDA/remission 187 (49%) 3.09 (2.89 to 3.28) 79/91 63% 87% 52/60 58% 87%
End-point LDA/remission 114 (30%) 2.20 (2.09 to 2.32) 62/91 82% 68% 46/60 79% 77%
TACIT trial74 (n = 192) Sustained remission 10 (5%) 1.66 (1.32 to 2.00) 6/31 97% 19% 4/17 96% 19%
Point remission 80 (42%) 2.81 (2.53 to 3.10) 19/31 63% 68% 13/17 62% 77%
End-point remission 41 (22%) 1.92 (1.77 to 2.08) 17/31 85% 55% 10/16 82% 59%
Sustained LDA/remission 17 (9%) 1.75 (1.50 to 2.00) 8/31 94% 26% 6/17 94% 35%
Point LDA/remission 119 (62%) 3.18 (2.94 to 3.43) 29/31 44% 94% 17/17 41% 100%
End-point LDA/remission 66 (35%) 2.29 (2.14 to 2.44) 23/31 72% 74% 13/17 69% 81%
RA centre (n= 752) Sustained remission 67 (9%) 1.56 (1.46 to 1.67) 52/180 97% 29% 21/59 93% 36%
Point remission 437 (58%) 2.83 (2.75 to 2.91) 160/180 50% 89% 55/59 42% 93%
End-point remission 167 (22%) 1.98 (1.90 to 2.05) 106/180 87% 57% 37/59 78% 52%
Sustained LDA/remission 120 (16%) 1.91 (1.81 to 2.01) 73/180 92% 41% 24/59 86% 41%
Point LDA/remission 560 (74%) 3.07 (2.99 to 3.14) 174/180 31% 97% 57/59 25% 97%
End-point LDA/remission 310 (41%) 2.41 (2.34 to 2.48) 142/180 70% 79% 50/59 62% 85%
LDA, low disease activity.
Sustained remission: in TACIT and CARDERA this is a DAS28-ESR < 2.6 from 6 months onwards and in the RA centre at all time points; point remission: a DAS28-ESR < 2.6 at any
time point; end-point remission: a DAS28-ESR < 2.6 at the final time point in each cohort. For LDA/remission a DAS28-ESR cut-off of ≤ 3.2 is used. In TACIT normal EQ-5D scores
are ≥ 0.82; in CARDERA and the RA centre they are ≥ 0.8.
Reprinted from Seminars in Arthritis and Rheumatism, Volume 49, Scott IC, Ibrahim F, Panayi G, Cope AP, Garrood T, Vincent A, et al. The frequency of remission and low disease

























































Treatment targets: optimal responses in DAS28-ESR scores
An alternative way of assessing the inter-relationship between DAS28-ESR scores, disability and
quality of life was examining the impact of EULAR responses in clinical trial settings. This approach
was taken in another study208 that evaluated the impacts of moderate and good EULAR responses on
changes in HAQ scores at the end points of early and established RA trials.
Moderate EULAR responders’ mean HAQ scores decreased by 0.39 and 0.33 in the CARDERA and
TACIT trials, respectively.73,74 In contrast, EULAR good responders had reductions of 0.88 and 0.64,
respectively. In both trials, the difference between moderate and good responders exceeded the
minimum clinically important difference for HAQ scores (0.22). The differences in mean reductions of
0.49 and 0.30 between moderate and good responders were significant (p < 0.01, unpaired t-test).
There were similar findings for EQ-5D scores. In moderate EULAR responders, EQ-5D scores increased
by 0.18 and 0.15. In good EULAR responders, EQ-5D scores increased by 0.30 in both trials. The
differences (0.12 and 0.15) between moderate and good responders also exceeded the minimum
clinically important difference, which is generally considered to be 0.07, and were significant (p < 0.01,
unpaired t test).
In addition, the frequencies of large and minimal improvements in disability and quality of life were assessed
in these patients (Figure 10). With HAQ scores between 41% and 18%, good EULAR responders had large
decreases in HAQ score (> 1.00) in early and established RA. However, only 13% and 9% of moderate
EULAR responders had such reductions. By contrast, only 21% and 20% of good EULAR responders had
minimal changes in HAQ score (> 0.22), compared with 37% and 43% of moderate EULAR responders.
Treatment targets: DAS28-ESR and alternative assessments
The inter-relationships between the four components of DAS28-ESR scores were assessed over
the four disease activity levels: (1) remission, (2) low disease activity, (3) moderate disease activity
and (4) high disease activity. Initially, these inter-relationships were assessed in an observational
study of 747 European white patients. This analysis showed that ESRs contributed most to mean
DAS28-ESR scores at all activity levels. However, their contribution was greatest in remission, when
ESRs accounted for 70% of DAS28-ESR scores. The contribution of ESR decreased to 40% of DAS28-ESR































FIGURE 10 Changes in HAQ score in moderate and good EULAR responders. In early and established RA trials (CARDERA
trial73 and TACIT trial,74 respectively). Shows per cent of patients with substantial (> 1.00) and minimal changes (< 0.22).
Adapted with permission from Mian et al.208 This is an Open Access article distributed in accordance with the terms of the
Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work,
for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The figure
includes minor additions and formatting changes to the original figure.
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declined as DAS28-ESR fell. Swollen joint counts and patient global assessments showed small stable
contributions to DAS28-ESR scores over all disease activity levels.
These findings were replicated in two further observational studies of 197 black African/Caribbean
British patients223 and 430 Arab patients.222 They were also replicated in three clinical trials
(i.e. CARDERA,73 TACIT74 and OPTTIRA224) that involved 97–369 patients. Figure 11 shows the
contributions of ESR and tender joint counts to DAS28-ESR disease activity levels in all six of these
observational studies and trials.
Two other composite scores – CDAI and RAPID3 – were studied in a comparative manner in one early
RA trial (i.e. the CARDERA trial73). These alternative composite scores showed different patterns of
variation across disease activity levels, which is also shown in Figure 11. With the CDAI, patient and
assessor global assessments dominated in remission and swollen and tender joint counts dominated
in active disease. With RAPID3, patient global score, pain score and HAQ score made relatively stable
contributions to the overall score across all activity levels.
Treatment targets: DAS28-ESR and health-related quality of life
The association between different components of the DAS28-ESR and health-related quality of life was
assessed using the SF-36. The inter-relationships were evaluated in clinical trials of 672 patients with
early and established RA.
Linear regression models, which included all four DAS28-ESR components, examined the relationships
to SF-36 physical component score (PCS) and mental component score (MCS). The regression models
were adjusted for treatment, age, sex and disease duration. The regression models found significant
correlations between patient global scores and both SF-36 summary scores in early and established RA
(Table 4). Other components of DAS28-ESR had significant correlations in early RA patients, but did
not have significant correlations in established RA patients.
Predictive factors: simple four-point scores
The first approach to predicting RA outcomes involved developing and testing a simple predictive score
using data that are regularly collected in routine care settings. It focused on predicting persisting active
RA. The score was developed in an observational study (ERAN),206 using 155 early RA patients who
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FIGURE 11 Contributions of different components to activity scores in different states of disease activity. Tender joints
and ESR in DAS28 in data from six studies72–74,221–224 and components CDAI and RAPID3 in data from the CARDERA
trial.73 (a) DAS28 tender joints; (b) CDAI all components; (c) DAS28-ESR; and (d) RAPID3 all components. (continued )
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FIGURE 11 Contributions of different components to activity scores in different states of disease activity. Tender joints
and ESR in DAS28 in data from six studies72–74,221–224 and components CDAI and RAPID3 in data from the CARDERA
trial.73 (a) DAS28 tender joints; (b) CDAI all components; (c) DAS28-ESR; and (d) RAPID3 all components.
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identified three main predictors for persisting active disease: (1) tender joint counts, (2) HAQ scores
and (3) ESR. Each of these predictors was then dichotomised (six or more tender joint counts, HAQ
score of ≥ 1.0 and an ESR of ≥ 20 mm/hour) to give a four-point score. This index predicted persisting
active disease (i.e. a DAS28-ESR score of > 3.2) at 6 and 12 months during follow-up in ERAN.
The value of this four-point score was then assessed in clinical trials in 558 patients with early and
established RA. In the early RA trial, only 20% of patients with no predictors had persistent active
disease, whereas 80% of patients with all three predictors had persistent active disease (Figure 12).
This relationship was significant (p < 0.01). There was a similar relationship in the established RA trial,
although this was weaker because none of the patients in the established RA trial had no initial
predictive factors. In these patients, 20% of patients with one predictive factor had persistent active
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FIGURE 12 Simplified predictors of persistently active disease in trial patients.
TABLE 4 DAS28-ESR components and SF-36 PCS and MCS at final trial time points (assessed in multiple linear
regression models)
SF-36
Early RA trial Established RA trial
Standardised β (SE) p-value Standardised β (SE) p-value
PCS
Swollen joint count −0.19 (0.05) < 0.001 −0.06 (0.08) 0.412
Tender joint count 0.00 (0.05) 0.977 −0.08 (0.09) 0.370
ESR −0.08 (0.04) 0.036 0.03 (0.07) 0.676
Patient global assessment −0.45 (0.05) < 0.001 −0.36 (0.08) < 0.001
MCS
Swollen joint count −0.12 (0.06) 0.029 0.05 (0.08) 0.527
Tender joint count 0.15 (0.05) 0.003 −0.16 (0.09) 0.080
ESR −0.12 (0.04) 0.008 0.00 (0.07) 0.974
Patient global assessment −0.43 (0.05) < 0.001 −0.33 (0.08) < 0.001
β, β-coefficient; SE, standard error.
Reproduced with permission from Scott et al.209 This is an Open Access article distributed in accordance with the terms
of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build
upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/
licenses/by/4.0/. The table includes minor additions and formatting changes to the original table.
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Predictive factors: high baseline Health Assessment Questionnaire score as an
outcome predictor
A second approach to predicting outcomes used initial HAQ scores alone. The value of baseline HAQ
scores in predicting outcomes was assessed in 558 patients in early and established RA trials73,74 and
752 patients followed over ≥ 3 years in the observational study.
In both trials,73,74 patients with low baseline HAQ scores (≤ 1.50) had significantly more good EULAR
responses (both p = 0.013) and significantly lower final mean DAS28-ESR scores (both p > 0.001) than
patients with high baseline HAQ scores (> 1.50). These differences are shown in Figure 13. In the
observational study, patients with low baseline HAQ scores had significantly lower overall mean
DAS28-ESR scores (p < 0.001). In both trials, patients with high initial HAQ scores (> 1.50) had the
largest end-point decreases in HAQ score if they achieved good EULAR responses. The observational
study showed the same pattern.
Sequential changes in DAS28-ESR scores in both trials73,74 and the observational study showed that
patients with low baseline HAQ scores had lower mean DAS28-ESR scores at all subsequent follow-up
time points (Figure 14). The pattern of response was similar in all three groups, although the difference















































































FIGURE 14 Sequential changes in mean DAS28-ESR scores in patients with high (> 1.50) and low (≤ 1.50) baseline HAQ
scores. Standard errors are shown. (a) Early RA trial;73 (b) established RA trial;74 and (c) observational study. (continued )
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The relationship between baseline HAQ scores, subsequent remissions during treatment and changes in
HAQ scores with treatment are shown in Table 5. The analysis shows two main things. First, patients with
high baseline HAQ scores had significantly fewer remissions. Second, when remissions occurred, especially




























FIGURE 14 Sequential changes in mean DAS28-ESR scores in patients with high (> 1.50) and low (≤ 1.50) baseline HAQ
scores. Standard errors are shown. (a) Early RA trial;73 (b) established RA trial;74 and (c) observational study.




HAQ score (95% CI)
Difference in HAQ
score (95% CI)Initial Final
CARDERA trial73 ≤ 1.50 None 1.01 (0.93 to 1.09) 1.04 (0.92 to 1.16) 0.03 (0.09 to 0.15)
One 0.92 (0.75 to 1.08) 0.72 (0.53 to 0.92) –0.19 (–0.46 to 0.08)
Two or more 0.93 (0.81 to 1.05) 0.37 (0.24 to 0.50) –0.56 (–0.71 to –0.40)
> 1.50 None 2.14 (2.08 to 2.19) 1.04 (0.71 to 1.36) –0.89 (–1.28 to –0.51)
One 1.93 (1.80 to 2.06) 1.04 (0.71 to 1.36) –0.89 (–1.28 to –0.51)
Two or more 2.03 (1.90 to 2.16) 0.65 (0.40 to 0.89) –1.38 (–1.62 to –1.14)
TACIT trial74 ≤ 1.50 None 1.18 (1.07 to 1.29) 0.94 (0.74 to 1.15) –0.24 (–0.44 to –0.03)
One 0.97 (0.76 to 1.18) 0.28 (0.01 to 0.55) –0.69 (–1.11 to –0.27)
Two or more 0.93 (0.73 to 1.12) 0.53 (0.33 to 0.74) –0.39 (–0.56 to –0.22)
> 1.50 None 2.25 (2.18 to 2.33) 2.00 (1.88 to 2.12) –0.26 (–0.35 to –0.16)
One 2.22 (2.07 to 2.38) 1.79 (1.50 to 2.09) –0.43 (–0.63 to –0.23)
Two or more 2.07 (1.95 to 2.19) 1.30 (1.07 to 1.54) –0.77 (–1.00 to –0.54)
Observational study ≤ 1.50 None 0.87 (0.78 to 0.97) 1.29 (1.16 to 1.42) 0.42 (0.27 to 0.56)
One 0.83 (0.70 to 0.96) 1.09 (0.92 to 1.26) 0.25 (0.06 to 0.44)
Two or more 0.73 (0.62 to 0.84) 0.67 (0.51 to 0.83) –0.06 (–0.22 to 0.09)
> 1.50 None 2.16 (2.10 to 2.22) 2.11 (2.01 to 2.20) –0.04 (–0.13 to 0.04)
One 2.09 (1.97 to 2.21) 1.92 (1.72 to 2.13) –0.17 (–0.40 to 0.07)
Two or more 2.08 (1.95 to 2.22) 1.49 (1.24 to 1.75) –0.59 (–0.81 to –0.36)
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Predictive factors: anxiety and depression
The final approach to predicting outcomes assessed the impact of anxiety and depression using EQ-5D,
which were related to outcomes in 379 patients in an early RA trial73 using linear regression models.
In unadjusted regression models, patients with moderate and high levels of depression and anxiety at
baseline had higher HAQ and DAS28-ESR scores over time and at the trial end point. After adjusting
for age, sex, disease duration, time, treatment type, baseline HAQ and DAS28-ESR scores and
rheumatoid factor status, there were no longer between-group differences for HAQ score (Table 6).
However, there continued to be a significant relationship between high levels of depression and
anxiety at baseline and higher end-point DAS28-ESR scores.
At the trial end point, 80 (21%) patients had remissions (i.e. DAS-28 scores < 2.6). Patients with
moderate levels of depression and anxiety at baseline had fewer clinical remissions than patients with
no depression and anxiety at baseline [odds ratio (OR) 0.50, 95% CI 0.29 to 0.88; p = 0.02]. Patients
with high levels of depression and anxiety symptoms at baseline also had reduced odds of reaching
remission; however, this comparison was not significant (OR 0.77, 95% CI 0.25 to 2.33; p = 0.64). This
is likely to reflect the small number of patients with extreme symptoms at baseline (n = 24), reducing
the power to find a significant effect because of an imprecise estimate.
Limitations
Studies in this section were limited because they involved secondary analyses of previously collected
data, omitted rheumatoid factor when predicting outcomes and enrolled patients using different
classification criteria for RA compared with the TITRATE trial.
Secondary analyses of existing data
Most studies in this section were post hoc analyses of existing data. They did not address prespecified
hypotheses. As a consequence, caution is needed interpreting their significance.
Rheumatoid factor and other autoantibodies
The prognostic studies did not consider the impact of rheumatoid factor isotypes or anti-citrullinated
peptide antibodies. These are recognised response predictors that, together with smoking status, are
linked to rheumatoid factor positivity.231–234 However, as autoantibodies are measured in many different
ways across centres, it is impractical to use them in current clinical practice studies. Smoking status is
also not usually recorded in routine clinical practice.
Diagnostic criteria and intensive management strategies
Rheumatoid arthritis patients in all studies assessed were enrolled before the introduction of new
diagnostic criteria for the classification of RA. There is evidence that these new criteria change the
patients classified as having RA, particularly patients with seronegative disease.45,235–238 The TITRATE
trial uses the most recent criteria and it would have been a mistake not to do so. This change makes it
difficult to relate historical findings exactly to new data.
The trials studied did not involve the same intensive management strategies used in the TITRATE
programme and the impact of changing treatment in patients who did not achieve sustained
remissions was not examined. These are general limitations with all trials involving intensive
management strategies.239–244
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0.21 (0.12) 0.30 0.08 0.59 (0.29) 0.42 0.04 0.06 (0.15) 0.09 0.68 0.07 (0.15) 0.09 0.64 8.72 (4.54) 0.40 0.06 0.38 (0.17) 0.44 0.02
ESR, erythrocyte sedimentation rate; PGA, patient global assessment; SE, standard error; SJC, swollen joint count; TJC, tender joint count.
a Primary outcomes model adjusted for age, gender, disease duration, time, baseline HAQ and DAS, treatment type and RF status. Secondary outcomes model adjusted for age, gender, disease duration, time, baseline SJC/ESR/PGA/or TJC,
treatment type and RF status.
Note
Reproduced with permission from Matcham et al.207 This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) license, which permits others to distribute,
























































Relation to overall programme
Our findings in this section focused on the impact of different durations of remission, the effect of
alternative remission assessments and the role of simple outcome predictors.
Duration of DAS28-ESR remission
We found that achieving sustained DAS28-ESR remission gave the greatest chance of minimising
disability and maximising health-related quality of life; however, this was uncommon, reflecting
international experience with sustained remission.217,245–249 More patients benefited when the treatment
target was to achieve DAS28-ESR remission at any time during follow-up.
End-point remission and low disease activity were both reasonable targets.
Other assessments of remission
Disease Activity Score for 28 joints based on ESR scores were dominated by the ESR at low levels and
in remission. Other composite disease activity assessments, such as CDAI and RAPID3, show different
patterns in their components as disease activity changes. However, there was no reason to favour
one composite index over another. These findings reflect the ongoing debate about how best to use
composite indices in assessing RA disease activity.250–254 We also found that patient global assessment,
a component of most composite measures, was most closely associated with patient-assessed health-
related quality of life. Several other recent reports255–257 have highlighted the importance of patient
global assessments in RA.
Simple outcome predictors
Poor outcomes were predicted by several simple baseline measures, including a simple four-point
predictive score, initial HAQ score and the presence of anxiety and depression. The situation with the
HAQ was complex, as the largest improvements with treatment were seen in patients who had high
initial HAQ scores and then showed substantial clinical improvements and achieved remission. Other
research has highlighted the relevance of baseline HAQ score258–261 and depression262–265 in predicting
RA outcomes.
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The studies in this section helped establish how best to provide intensive management to patientsand evaluated patients’ expectations and identified practical approaches for delivering care.
This part of the research had considerable PPI.
Aims
Research studies with four related aims are included in this section. These aims comprised assessment
of patients’ expectations, development of a patient handbook and clinician training manual, and design
of supportive material, including a training course for rheumatology practitioners. There was
considerable PPI in this part of the research. Four of these papers have been published.266–269
The overall objective of workstream A was patient-led development and implementation of an
experimental intensive management strategy for patients with RA with moderate disease activity.
The qualitative research was pragmatic and specific in its nature, namely to examine the acceptability,
development and evaluation of the intensive management intervention. A more phenomenological
approach would have provided richer data, but such a perspective would have been unsuitable for the
aims and objectives of the work package.
Qualitative study of patient expectations
We explored the views and expectations of patients with moderately active RA and their carers about
intensive management strategies. Several previous reports have examined the views of patients with
more active RA.270–272
Patient handbook
We developed a patient handbook to support patients who received intensive management, and this
reflects growing recognition of the importance of the involvement and shared decision-making of patients
in their disease management.273–277 Patients helped to identify relevant information and ensured that its
content was acceptable and accessible.
Clinician training manual
We developed a training manual to support clinicians to deliver intensive management. During the
development of the manual, we systematically reviewed the evidence for psychological approaches,
in general, and motivational interviewing (MI) to incorporate psychological approaches to support
patients receiving intensive management. Psychological interventions are likely to be beneficial as
adjunctive treatments for pain, fatigue and psychological distress in RA.278 Health-care professionals
can be trained to deliver psychological interventions to support patients with common long-term
disorders,279 and MI fits this niche.280,281
Motivational interviewing was identified as a candidate psychological technique because the trial
research questions focused on treat-to-target approaches. Stopping, starting and changing medications
and doses is a behaviour. Therefore, the intervention required a behavioural approach to support
discussions about medication, which could lead to assessment of motivation for behaviour change in
routine care by specialist nurses. The clinical and research expertise of Jackie Sturt, the academic lead
for the psychological intervention component, identified the potential of MI to deliver the required
behavioural changes around medication changes. Researchers undertook a review of the evidence to
understand whether or not MI had been used experimentally in RA and the ways in which MI had
been used in long-term condition self-care behaviours in general. The wealth of evidence in many
long-term conditions and the absence of evidence in RA confirmed our decision to use MI. We considered
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it a good fit from both the clinical and theoretical perspectives. In addition, we noted that there was no
existing evidence base for its use in this population.
Other developmental activities
Two other developments did not require primary research: (1) to devise treatment plans to capture
patients’ views about their treatments and (2) the development of training courses for clinicians to
deliver intensive management.
Methods
Qualitative studies of patient expectations
Focus groups and one-to-one interviews were conducted with nine patients with RA and five carers
from four rheumatology clinics in three London hospitals. Two non-English-speaking patients were
included and were assisted by a professional translator. The groups and interviews were audio-recorded,
transcribed and assessed using a framework analysis approach.282 Details of the patients and carers are
shown in Appendix 1, Table 32.
Audio-recordings were transcribed verbatim. Transcripts were analysed by the researcher (LP). A
second rater (HL) appraised the emergent themes from the transcripts and consensus between both
researchers was reached. The transcripts were analysed using a framework analysis approach.283
The process of framework analysis involves a series of stages: (1) familiarisation, (2) identification of
a thematic framework, (3) indexing, (4) charting and (5) mapping and interpretation.
A combined inductive–deductive approach was taken, as the study had some specific issues to explore;
however, it still allowed space to discover participants’ views and concerns. The codes were based on
an iterative process that incorporated both the research question and line-by-line analysis of two
patient and two carer transcripts. The remaining data were indexed in a systematic way in accordance
with the thematic framework. Where new codes were identified, previously indexed interview
transcripts were re-read to ensure that all relevant data were coded.283,284
Patient workshop
Handbook development was facilitated by an audio-recorded workshop that involved six patients, with
another patient giving more feedback via e-mail. None had substantial prior knowledge of intensive
management. The workshop transcript was analysed using thematic content analysis.285
Systematic reviews
Two systematic reviews were undertaken, searching MEDLINE and other databases using predefined
terms. The first assessed systematic reviews of psychological interventions in RA. The second assessed
MI in musculoskeletal diseases. Full details of these systematic reviews are given in Report Supplementary
Material 1 and 2, including a PRISMA flow diagram (see Report Supplementary Material 1, Figure 5) and
details of the included studies (see Report Supplementary Material 1, Tables 6–8).
Key findings
Patients’ and carers’ views and expectations
Patients’ and carers’ views about intensive management spanned several themes and are shown in
Tables 7 and 8. One theme was treatment expectations (i.e. patients want to have improved physical
symptoms, reduced pain, increased mobility and greater independence). A second theme was increased
medication. Patients had varying views about taking more medication, subject to the stability and
benefits of their current treatment regimens. Most patients did not receive drug combinations that
fully controlled their RA and they were willing to try more intensive managements, despite concerns
DELIVERING INTENSIVE MANAGEMENT
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TABLE 7 Accounts relating to hopes and expectations
Physical Outcomes
Reduce pain Maybe my general pain in my body will be reduced by this treatment . . . I have got constant
pain in my body
(Patient 9, male, 46 years)
Improve mobility Since 2006, I have to keep walking with my stick and if I don’t do that, sometimes I fall.
Imagine if one day I could put it away . . . I see some people when they do the intensive
management that happens to them
(Patient 1, female, 52 years)
Stabilise RA So as long as it (the RA) don’t get any worse . . . doesn’t spread to other parts of the body and you
can contain it, then I think that’s fair enough . . . If it’s stabilised, that’s as good as it’s going to get
(Carer 3, male, 71 years)
Reduce fatigue Well I would like to be a bit more active, because I do get fatigue quite a lot
(Patient 2, female, 62 years)
Increased Independence
Rely less on family . . . if you have got a wonderful family like I have got who . . . I could sit about and do nothing
all day. Because they would say ‘I’ll do it, Mum you can’t do it, I’ll do it’. So a bit more
independence is what I would like
(Patient 4, female, 62 years)
Engage in more activities It’s so frustrating; because there are things I want to do and I can’t . . . I can’t lift a kettle up if
it’s too full
(Patient 6, female, 64 years)
I think if something could help her [patient] get that lifestyle back, where she could still do
her own bits. She used to be a chef, so her not being able to cook, I think is one of the
hardest things for her
(Carer 1, female, 26 years)
Note
Patients’ and carers’ views and expectations about intensive management for moderate rheumatoid arthritis: a
qualitative study, Prothero et al.,269 Psychology, Health & Medicine, 2016, reprinted by permission of the publisher
(Taylor & Francis Ltd, www.tandfonline.com).
TABLE 8 Accounts relating to acceptability
Increased Medication
Positive views Yes, [I would try intensive management] anything that could be positive, because if it doesn’t
work, it doesn’t work, we go and try another one [treatment]
(Patient 1, female, 52 years)
Negative views Well at the moment we’re [carer and patient] doing fine . . . having had one very bad flare up
about three years ago [patient], I should hate for that to happen again and I’ll be very
apprehensive in changing the medication now. working, it’s balanced. Everything is nice and stable
(Carer 3, male, 71 years)
Monthly Appointments
Positive views I wouldn’t mind . . . I would like to be able to sit down with someone, someone break down
what these numbers mean from her [Mother’s] blood test . . . I just feel that if someone saw her
[Mother] a bit more frequently the medication could be changed as soon as it [RA] gets worse
(Carer 1, female, 26 years)
Negative views How would I feel about it [attending monthly appointments]? Well, personally [hesitates] it
would be a pain wouldn’t it really going up there [to the clinic] once a month? I know that
sounds really ungrateful and I don’t mean that . . . what I mean is perhaps it [monthly
appointments] might be a bit too much
(Patient 4, female, 62 years)
Note
Patients’ and carers’ views and expectations about intensive management for moderate rheumatoid arthritis: a
qualitative study, Prothero et al.,269 Psychology, Health & Medicine, 2016, reprinted by permission of the publisher
(Taylor & Francis Ltd, www.tandfonline.com).
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about potential side effects. Intensive management involved more frequent clinic appointments, but
these were generally acceptable to patients and carers.
Tables 7 and 8 provide both positive and negative views, reflecting variation in participant responses.
The findings identified that there was variation depending on individual circumstances.
Patients’ educational needs formed another theme. Some patients would readily take ‘whatever is
prescribed’. Most wanted some information. A few preferred as much information as possible. An
intervention needs to cater for all these requests. Continuity of care formed the final theme. Patients
liked to see ‘their own’ rheumatologist and were concerned this specialist would ‘not know what has
been happening’ when they saw different clinicians.
Development of the patient handbook: workshop for patients
Patients made several recommendations about the handbook content. They suggested that it include
information on (1) the aims of intensive management, (2) its benefits above standard care and (3) the
importance of patient’s active engagement with the trial.
The handbook included information about intensive management and what this would involve
(e.g. monthly blood tests), including guidance on self-management (the contents of which were informed
by the aims of the intervention) to help patients identify and work on key areas where they may be
challenged (e.g. pain, fatigue, physical activity, medication adherence and low mood/anxiety).
Two researchers (SG and LP) collected information, for example current treatments for RA, intensive
management in the TITRATE programme and self-management of life with RA. The information was
gathered from evidence-based sources, including publications and current clinical guidelines, expertise
from medical and allied health practitioners, and online sources from national charities National
Rheumatoid Arthritis Society (NRAS) and Arthritis Research UK. The relevant information was then
collated by one of the researchers (SG) into a draft handbook across nine sections.268 Further details
are given in Appendix 3.
Developing training manual: evidence for psychological support
Our systematic review of reviews on psychological support in RA identified eight relevant
publications.278,286–292 These systematic reviews all showed that psychological treatments resulted in
significant improvements in functional disability, pain, fatigue, self-efficacy and coping in analyses of
between 4 and 27 trials. The key findings are shown in Table 9. The effect sizes for these different
interventions ranged from –0.09 for pain to 0.46 for coping.
Developing training manual: evidence for motivational interviewing
Our systematic review identified seven relevant studies,293–299 including one systematic review,294
two clinical trials,293,298 two pilot studies297,299 and two interventional studies.295,296
The systematic review by Chilton et al.294 evaluated five trials of MI for the treatment of pain, fibromyalgia
and osteoporosis. Although, overall, its findings were inconclusive because of the heterogeneity of the
studies involved, it included considerable evidence favouring the use of MI.
The other six original research studies,293,295–299 which comprised clinical trials, pilot studies and interventional
studies, also all provided some evidence in favour of using MI in these patients. Three studies293,295,299
were most relevant to the TITRATE programme. First, the trial of Ang et al.293 showed short-term benefits
on physical activity and clinical outcomes from six MI sessions. The pilot study of Ferguson et al.299
provided some evidence that MI improved adherence with treatment. Finally, the interventional study
of De Gucht295 showed that patient education that involved MI resulted in increased physical activity.
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TABLE 9 Summary of effect sizes in selected systematic reviews






Disease activity/severity Nyssen et al. (2016)291 Post intervention –0.02 –0.37 to 0.32 p = 0.89, NS 3 10
Follow-up –0.61 –0.96 to –0.26 p < 0.001 3 10
Patient global assessment Riemsma et al. (2003)292 Post intervention –0.30 –0.55 to –0.04 p = 0.02 4 11
Tender and swollen joints Astin et al. (2002)278 Post intervention 0.15 –0.09 to –0.39 NS 7 6
Follow-up 0.30 0.04 to –0.56 p = 0.005 5 6
Inflammation Nyssen et al. (2016)291 Post intervention 0.10 –0.34 to 0.53 p = 0.67, NS 3 10
Functional disability Astin et al. (2002)278 Post intervention 0.27 0.12 to –0.42 p < 0.001 12 6
Follow-up 0.12 –0.09 to –0.33 NS 7 6
Riemsma et al. (2003)292 Post intervention –0.23 –0.36 to –0.10 p < 0.001 27 11
Follow-up –0.10 –0.23 to 0.02 p = 0.10, NS 18 11
Knittle et al. (2010)289 Post intervention 0.32 0.13 to 0.51 p < 0.001 17 6
Pain Astin et al. (2002)278 Post intervention 0.22 0.07 to –0.37 p = 0.003 13 6
Follow-up 0.06 –0.17 to –0.29 NS 6 6
Riemsma et al. (2003)292 Post intervention –0.09 –0.19 to 0.02 p = 0.10, NS 26 11




























































































































































































































































































TABLE 9 Summary of effect sizes in selected systematic reviews (continued )






Fatigue Cramp et al. (2013)287 Post intervention –0.24 –0.40 to –0.07 Significant 13 11
Depression Astin et al. (2002)278 Post intervention 0.15 –0.01 to –0.31 p = 0.03 12 6
Follow-up 0.33 –0.07 to –0.59 p = 0.01 5 6
Riemsma et al. (2003)292 Post intervention –0.14 –0.25 to –0.04 p = 0.009 13 11
Follow-up 0.12 –0.25 to 0.01 p = 0.07, NS 13 11
Knittle et al. (2010)289 Post intervention 0.23 0.06 to 0.39 p = 0.01 19 6
Anxiety Knittle et al. (2010)289 Post intervention 0.17 0.02 to 0.32 p = 0.03 11 6
Self-efficacy Astin et al. (2002)278 Post intervention 0.35 0.11 to 0.59 p = 0.017 5 6
Follow-up 0.20 –0.08 to –0.48 NS 3 6
Coping Astin et al. (2002)278 Post intervention 0.46 0.09 to 0.83 p = 0.007 4 6
Follow-up 0.52 –0.07 to –1.11 p = 0.04 3 6
Physical activity Knittle et al. (2010)289 Post intervention 0.47 0.12 to 0.83 p = 0.009 4 6
Follow-up 0.36 0.06 to 0.67 p = 0.02 4 6
NS, non-significant; RCT, randomised controlled trial.
Note
Reprinted from International Journal of Nursing Studies, vol. 82, Prothero et al.267 The evidence base for psychological interventions for rheumatoid arthritis: a systematic review of














































Completed patient handbook and clinician training manual
Based on these studies and associated developmental work, the handbook and training manual were
finalised and used throughout the TITRATE trial.
Other developmental work
Activities that did not require primary research were the creation of a treatment plan for individual
patients and devising a 2-day training course for specialist nurses and other clinicians involved in
intensive management in the TITRATE trial. The course involved group-based participative experiential
workshops over 2 days. It incorporated psychological and behavioural approaches to deliver supportive
care together with clinical assessment and pharmacological prescribing algorithms to ensure that
patients were able to receive intensive management. These were supplemented by remote one-to-one
support while practitioners delivered the TITRATE intervention to their first three patients.
Limitations
The main limitations of the research in this section were doubts about the extent patients’ views
should be generalised and limitations in evidence to support intensive management.
Generalisability of patients’ views
The patients’ and carers’ perspectives in the qualitative study and in the development of the handbook
might not be generalisable to all patients with moderate RA. Some patients might have very different
perspectives, although focus groups allow insights into the wide range of views that participants had
about a specific issue, as well as how they interacted in a more ‘naturalistic’ setting.300,301
Limitations of evidence
Although the manual and training course for clinicians delivering intensive management were evidence
based, they had to reflect a range of expert opinions on management in addition to evidence-based
care. There are also complex issues in the assessment of patients’ perspectives. For example, as RA
predominantly affects women, the views of men with RA may be overlooked.302
Participants were given the option of taking part in a focus group or a semistructured interview
(in-person or via telephone). The reason for this was to provide choice to participants, minimise
participant burden and also accommodate those experiencing RA symptoms. Focus group and
semistructured interview data were analysed in the same way. This is a limitation of the study, as
semistructured interviews are more suited to exploring individual experiences and focus groups more
exploratory research. Telephone interviews were advantageous in this study for participants who may
not have had the time or ability to take part had the interview been in person.
Relation to overall programme
Studies in this section focused on information and training needs. The studies highlighted the diversity
of patients’ views and needs and showed the importance of developing a range of supportive material
for patients.
Patients’ perspectives
Patients and carers had a range of views on intensive management. As they want improved physical
symptoms and greater independence, most will try intensive management and accept the need for
frequent appointments. However, they want sufficient information and continuity of care.
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Supportive material
We developed a patient handbook and clinician training manual, which included patients’ views and
the evidence about psychological interventions, and a training course for clinicians delivering intensive
management. There is evidence that techniques such as MI can be used by clinicians after relatively
brief training280 and that MI is relevant for patients with RA.
DELIVERING INTENSIVE MANAGEMENT
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The TITRATE trial
This section reports the main results from the TITRATE trial, which formed the centrepiece ofthe programme. Previous sections have provided the rationale for the trial. These include the
continuing high frequency of moderate RA, which is often associated with substantial disability,
the extensive evidence that intensive management is effective and can increase remission rates,
and the observational evidence that when patients with moderate RA achieve remission they have
overall reductions in disease activity and disability subsequently.
Aims
The largest group of RA patients attending specialist clinics continue to have moderately active
established RA and receive conventional synthetic DMARDs. These patients have potentially poor
long-term outcomes.303 The crucial unresolved question is whether or not intensive management will
benefit them. The evidence in previous sections shows only one trial from the prebiologic era – the
BROSG (British Rheumatoid Outcome Study Group) trial184 – that evaluated intensive management
regimens in such patients. It reported only modest non-significant increases in remissions with
intensive management.
The TITRATE trial bridges the gap in current evidence. It studied moderately active established RA
patients receiving conventional synthetic DMARDs seen in specialist clinics. It tested the hypothesis
that intensive management using drug therapy and a treatment support programme of non-drug
approach given by specialist nurses resulted in higher remission rates than standard care.
In addition to optimising drug therapy, specialist nurses can provide holistic care to RA patients using
other non-drug approaches. The TITRATE trial therefore also explored whether or not non-drug
management by nurses can improve general symptoms such as pain and fatigue304–306 at the same time
as delivering intensive management within a treat-to-target approach. The trial protocol was designed
with substantial input and advice from patients and their carers. The TITRATE trial protocol and main
trial findings have been published.307,308
Methods
Design
This was an open-label 12-month pragmatic randomised multicentre, two-arm, parallel-group
superiority trial.
Participants
Patients were recruited from 39 English rheumatology centres. Included patients were males and
females aged > 18 years who met the 2010 RA classification criteria,309 had received at least 6 months’
treatment with conventional DMARDs, were currently receiving at least one DMARD, had moderate/
intermediate disease activity (defined as a DAS28-ESR score of 3.2–5.1 with three or more swollen
and/or tender joints out of 66/68 and at least one swollen joint) and who were able and willing to
follow intensive management. Excluded patients included patients who had comorbidities that made
intensive treatment inadvisable; in whom treatment with five or more DMARDs had failed; who had
taken biologics; who had irreversible disability from extensive joint damage; who were women who
were pregnant, breastfeeding or at risk of conceiving; who had recently been in another trial; or who
were currently on an early RA pathway.310
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Clinicians followed local RA pathways for managing intermediate/moderate disease activity patients,
which reflected national guidance.304 There was no management goal, no specific treatment plan and
no predefined follow-up plan.
Intensive management
Intensive management was delivered by rheumatology nurses or comparable health-care professionals
trained to follow a predefined treatment support programme. Patients were reviewed monthly.
The nurses (1) assessed patients’ RA and general functioning, (2) evaluated their drug treatment,
(3) modified the drug treatment using a decision tool that reflected a ‘shared treatment plan’ that
was planned together with patients during the first visit and (4) provided structured psychoeducation
support using MI techniques.
Intensive management in the TITRATE trial spanned four strands:
1. Patients received information about their RA together with a handbook that outlined intensive
treatments, possible medication side effects and ways of coping with the impact of RA on
everyday life.
2. Drug treatment with conventional DMARDs and biologics was optimised following a treatment
algorithm, which recommended options based on previous treatment, present treatment,
contraindications, the patient’s preferences and clinical assessments.
3. Patients were given an intramuscular steroid injection if arthritis was not fully controlled.
4. Patients were provided with ‘treatment support’, with a particular focus on pain and fatigue
management, physical activity, medication adherence, sleep and low mood/anxiety.
All medication given to patients was in accordance with national guidance from NICE or the national
specialist society (i.e. the British Society for Rheumatology).311
Assessments
All measures were assessed at baseline and at 6 and 12 months, except radiographs, which were
taken at baseline and at 12 months. In addition, psychosocial measures (i.e. mood, anxiety, health
beliefs and illness perceptions) were measured at baseline. Individual assessments were combined in
composite indices [i.e. DAS28-ESR, Disease Activity Score for 28 joints based on C-reactive protein
levels (DAS28-CRP), SDAI and CDAI]. A record was made of DAS28-ESR low disease activity states
(i.e. a score of ≤ 3.2). Further details are given in Appendix 2.
Primary outcome measure
The primary outcome measure was DAS28-ESR remission (i.e. a DAS28-ESR score of < 2.6) at
12 months.212,312 Alternative remission definitions consisted were a DAS28-CRP score of < 2.6, a SDAI
score of ≤ 3.3, a CDAI score of ≤ 2.8 and ACR/EULAR Boolean remission at 12 months.212,218,313,314
Secondary outcome measures
Secondary outcome measures included tender joint counts (28 and 68 joints), swollen joint counts
(28 and 66 joints), ESR, CRP level, patient global assessments on 100-mm visual analogue scales
(VASs), assessor global assessments on 100-mm VASs, pain and fatigue on 100-mm VASs, the HAQ,228
EuroQol-5 Dimensions, five-level version (EQ-5D-5L), score,315 plain-film radiographs of the hands and
feet (scored using a modified Larsen score)316 and adverse events.
Sample size calculation
The most relevant UK trial129 compared treat to target with standard care in active early RA. Sixteen
per cent of patients receiving standard care had end-point Disease Activity Score (DAS) remission.129
THE TITRATE TRIAL
NIHR Journals Library www.journalslibrary.nihr.ac.uk
42
We assumed that standard care in the TITRATE trial would also lead to 16% of patients achieving
end-point DAS28-ESR remissions. We proposed rejecting the null hypothesis (i.e. RA patients with
intermediate disease activity on DMARDs have no more remission after 12 months of intensive
management) if intensive management increased remission at 12 months by ≥ 15%. Demonstrating this
difference with 5% significance and 90% power meant randomising 358 patients (179 patients per
group). We ended recruitment, for organisational reasons, after 3 years and when 335 patients were
randomised (i.e. 94% of the planned sample size).
Randomisation
Potentially eligible patients were screened and reasons for non-entry recorded. Consenting patients
were individually randomised using block randomisation with randomly varying block sizes. Stratifying
by site ensured prerandomisation allocation concealment. Patients were randomised to intensive
management or standard care in a 1 : 1 ratio. All staff involved in the conduct of the trial were
unaware of the allocation sequence.
Blinding
The TITRATE trial was un-blinded, as patient involvement in their intensive management made blinding
impossible. Independent assessors uninvolved in managing trial patients undertook clinical assessments.
No specific checks were made on their knowledge of patients’ treatments. Pain, fatigue, disability and
quality of life were self-assessed by patients. Radiographic reading was blinded to treatment group.
Statistical methods
Baseline characteristics were summarised by randomisation group as means and SDs and frequencies
and percentages (categorical variables).
Randomised patients who received treatment were assessed on an intention-to-treat (ITT) basis. All
participants had complete observations at baseline. Missing data at follow-up were imputed regardless
of the reason(s) that they were missing. For subjects with missing outcomes, the baseline outcomes
and other explanatory covariates (i.e. treatment group, sex, age, ethnicity, NHS region and disease
duration) were used to impute the missing outcome data using predictive mean matching (PMM)
with five nearest neighbours, assuming that unobserved measurements were missing at random
(see Appendix 3 for detailed imputation descriptions).
A logistic regression analysis was used to analyse the primary outcome of remission at 12 months.
Univariate analyses were adjusted for NHS region (design variable). Multivariable analyses were
adjusted for sex, ethnicity, age, NHS region and disease duration. Alternative remission definitions
were analysed similar to the primary outcome measure. Linear regression evaluated change at
12 months for the continuous primary outcome (i.e. DAS28-ESR) and secondary outcome measures.
For primary and secondary analyses that involve longitudinal measurements, linear mixed models were
used to estimate the effect of treatment. Working correlation matrices were unstructured, which is not
unduly complicated given that measurements were taken at three time points. Interactions between
time and treatment group were also assessed in these models.
Valid/robust estimates of the precision of effects were obtained through use of the information
sandwich estimator for all analyses. The estimates for primary outcome were presented as ORs with
95% CIs for the effect of intensive management. Statistical significance was determined at the 5% level
using a two-sided test throughout. Serious adverse events and adverse rates in the two treatment
arms were compared using comparisons of two independent proportions. Finally, complete-case
analyses were also undertaken, which evaluated patients who followed the protocol and received
12 months’ treatment. All analysis was carried out using Stata® (StataCorp LP, College Station, TX, USA).
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Between August 2014 and July 2017, a total of 1405 patients were invited to participate, 459 patients
were screened and 335 patients were randomised and treated (Figure 15). Of the randomised patients,
303 of 335 (90%) patients provided a primary outcome measure at 12 months, including three patients
who withdrew but agreed to medical review only. Thirty-two (10%) patients were lost to follow-up.
Patients not eligible after screening
(n = 118)
• DAS28 score too high, n = 70
• DAS28 score too low, n = 24
• Fewer than three active joints, n = 8
• No swollen joints, n = 9
• Treatment (on biologic), n = 1
• Disease duration too long or too short, n = 1
• Signif icant comorbidities, n = 1
• Other, n = 4





























• Patient died, n = 1
• Patient decision, n = 6
• Unable to contact, n = 7
• Discontinued intervention but agreed
    to medical note review only, n = 2
Lost to follow-up
(n = 14)
• Patient died, n = 2
• Patient decision, n = 6
• Unable to contact, n = 8
• Unable to travel, n = 1
• Other, n = 1
• Discontinued intervention but agreed
    to medical note review only, n = 1
Lost to follow-up
(n = 18)
• Not interested in research, n = 241
• Did not want to change treatment, n = 84
• Personal circumstances, n = 200
• Other patient refusal, n = 168
• Willing but not eligible, n = 253
Not consented
(n = 946)
• Patient not eligible, n = 118a
• Patient withdrew consent, n = 4
• Other, n = 2
Screen failures
(n = 124)
• ITT, n = 168
• Completer, n = 134
Analyses
• ITT, n = 167
• Completer, n = 124
Analyses
• Received intervention, n = 168
Intensive management arm
• Received intervention, n = 167
Standard care arm
FIGURE 15 A CONSORT (Consolidated Standards of Reporting Trials) flow diagram for the TITRATE trial. Reproduced
with permission from Scott et al.308 This is an Open Access article distributed in accordance with the terms of the
Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this
work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
The figure includes minor additions and formatting changes to the original figure.
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Baseline data and numbers analysed
Demographic and disease assessments were similar in both patient groups (Table 10). The ITT analysis
included all 335 randomised patients (168 patients received intensive management and 167 patients
received standard care). The complete-case analysis, in which all data were present, comprised
258 patients (134 patients received intensive management and 124 patients received standard care).
Additional baseline data are provided in Appendix 4, Table 38.
TABLE 10 Baseline characteristics and assessments
Assessment
Treatment group
Intensive management (N= 168) Standard care (N= 167)
Demographic
Age (years), mean (SD) 56.4 (12.2) 56.8 (12.0)
Disease duration (years), mean (SD) 6.6 (7.0) 5.2 (5.5)
Female, n (%) 140 (83) 130 (78)
Clinical assessment, mean (SD)
DAS28-ESR 4.4 (0.5) 4.3 (0.5)
DAS28-CRP 4.5 (0.6) 4.5 (0.6)
CDAI 19.7 (6.5) 20.4 (6.8)
SDAI 20.6 (6.3) 21.1 (6.6)
Tender joint counts (68 joints) 12 (9) 13 (9)
Swollen joint counts (66 joints) 6 (5) 5 (4)
ESR (mm/hour) 18 (14) 15 (13)
CRP (mg/l) 8 (11) 7 (8)
Assessor global rating (mm) 39 (18) 41 (18)
Patient global assessment (mm) 43 (19) 46 (21)
Fatigue VAS (mm) 59 (25) 52 (25)
Pain VAS (mm) 40 (23) 43 (23)
HAQ 1.2 (0.7) 1.2 (0.7)
EQ-5D-5L 0.71 (0.16) 0.70 (0.19)
Larsen score 11 (17) 9 (11)
Drug treatment, n (%)
Oral methotrexate 59 (35) 67 (40)
Subcutaneous methotrexate 22 (13) 19 (11)
Sulfasalazine 30 (18) 19 (11)
Leflunomide 12 (7) 11 (7)
Hydroxychloroquine 29 (17) 37 (22)
Azathioprine 1 (1)
Oral methotrexate/hydroxychloroquine 7 (4) 8 (5)
Oral methotrexate/sulfasalazine 2 (1) 1 (1)
Subcutaneous methotrexate/hydroxychloroquine 3 (2) 2 (1)
Subcutaneous methotrexate/sulfasalazine 2 (1)
Sulfasalazine/hydroxychloroquine 1 (1) 3 (2)
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Baseline treatments
All patients were taking one conventional DMARD and 15 of 168 (9%) intensive management patients
and 14 of 168 (8%) standard care patients took two DMARDs. Methotrexate was the main conventional
DMARD and was taken by 81 patients in the intensive management group and 86 patients in the
standard care group (see Table 10).
Intensive management sessions
A total of 161 of 168 patients randomised to intensive management attended at least one session.
Seven patients missed all sessions (three patients changed from intensive management to standard
care after their first visit and four patients withdrew from the study and were lost to follow-up).
A total of 139 of 161 (86%) patients attended at least eight (mean 11, SD 1.34) sessions. Twenty-two
of 161 (14%) patients attended fewer than eight (mean 4, SD 1.94) sessions.
Intensive management treatments
A total of 140 patients started one conventional DMARD during the trial, 64 patients started a second
and three patients started a third. These treatments were predominantly with non-methotrexate
major DMARDs (hydroxychloroquine, n = 73; sulfasalazine, n = 55; leflunomide, n = 33). DMARD doses
were increased in 69 patients and decreased in 15 patients. Biologics were given to 46 patients, and
seven patients had a second biologic and two patients had a third biologic. Etanercept (as Enbrel®;
Pfizer Inc., New York, NY, USA) was the main biologic and was given to 37 patients. Biologic doses
were increased in two patients and reduced in two patients. Depot steroid injections were given to
72 patients (22 patients received one injection, 33 patients received two to four injections and
17 patients had five or more injections). These treatments are summarised in Table 11.
Standard care treatments
A total of 128 patients started one conventional DMARD during the trial, 35 patients started a second
DMARD and two patients started a third DMARD. These treatments were predominantly with non-
methotrexate major DMARDs (hydroxychloroquine, n = 50; sulfasalazine, n = 47; leflunomide, n = 25).
DMARD doses were increased in 32 patients and decreased in nine patients. Biologics were given to
24 patients and two patients had a second biologic. Etanercept was the main biologic given to 12 patients.
Biologic doses were not increased in any patient and were reduced in one patient. Depot steroid injections
were given to 50 patients (28 patients received one injection, 19 patients received two to four injections
and 3 patients had five or more injections). Table 11 summarises treatments during follow-up.
Primary outcome
Intensive management increased the frequency of DAS28-ESR remissions at 12 months compared
with standard care. With intensive management, 32% (95% CI 25% to 40%) of patients had achieved
remission, compared with 18% (95% CI 12% to 24%) of patients receiving standard care (Figure 16).
Both unadjusted and adjusted logistic regression showed that these differences were significant
(p < 0.01) and these differences are summarised in Table 12.
Other remission criteria and low disease activity at 12 months
Other types of remission
Disease Activity Score for 28 joints based on C-reactive protein levels, SDAI, CDAI and ACR/EULAR
Boolean remissions at 12 months (see Table 12) also showed higher achievement of remission with
intensive management (21%, 17%, 18% and 13%, respectively) than with standard care (10%, 10%, 10%
and 6%, respectively). Logistic regression showed that most of these differences were significant (p< 0.05).
DAS28-ESR low disease activity
Low disease activity states were achieved by 48% (95% CI 39% to 56%) of patients receiving intensive
management and 32% (95% CI 25% to 40%) of patients receiving standard care. Logistic regression
showed that this difference was significant (unadjusted OR 1.94, 95% CI 1.22 to 3.10, p = 0.005;
adjusted OR 2.04, 95% CI 1.25, 3.31, p = 0.004).
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TABLE 11 Additional treatments during trial follow-up
Additional drug
Treatment group, n (%)








MTX (N= 21) SSZ (N= 22) LEF (N= 11) HCQ (N= 37)
None 13 (19) 4 (15) 3 (10) 2 (7) 20 (26) 5 (24) 7 (32) 3 (27)
One DMARD 23 (34) 12 (44) 12 (39) 3 (25) 5 (17) 33 (43) 12 (57) 9 (41) 5 (45) 18 (49)
Two DMARDs 13 (19) 6 (22) 11 (35) 5 (33) 9 (31) 14 (18) 1 (5) 5 (23) 11 (30)
Enbrel 16 (24) 4 (15) 4 (13) 4 (42) 9 (31) 4 (5) 1 (5) 1 (4) 2 (18) 4 (11)
Benepali™ (Biogen Biosimilars,
Maidenhead, UK)
1 (1) 1 (4) 1 (3) 1 (4) 2 (3)
Other TNFis 2 (3) 3 (10) 3 (4) 2 (10) 1 (9) 4 (11)
HCQ, hydroxychloroquine; LEF, leflunomide; MTX, methotrexate; SSZ, sulfasalazine.
Notes
Patient who had azathioprine at baseline also had additional HCQ.
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Clinical outcomes at 12 months
Disease activity scores and their components
The mean DAS28-ESR scores were significantly lower (p = 0.015 in unadjusted regression analyses and
p = 0.001 in adjusted regression analyses) with intensive treatment (Table 13). There were also significant
differences in DAS28-CRP, SDAI and CDAI scores. The mean tender and swollen joint counts and assessor
and patient global scores were lower with intensive management (see Table 13). These differences were
significant in unadjusted and adjusted linear regression analyses. However, mean ESR and CRP levels
were unchanged during the trial, with no significant differences between treatment groups at 12 months.
Disability and quality of life
There were only small improvements in disability assessed by the mean HAQ score and quality of life
assessed by the mean EQ-5D score. The differences between treatment groups were not significant at




























FIGURE 16 Remission rates with intensive treatment and standard care.




OR (95% CI) p-value OR (95% CI) p-value
DAS28-ESR 2.17 (1.28 to 3.68) 0.004 2.38 (1.36 to 4.17) 0.002
DAS28-CRP 2.44 (1.27 to 4.70) 0.008 2.52 (1.28 to 4.99) 0.008
SDAI 1.81 (0.94 to 3.47) 0.074 1.90 (0.97 to 3.72) 0.060
CDAI 1.92 (1.00 to 3.68) 0.049 2.10 (1.07 to 4.09) 0.030
ACR/EULAR Boolean 2.32 (1.04 to 5.18) 0.040 2.44 (1.06 to 5.64) 0.036
a Adjusted for demographics (age, sex, ethnicity, disease duration), design factors (NHS region) and baseline values.
ACR/EULAR Boolean remissions were adjusted for only demographics; the standard of care arm was the
reference group.
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TABLE 13 Clinical assessments at 12 months in ITT population
Assessment


















DAS28-ESR 3.4 (0.1) 3.8 (0.1) –0.6 (–0.9 to –0.3) < 0.001 –0.5 (–0.8 to –0.2) 0.001 –0.4 (–0.7 to –0.2) 0.001 –0.4 (–0.6 to –0.1) 0.003
Tender joints 7.5 (0.7) 10.8 (0.8) –2.4 (–4.4 to –0.3) 0.023 –2.7 (–4.5 to –0.8) 0.004 –1.4 (–3.4 to 0.7) NS –1.7 (–3.5 to 0.2) 0.076
Swollen joints 3.5 (0.4) 4.9 (0.5) –1.9 (–3.0 to –0.7) 0.002 –1.6 (–2.7 to –0.5) 0.004 –1.5 (–2.6 to –0.5) 0.005 –1.3 (–2.3 to –0.4) 0.006
ESR 17 (1) 15 (1) –1.5 (–3.9 to 1.0) NS –1.1 (–3.4 to 1.1) NS –1.1 (–3.2 to 1.0) NS –0.7 (–2.7 to 1.2) NS
CRP 9 (2) 7 (1) 0.9 (–2.6 to 4.4) NS 1.5 (–1.8 to 4.7) NS 0.6 (–2.0 to 3.1) NS 1.3 (–0.9 to 3.5) NS
Assessor global 23 (2) 31 (2) –6 (–12 to –0.2) 0.043 –8 (–13 to –3) 0.003 –4 (–9 to 2) NS –5 (–10 to –1) 0.015
Patient global 29 (2) 41 (2) –9 (–15 to –2) 0.010 –11 (–17 to –6) < 0.001 –6 (–12 to –1) 0.026 –9 (–14 to –4) < 0.001
Fatigue 40 (2) 50 (2) –18 (–24 to –11) < 0.001 –15 (–21 to –9) < 0.001 –16 (–21 to –10) < 0.001 –13 (–18 to –8) < 0.001
Pain 28 (2) 37 (2) –6.5 (–13.4 to 0.4) 0.064 –8.4 (–14.5 to –2.3) 0.007 –4 (–11 to 2) NS –6 (–12 to –1) 0.015
HAQ 1.0 (0.1) 1.1 (0.1) –0.1 (–0.2 to 0.0) 0.055 –0.1 (–0.2 to 0.0) 0.046 –0.1 (–0.1 to 0.0) NS –0.1 (–0.2 to 0.0) NS
EQ-5D-5L 0.76 (0.02) 0.72 (0.02) 0.02 (–0.02 to 0.06) NS 0.03 (–0.01 to 0.07) 0.078 0.02 (–0.01 to 0.05) 0.275 0.02 (–0.01 to 0.05) 0.121
Larsen score 13 (1) 10 (1) 0.5 (–0.1 to 1.0) NS 0.4 (–0.2 to 0.9) NS
NS, not significant; SE, standard error.
Change from baseline analysed and adjustments made for demographics (age, sex, ethnicity, disease duration), design factors (NHS region) and baseline score; the standard of care
arm was the reference group.
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The mean pain and fatigue scores were significantly lower with intensive management in unadjusted
and adjusted linear regression analyses (see Table 13). Clinically meaningful improvements (i.e. ≥ 10 points)
in pain were achieved by 52% (95% CI 44% to 60%) of patients receiving intensive management and
42% (95% CI 34% to 49%) of patients receiving standard care. Logistic regression showed that this
difference was not significant at the 5% level (adjusted OR 1.51, 95% CI 0.95 to 2.38; p = 0.080).
Clinically meaningful improvements in fatigue (also 10 points of change) were achieved by 58% (95% CI
51% to 66%) of patients receiving intensive management and 35% (95% CI 28% to 42%) of patients
receiving standard care. Logistic regression showed that this difference was significant (adjusted OR
2.81, 95% CI 1.76 to 4.48; p < 0.001).
Radiological scores
The mean Larsen scores increased from 11 to 13 with intensive management and from 9 to 10 with
standard care, with no significant difference between groups (see Table 13).
Clinical outcomes over 6 and 12 months
Longitudinal analyses assessed changes over both 6 and 12 months using mixed-effects models
(see Table 13). Unadjusted and adjusted analyses showed significant differences between groups
for DAS28-ESR, swollen joint counts for 66 joints, patient global assessments, fatigue and pain.
The coefficients for fatigue between treatment groups were particularly large in the unadjusted
(–15.7, 95% CI –21.3 to –10.1) and adjusted (–13.1, 95% CI –18.1 to –8.1) analyses.
Complete-case analyses
Remission and changes in clinical outcomes at 12 months
The effect of intensive management on remission and clinical outcomes was similar in the complete-
case analyses to the ITT analyses. DAS28-ESR remissions occurred in 43 of 134 (32%) patients
receiving intensive management and 23 of 124 (19%) patients receiving standard care, with an
unadjusted OR of 2.07 (95% CI 1.16 to 3.70; p = 0.014). Low disease activity on DAS28-ESR scores
occurred in 61 of 134 (46%) patients receiving intensive management and 39 of 124 (31%) patients
receiving standard care (OR 1.84, 95% CI 1.10 to 3.08; p = 0.020).
Remission, low disease activity, disability and quality of life with intensive management
The 134 patients who had intensive management included 43 patients with 12-month DAS28-ESR
remissions, 61 patients with low disease activity and 73 patients with moderate or high disease
activity. HAQ and EQ-5D scores showed only minimal changes in patients who did not achieve
remissions or low disease activity states. However, in patients who achieved remissions, the 12-month
change in HAQ score was –0.40 (95% CI –0.57 to –0.22) and the 12-month change in EQ-5D score
was 0.13 (95% CI 0.09 to 0.17) (Table 14). There were similar improvements in patients who achieved
low disease activity states. In addition, low end-point HAQ scores of < 0.5 occurred in 23 of 43 (53%)
patients in DAS28-ESR remission and in 25 of 61 (41%) patients in low disease activity states
compared with 13 of 73 (18%) patients with moderate or active disease activity at 12 months.
Remission, low disease activity, fatigue and pain with intensive management
A similar analysis of fatigue and pain showed that only the patients who achieved remission or
low disease activity states had substantial improvements in fatigue and pain (see Table 14).
The improvements with remission and low disease activity states were virtually identical.
Harms
Fourteen patients receiving intensive management and 11 patients receiving standard care
experienced one or more serious adverse events or died (Table 15). There was no significant difference
in proportion of serious adverse events between treatment groups (RR 1.27, 95% CI 0.56 to 2.92).
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TABLE 14 Relationship of DAS28-ESR remission and low disease activity to disability and other outcomes in patients
receiving intensive management





HAQ Initial 1.00 (0.80 to 1.21) 1.19 (1.01 to 1.38) 1.27 (1.13 to 1.41)
12 months 0. 60 (0.42 to 0.79) 0.82 (0.63 to 1.01) 1.23 (1.09 to 1.37)
Change –0.40 (–0.57 to –0.22) –0.38 (–0.51 to –0.23) –0.04 (–0.13 to 0.05)
EQ-5D-5L Initial 0.74 (0.69 to 0.78) 0.71 (0.67 to 0.75) 0.73 (0.70 to 0.77)
12 months 0.86 (0.83 to 0.90) 0.82 (0.78 to 0.86) 0.72 (0.67 to 0.77)
Change 0.13 (0.09 to –0.17) 0.11 (0.07 to 0.02) –0.02 (–0.05 to 0.01)
Fatigue Initial 51.8 (42.0 to 61.7) 55.0 (47.3 to 62.1) 62.0 (57.0 to 66.8)
12 months 24.7 (16.4 to 33.0) 28.2 (20.9 to 35.5) 50.6 (44.1 to 57.1)
Change –27.1 (–36.8 to –17.5) –26.5 (–34.4 to –18.6) –11.3 (–18.3 to –4.3)
Pain Initial 37.6 (30.0 to 45.5) 40.9 (34.6 to 47.2) 40.9 (36.6 to 45.4)
12 months 9.8 (6.4 to 13.3) 14.9 (10.3 to 19.5) 38.6 (32.7 to 44.6)
Change –27.8 (–36.3 to –19.2) –26.0 (–32.6 to –19.5) –2.3 (–9.0 to 4.4)
Note
Data presented are means and (95% CIs) for complete-case population (N= 134).
TABLE 15 Adverse events
Category Body system
Treatment group
Intensive management Standard care






Cardiovascular Heart failure Microvascular angina
Myocardial infarction Paroxysmal arrhythmia
Dyspnoea/chest tightness
Hypotension headache




Immunological Tonsillitis with neutropenia




Cerebral spinal fluid leak
Respiratory Chest infection/asthma Exacerbation of asthma
continued
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The three patients who died comprised two in the intensive management group and one in the standard
care group. None of the deaths was considered to be treatment related. Other serious adverse events
spanned a range of systems and there was no indication that any of the events were treatment related.
Overall, 132 patients (60 intensive management patients and 72 standard care patients) had 265
adverse events (114 in the intensive management group and 151 in the standard care group)
(see Table 15). These events spanned a range of body systems. There was no evidence that intensive
management increased the risk of an adverse event.
Strengths and limitations
Strengths
The TITRATE trial had two strengths. First, it was a relatively large trial, involving almost 40 different
specialist centres and a range of patients. Its findings are therefore likely to be robust. Second, the
predicted and the actual outcomes were very similar, showing that it delivered the expected degree of
improvements based on previous studies in early RA.
Limitations
The TITRATE trial also had a number of limitations. First, it did not compare the sustainability of remission
between groups;216,317 however, to assess standard care patients more often than every 6 months would
mean that they were no longer receiving standard care and, therefore, invalidating them as a control group.
TABLE 15 Adverse events (continued )
Category Body system
Treatment group
Intensive management Standard care
All other adverse events Number of episodes 114 151
Allergies, n (%) 1 (1) 3 (2)
Dermatological, n (%) 8 (7) 17 (11)
Cardiovascular, n (%) 5 (4) 8 (5)
Eyes, ear, nose and
throat, n (%)
10 (9) 15 (10)
Gastrointestinal, n (%) 9 (8) 27 (18)
Genitourinary/renal, n (%) 3 (3) 10 (7)
Haematological, n (%) 5 (4) 3 (2)
Hepatic, n (%) 6 (5) 2 (1)
Immunological, n (%) 2 (2) 1 (1)
Musculoskeletal, n (%) 21 (18) 17 (11)
Neoplasia, n (%) 1 (1) 3 (2)
Neurological, n (%) 11 (10) 6 (4)
Other, n (%) 10 (9) 8 (5)
Psychological, n (%) 0 (0) 2 (1)
Respiratory, n (%) 22 (19) 29 (19)
Reproduced with permission from Scott et al.308 This is an Open Access article distributed in accordance with the terms
of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build
upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/
licenses/by/4.0/. The table includes minor additions and formatting changes to the original table.
THE TITRATE TRIAL
NIHR Journals Library www.journalslibrary.nihr.ac.uk
52
Second, the TITRATE trial lasted only 12 months. Ideally, strategy trials would last for several years; for
example, 10-year results have now been reported for the BeSt strategy trial.175 However, undertaking
such long-term trials of intensive treatment strategies has organisational and funding complexities
and could not be pursued in the TITRATE trial. Third, there is uncertainty as to which outcome is
preferable.318 ACR/EULAR Boolean remissions appear ideal but are not often achieved, whereas low
DAS28-ESR scores may have fewer benefits but were achieved by almost half the patients receiving
intensive management. In addition, although the TITRATE trial included a range of patient-reported
outcome measures, the trial was designed before newer measures, such as the Rheumatoid Arthritis
Impact of Disease (RAID) score, became widely used and patients’ perspectives on their outcomes may
have provided important additional information. Fourth, intensive management is not effective in all
patients. The TITRATE trial does not provide any information on how best to manage patients who did
not respond to intensive management. Failure to respond to different forms of intensive treatment,
particularly biological therapies, is increasingly recognised as being relatively common and a source of
high health-care costs.319–321 Fifth, the use of monthly sessions was planned when the trial was designed
and patients did not have any particular input into deciding if this was an optimal time for assessing their
progress or if less frequent assessments would be preferable. An additional issue is that some centres
may use ultrasound assessments to evaluate joint inflammation in patients with moderate disease activity,
although most centres do not take this approach.
One inevitable limitation of a treatment strategy trial, like the TITRATE trial, in which patients receive
a range of different interventions, is the uncertainty about the extent to which different parts of the
intervention contributed to the overall benefit of intensive management. Increasing conventional
DMARDs, starting biological treatments and supportive management from the specialist nurses are all
likely to have contributed. However, we do not know which of these was most important or if all were
needed. Such challenges are commonplace in complex interventions.322–324
Relation to overall programme
Impact of intensive management on remission
The TITRATE trial shows that managing patients with established moderate RA who are receiving
conventional DMARDs and who are being followed in specialist rheumatology clinics achieve more
remission at the end of 12 months’ intensive management following a treat-to-target strategy
compared with standard care. Five different remission criteria showed that intensive management
was more effective than standard care. More patients also achieved low disease activity states with
intensive management. Although we cannot entirely disentangle the contributions of drug therapy
from support from the specialist nurses, the balance of evidence suggests that both contributed to
achieving remission.
Other benefits of intensive management
The TITRATE trial also showed that when trained nurses provide holistic care in addition to adjusting
drug therapy using treat-to-target approaches, it could help minimise symptoms, which is important
to patients.
Safety of intensive management
There was no evidence that intensive management led to more adverse events or serious adverse events.
Extent of benefits
In the complete-case analyses, 32% of patients receiving intensive management achieved 12-month
DAS28-ESR remissions and 46% of patients achieved low disease activity states. Achieving remission
was associated with substantial improvements in disability and health-related quality of life. Patients
receiving intensive management also had substantial improvements in fatigue and pain, and these
changes were also most marked in patients achieving remission. Overall, these findings suggest that
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between one-third and a half of patients receiving intensive management achieved substantial benefits
from this treatment approach.
Differences between strategies
Intensive management patients received more conventional DMARDs, more biologics and more steroid
injections. They also had more changes in DMARD and biologic dose. However, the magnitude of these
differences was relatively small. Biologic use is the most important example of the difference between
strategies. With intensive management, 49 of 168 (29%) patients had 58 different biologics. With
standard care, 24 of 167 (14%) patients had 26 biologics.
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Health economic evaluation of the
TITRATE trial
This section provides a cost-effectiveness analysis of the TITRATE trial. It assessed the economicbenefits of intensive management from the perspective of English patients managed in the NHS.
Aims
This economic analysis evaluated effectiveness using quality-adjusted life-years (QALYs) during the
TITRATE trial. It was conducted in line with the NICE Guide to the Methods of Technology Appraisal325
to ensure NHS relevance. The analysis used an NHS and Personal Social Services (PSS) perspective for
costs in the base-case analysis. Participant variation in resource use and effectiveness were estimated
separately. The economic outcome was expressed as the incremental cost per QALY gained of intensive




NHS resources were measured for each participant between baseline and final follow-up. This included
medication costs, visits to health services and any social care and community support. Medication usage,
the number of hospital visits and intensive management appointments were taken from trial records.
NHS and PSS resources were self-reported by participants at 6 and 12 months, with the widely used
and validated Client Service Receipt Inventory (CSRI) questionnaire.326 It included questions related to
time off work, which was used in sensitivity analysis.
Unit costs for all resources were obtained for the financial year 2018–19 from national sources.
Medication use was taken from a form that collected current RA medication information over the
trial. This included the duration of the medication (start date and end date of the medication), the
dosage and the frequency of the medication. NHS unit costs for the medications were based on
the drug tariff price reported in the British National Formulary (BNF)327 (see Appendix 5, Table 41).
If the drug tariff price was not reported in the BNF, then we used the average NHS indicative price
from all manufacturers of the medication. NHS and social services costs were from Unit Costs of Health
and Social Care.328
Total NHS costs and social services costs included medication, primary care, secondary care and social
services contact. The unit costs are summarised in Appendix 5, Tables 41 and 42. Data on the use of
secondary health-care service visits were collected by the research nurse at each centre based on
forms designed to capture information on all hospital admissions and the frequency and type of
intensive management sessions. Detail on the nature of the reported hospital admissions was
not captured and we assumed the cost to be the cost of 1 hour with a rheumatologist. Intensive
management sessions were excluded from reported hospital admissions to avoid double counting.
The average costs of intensive management sessions were derived from bottom-up micro-costing
based on the type of practitioner seen and the duration of the appointment (see Appendix 5, Table 44).
Primary care and social services contact were captured by the CSRI health resource questionnaire. The
CSRI provides a 3-month recall and is measured at 6-month intervals. Linear interpolation was used to
estimate the costs in the unobserved months. Participants were asked whether or not they had been
in contact with a general practitioner (GP) (i.e. a visit to the GP, telephone call and/or GP home visit)
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and, if so, how many contacts they had had over the previous 3 months. This time was costed based
on the average patient’s contact with a GP in the UK lasting 9.22 minutes.328 Responses to questions
on the CSRI relating to appointments with other NHS health-care workers (e.g. practice nurse, NHS
physiotherapist, NHS occupational therapist) and social care workers (e.g. staff help at the participant’s
home and appointments with social workers) were also recorded and staff time was costed per
working hour (see Appendix 5, Table 44). Participants could also report any use of other health or social
services, which was costed in a similar manner (i.e. a single working hour for staff on NHS band 5, £34)
and included participants’ use of blood tests at walk-in centres, support from a mental health worker,
visit to a memory clinic, installation of handrails and toilet seats, and appointments with podiatrists
and orthopaedists.
Participants were asked if the NHS or social services paid for their transport to get to health-care
appointments and the reported total was used for the cost of transport. The travel cost of staff to
participants’ homes or to general practices for hospital-based staff was estimated as the sum of travel
time and cost of transport. Travel time was assumed to be 15 minutes (i.e. one-quarter of the cost of a
working hour), and we applied the NHS reimbursement rate for a 4-mile journey (i.e. 56 pence/mile,
thus £2.24) for the cost of transport. Receipt of Meals on Wheels services was asked directly in the
CSRI health resource questionnaire and costed for £4.40 per meal based on a 2018 national survey of
the programme.329
Indirect costs were defined as the production losses resulting from treatment when the participant
was unable to return to normal activity. Information regarding participants’ recovery was collected
in the CRSI questionnaire at 6 and 12 months. Individual participant costs comprised the amount of
whole days or hours the individual has taken off work and the amount taken off by friends of relatives
to care for them. Unit time costs were combined and costed using standard economic conventions
(i.e. the human capital approach to estimating time costs) and Office for National Statistics data on
UK median wages and working hours, and330 this gave a cost estimate of £92 for each day of work lost
because of RA (see Appendix 5, Table 42).
The total cost to the NHS and PSS was computed by adding the estimated treatment and follow-up
costs for each participant. There was no missing medication, primary care and PSS data. Missing data in
the use of secondary health-care services were estimated with multiple imputation and the participant
was included in the analysis. The sum of participants’ NHS, PSS and indirect costs was the societal cost
of RA illness.
Health-related quality of life
The QALYs gained were estimated by applying the trapezium rule to estimate the area under the
curve. QALYs were then adjusted for participants’ baseline level of utility using linear regression.
Health utilities were derived from participant responses to the EQ-5D-5L at baseline and at 6 and
12 months. The EQ-5D-5L was designed in 2009 with the intention of improving the discriminative
power of the instrument at levels of health near to full health, as compared with the widely used
three-level version [EuroQol-5 Dimensions, three-level version (EQ-5D-3L)]. However, the position
of NICE331 is that to have consistency with the current reference case analysis (which is based on
EQ-5D-3L utility scores), and because of concerns raised about the validity of the EQ-5D-5L value
set for England,332 the utility values should be established by mapping responses to the EQ-5D-5L
descriptive system data onto the EQ-5D-3L valuation set using the mapping approach reported by
Devlin et al.333 We take this approach in the reference case. Sensitivity analysis will be undertaken
with QALYs estimated using EQ-5D-5L responses and two alternative approaches for estimating
EQ-5D-3L from responses to the EQ-5D-5L.334 The mapping approaches were established based
on two reference data sets of patients who completed the EQ-5D: (1) FORWARD (the National
Databank for Rheumatic Diseases)334 and (2) a EuroQol Group-co-ordinated data collection study.333,334
The EQ-5D-3L and EQ-5D-5L scores were estimated using the EQ-5D population tariffs that are
based on the UK (EQ-5D-3L version) and England (EQ-5D-5L version) population responses.333,335
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Missing observations
Multiple imputation was used to create observations for missing data, which were assumed to be
missing at random. Regardless of the possible reason outcomes were missing, we imputed missing
values for the EQ-5D data (both EQ-5D-3L and EQ-5D-5L values) at 6 and 12 months, the number
of clinical visits to the hospital and number of intensive management sessions. Missing values on the
number of clinical visits to the hospital and number of intensive management sessions were dealt
with in the same way as the EQ-5D. For each outcome, the method of imputation was PMM.336
This approach imputes missing values by means of the five nearest neighbour donors, with distance
based on the expected values of the missing variables. In our analysis, the expected values of missing
variables were conditional on treatment group, sex, age, ethnicity, NHS region and health utility values
at baseline. We then replaced each missing value with the mean value of 20 imputations created by
the PMM approach (see Appendix 5, Table 43).
Economic outcomes
For each participant, we estimated total costs over the trial period and the QALYs gained. The mean
differences between the two trial arms are presented with sample 95% CIs and bootstrapped bias-
corrected 95% CIs. The cost and health information were combined in an estimate of incremental
cost-effectiveness ratio (ICER) of intensive management compared with standard care. Non-parametric
bootstrapping was used to generate CIs for the estimated mean incremental costs and effects and to
summarise the uncertainty surrounding the ICERs. Uncertainty was visualised as a two-dimensional
cost-effectiveness plane and as a cost-effectiveness acceptability curve, which reports the probability
that the intervention is cost-effective for any given level of willingness to pay (WTP).
Sensitivity analysis
To further test the robustness of results derived from the base-case analysis, several deterministic
sensitivity analyses were conducted. This included estimating an ICER with alternative approaches to
establishing health utilities334 and a societal cost perspective that includes NHS and social services
costs and productivity losses.337 Such analyses examine the effect of estimated or uncertain parameters
on the decision.
Subgroup analysis
To explore the sensitivity of the EQ-5D instrument to detect changes in remission, we summarise the
mean QALY gain at 12 months for participants who achieved remission compared with those who did
not. Remission is defined as a DAS28-ESR score of < 2.6 at 12 months.
To examine if there are subgroups of the population that respond differently to the intervention,
we used regression analysis to explore associations of patient characteristics with the change in
health utility score from baseline to 12 months. Logistic regression was used to examine which patient
characteristics are associated with any improvement in EQ-5D-3L score at 12 months and, therefore, the
dependent variable was 1 for participants who experienced any improvement at 12 months and zero
otherwise. Ordinary least squares regressions explored which patient characteristics were associated with a
change in the level of EQ-5D score (magnitude of the health gain) at 12 months and a separate regression
explored these associations in the subgroup of patients who had achieved remission at 12 months. The
regressions included as explanatory variables the region of health centre the participant receives RA
treatment, sex, age, ethnicity, the duration of RA disease, intervention group and whether or not the
patient moved to biologic medication during the trial. We also investigate the number of hospital visits,
intensive management sessions and biologic use in participants who achieved remission compared with
those who did not. The purpose of this analysis is to examine if more resources were used in patients
who achieved and maintained remission, as this has implications for any future analysis that may wish to
the extrapolate costs and health findings beyond the duration of this trial.
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Key findings
The base-case ICER was £43,972 from an NHS and PSS cost perspective (Table 16). At £20,000 and
£30,000 per QALY, which is generally considered to be the range that NICE operates in the UK for
most standard health technologies, the probability that intensive management is cost-effective
compared with standard care is 2% and 17%, respectively (Figure 17, see also Appendix 5, Table 45).
Figure 18 shows the empirical estimate of the joint distribution of mean incremental costs and effects
for intensive management compared with standard care obtained using the results of the bootstrap
replicates. The estimates indicate that intensive management is likely to be more costly to the NHS and
PSS by £1526 per patient (p < 0.001), with a statistically significant (p = 0.02) increase in health benefit
of 0.03 QALYs per patient over the trial period (see Table 16). A detailed summary of the between-
group differences in cost components and QALY outcomes is shown in Appendix 5, Tables 47 and 48.
Sensitivity analysis showed that the ICER fell to £29,363 when we included the value of time off work.
This corresponded to a 50% probability that intensive management is cost-effective at a WTP value
of £30,000 per QALY (see Appendix 5, Table 45). The ICER increases with all alternative methods for
valuing health gain. The largest ICER is £57,849 when QALYs were based on EQ-5D-5L index, and this
corresponded to an estimate of 7% probability that intensive management is cost-effective at a WTP
value of £30,000 per QALY (see Appendix 5, Table 45).
TABLE 16 Economic outcomes from the trial evaluation
Cost perspective
Treatment group (bootstrapped bias-corrected 95% CI)
Mean differenceIntensive management (n= 168) Standard care (n= 167)
All NHS and personal social
service costs (£)
3784 (3371 to 4246) 2258 (1974 to 2585) 1526




0.64 (0.62 to 0.66) 0.61 (0.58 to 0.63) 0.035; p = 0.02
ICER (NHS and PSS costs) (£) 43,972
Sensitivity analysis
ICER (societal cost perspectivea) (£) 29,363
QALYs estimated using Hernández-Alava and Pudney’s334 mapping function derived from the EuroQol Group
co-ordinated data set
ICER (NHS and social services costs) (£) 47,293
ICER (societal cost perspective) (£) 31,580
QALYs estimated using Hernández-Alava and Pudney’s334 mapping function derived from the FORWARD National
Databank for Rheumatic Diseases
ICER (NHS and social services costs) (£) 52,188
ICER (societal cost perspective) (£) 34,849
QALYs based on EQ-5D-5L index scores
ICER (NHS and social services costs) (£) 57,849
ICER (societal cost perspective) (£) 38,629
a Societal costs include NHS and social services costs and productivity losses.
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Patients who experienced remission had an improvement in health utility of 0.151 (95% CI 0.111 to
0.191) at 12 months, compared with just 0.012 for patients without remission (Table 17). A large
proportion of both groups did not respond to treatment. Sixty-four (38%) patients in the standard care
group and 50 (30%) patients in the intensive management group experienced a decline in health utility
at 12 months, compared with baseline, whereas there was an improvement in utility in 103 (62%) and
113 (70%) patients, respectively. We did not identify any patient characteristics that were associated
with whether there was an increase in health utility at 12 months or a decline (see Appendix 5, Table 48).
However, the use of biologics during the trial period was associated with an increase of 0.059 in health
utility at 12 months, compared with baseline, after controlling for intervention group and patient
characteristics (see Appendix 5, Table 49). This increase was slightly lower (0.056 QALYs) in patients who
achieved remission at 12 months (see Appendix 5, Table 50). This suggests that greater biologics use in
intensive management was a key driver of the health improvement experienced in comparison with
standard care.
More patients achieved remission in the intensive management group (28%, n = 48) compared with the
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FIGURE 18 Cost-effectiveness plane: intensive management vs. standard care from NHS and social services cost
perspective.
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achieved remission (see Appendix 5, Table 51). Six per cent of patients (n = 10) in the intensive
management group were on biologics and in remission, compared with 10% of patients (n = 16) in
the standard care group. The lower percentage of patients in remission and on biologics in the intensive
management group suggests that greater use of biologics is not the primary cause of the larger
percentage of patients in the intensive management group who achieved remission. This leaves open
other possible explanations and this must include the use of conventional DMARDs more effectively
in the intensive management group. There is closer management of patients who achieved remission
in the intensive management group both in comparison to patients who did not achieve remission in
the intensive management group and to patients who achieved remission in the standard care group.
For example, the number of hospital visits (including intensive management sessions) to the hospital
for patients who achieved remission was larger in intensive management group (14.2 visits) than for
the standard care group (7.4 visits) (see Appendix 5, Tables 52 and 53). In addition, within the intensive
management group, the number of intensive management sessions was larger in patients with remission
(11 sessions) than in patients without remission (9.1 sessions), (see Appendix 5, Table 54).
Limitations
Duration of assessment
The costs and benefits of the intervention were not extrapolated beyond the trial period in a decision-
analytic model to allow a lifetime estimate of expected costs and QALYs. Such a model would require
time to loss of efficacy of intensive management sessions to determine the future treatment pathway
for the patient populations once a switch from intensive DMARD therapy is estimated, including
biologics if patients progress to severe RA.
Duration of treatment
It is plausible that the cost per QALY gained from the intervention would improve over a longer
duration of treatment. We found that a key driver of improvement in health-related quality of life was
whether or not patients achieved remission, and there is evidence that patients receiving intensive
management who did not achieve remission within the trial period are more likely to have done had
the trial lasted longer. The number of remissions were larger in the intensive management group and
patients without remission had gains in health-related quality of life (mean gain in health utility of
0.024) that were not found in the standard care group (mean gain in utility of 0.0002). In addition, if
patients in the intensive management group continue to achieve and maintain remission, then the costs
of intensive management treatment would be expected to decrease because we found fewer hospital
visits and biologic use in intensive management patients with remission than in patients without remission.
TABLE 17 Difference between EQ-5D-3L scores at 12 months compared with baseline
EQ-5D improvement at 12 months Mean (SD) 95% CI Number of observations
For patients without remissiona
Intensive management group 0.024 (0.160) –0.004 to 0.053 120
Standard care group 0.0002 (0.194) –0.032 to 0.033 139
Combined groups 0.012 (0.179) –0.010 to 0.033 259
For patients with remissiona
Intensive management group 0.145 (0.142) 0.104 to 0.186 48
Standard care group 0.161 (0.223) 0.075 to 0.247 28
Combined groups 0.151 (0.175) 0.111 to 0.191 76
a Remission is defined as a DAS28-ESR score of < 2.6 at 12 months.
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This would serve to reduce the incremental costs between groups and improve the cost-effectiveness
of the intervention. Therefore, the proportion of patients who move to biologics and the time it takes
for them to move to biologics is expected to be key driver of costs and possibly health benefits in
an extrapolation.
Relation to overall programme
Overall health economic benefit
The ICER of intensive management compared with standard care was £43,972 and it decreased to
£29,363 when a societal cost perspective was taken. Intensive management is therefore unlikely to be
cost-effective at the threshold range of £20,000 to £30,000 per QALY, which is typically used by UK
decision-makers when assessing short-term within-trial costs and benefits.
Longer-term perspectives
Resource constraints within the project prevented an economic evaluation beyond the 12-month
follow-up period (outlined in the protocol as a potential tertiary analysis). This is needed in future
research, as within-trial assessments underestimate the benefits of improved earlier treatment and
potentially reduced biologic drug use over the longer term.
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Response predictors and persistence in
the TITRATE trial
The studies in this section evaluated different aspects of the TITRATE trial. The studies spannedpredictors of responders and non-responders and the persistence of response of patients who
received intensive management in the 6-month extension study.
Aims
The three research aims in this section represented separate secondary aspects of the TITRATE trial.
These were (1) baseline response predictors, (2) an analysis of non-responders and (3) an evaluation of
response persistence.
Baseline response predictors
We evaluated whether or not baseline response predictors would identify patients who showed limited
responses to intensive management. We focused on predictors of DAS28-ESR remissions and improved
fatigue scores, which were dominant clinical outcomes in the trial. Many previous studies have
evaluated predictors of remission338–342 and fatigue343–348 in RA in trials and observational studies.
Analysis of non-responders
We also examined whether or not baseline factors identified patients who showed no improvement
over 12 months (with decreases in DAS28-ESR of < 0.6 over 12 months). In addition, we assessed the
extent to which non-responders showed some improvements in DAS28-ESR scores during treatment.
Response persistence
We undertook an 18-month follow-up assessment of patients receiving intensive management in the
TITRATE trial, assessing the extent to which remissions and reductions in DAS28-ESR and fatigue were
maintained after intensive management. Long-term follow-up of patients in RA intensive management
trials has advantages,349 although these can be difficult to achieve.
Methods
Patients
We studied patients enrolled in the TITRATE trial. Studies of response predictors were confined to the
298 patients in whom 12-month DAS28-ESR and fatigue measures were present. Studies of response
persistence were restricted to the 95 patients who were assessed at 18 months. Baseline assessments
of these patients were similar from the overall group of patients recruited into the TITRATE trial.
Details of these patients are shown in Appendix 4, Table 38.
Assessments
These were confined to the clinical assessments made in the TITRATE trial (see The TITRATE trial).
Statistical analyses
Data were analysed descriptively using means, SDs and 95% CIs or medians and IQRs. Predictors were
assessed using logistic regression.
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Key findings
Baseline predictors of remissions at 12 months
Significant predictors on unadjusted logistic regression analyses comprised male sex, baseline DAS28-ESR,
HAQ scores, body mass index (BMI) and receiving intensive management. These factors remained
significant in adjusted analyses (Table 18). Factors unrelated to 12-month remissions included age,
disease duration, pain, fatigue, Patient Health Questionnaire-9 items (PHQ-9), Generalised Anxiety
Disorder-7 (GAD-7) and scores on the Beliefs About Medicines Questionnaire (BMQ).
Combining these predictors identified a group of 40 patients who were unlikely to achieve remission
irrespective of the treatment they received. The subset of patients who were obese (i.e. had a BMI of
> 30 kg/m2) and had high baseline HAQ scores (i.e. > 1.50) had few remissions. Only 1 in 17 (6%)
patients receiving standard care and 3 in 23 (13%) patients receiving intensive management had
remissions at 12 months (chi-squared 0.6; p > 0.05).
In contrast, the 124 patients with neither of these predictors had more remissions. Fifteen of 66 (23%)
patients receiving standard care and 30 of 59 (51%) patients receiving intensive management achieved
remissions at 12 months (chi-squared 9.5; p = 0.002).
Baseline predictors of 12 months improved fatigue
Significant predictors on unadjusted logistic regression analyses comprised baseline fatigue, BMI and
intensive management (see Table 18). Factors unrelated to 12-month improved fatigue included sex,
age, disease duration, DAS28-ESR, HAQ, pain, PHQ-9, GAD-7 and the BMQ.
TABLE 18 Predictors of 12-month DAS28-ESR remission, fatigue and DAS28-ESR non-responders
Predictor
Unadjusted Adjusted
Coefficient (95% CI) Significance Coefficient (95% CI) Significance
12-month DAS28-ESR remission
Male sex 1.97 (1.07 to 3.66) p = 0.031 1.96 (0.99 to 3.90) p = 0.055
DAS28-ESR 0.56 (0.34 to 0.93) p = 0.024 0.58 (0.33 to 1.01) p = 0.052
HAQ 0.53 (0.35 to 0.80) p = 0.003 0.61 (0.39 to 0.95) p = 0.027
BMI 0.91 (0.86 to 0.96) p < 0.001 0.91 (0.86 to 0.96) p = 0.001
Intensive management 2.09 (1.22 to 3.36) p = 0.007 2.63 (1.46 to 4.72) p = 0.001
12-month reductions in fatigue of ≥ 10mm
Fatigue 1.03 (1.02 to 1.04) p < 0.001 1.03 (1.02 to 1.04) p < 0.001
BMI 0.96 (0.93 to 0.99) p = 0.025 0.94 (0.91 to 0.98) p = 0.004
Intensive management 2.69 (1.68 to 4.30) p < 0.001 2.60 (1.58 to 4.30) p < 0.001
12-month DAS28-ESR non-response (decreases < 0.60)
BMI 1.04 (1.00 to 1.08) p = 0.028 1.05 (1.01 to 1.09) p = 0.011
BMQ (general) 1.05 (1.00 to 1.11) p = 0.042 1.06 (1.00 to 1.12) p = 0.035
Intensive management 0.48 (0.30 to 0.76) p = 0.002 0.48 (0.30 to 0.78) p = 0.003
Note
Baseline factors assessed included sex, age, disease duration, DAS28-ESR, HAQ, BMI, pain, fatigue, PHQ-9, GAD-7 and
the BMQ.
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Non-responder at 12 months
Significant baseline predictors of non-response at 12 months on unadjusted logistic regression analyses
comprised BMI, the BMQ (general) and receiving intensive management. Unrelated factors included
age, disease duration, DAS28-ESR, HAQ, pain, fatigue, PHQ-9 and GAD-7. These factors remained
significant in adjusted analyses (see Table 18).
Changes in DAS28-ESR during follow-up in non-responders at 12 months
One hundred and two patients who received intensive treatment did not achieve 12-month remissions.
In 99 of these patients, information was available about remissions occurring during their monthly
monitoring visits. Fifty-one of these patients had no remissions during these visits and 48 patients had
some remissions (16 patients had a single remission, 13 patients had two remissions and 19 patients
had three or more remissions), with the maximum number of remissions being eight. Leaving aside
18 patients who withdrew before 12 months and three patients for whom monthly DAS28-ESR data
were not available, there were three subgroups of patients receiving active treatment: (1) 48 patients
achieved remissions at 12 months, (2) 48 patients had some remissions during treatment, but these
were not sustained until 12 months, and (3) 51 patients had no remissions. These patients showed
differing patterns of changes in their DAS28-ESR scores. Details are shown in Appendix 4, Figure 28.
Persistence of response
The 95 patients who had received intensive management in the TITRATE trial and had attended
for follow-up at 18 months were divided into two groups on the basis of achieving remission in the
trial. First, 48 patients had no or only one DAS28-ESR remission during intensive management and
second, 47 patients had two or more DAS28-ESR remissions in this period (median 4 remissions;
range 2–10 remissions).
Analysis of DAS28-ESR remissions at 6, 12 and 18 months showed a small decline in the overall
frequency of remissions at 18 months, which was least in patients achieving two or more remissions
during intensive management (Figure 19). There was also a gradual return in DAS28-ESR levels towards
low or moderate levels, which was least in patients achieving two or more remissions (see Figure 19).
There was a more marked return in fatigue over 18 months, although this is also least in patients
achieving two or more remissions. There were also marked temporal variations in frequencies of
different DAS28-ESR categories. Patients with initial moderate RA showed a wide range in activity levels
during intensive management (Figure 20). In addition to achieving remission and low disease activity



















FIGURE 19 Disease Activity Score for 28 joints based on ESR remissions, DAS28-ESR and fatigue. Mean scores over
18 months. (a) DAS28-ESR remissions; (b) mean DAS28-ESR; and (c) mean fatigue. (continued )
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We also assessed changes in disease activity states in these patients at 12 and 18 months. This analysis
showed considerable variability in the persistence of remission and low disease activity states in these
patients, with many patients continuing to change between activity states. Details are shown in
Appendix 4, Table 40.







































FIGURE 19 Disease Activity Score for 28 joints based on ESR remissions, DAS28-ESR and fatigue. Mean scores over
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FIGURE 20 Disease activity levels over 18 months with intensive management.
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Identifying predictive factors in single trials is invariably limited by uncertainty about replication. As a
consequence, caution is needed and further studies need to show similar findings before any certainty
can be placed on our findings. These issues have been highlighted in publications from the PROGnosis
RESearch Strategy (PROGRESS) Group.350–353
Persistence of effect
Assessing what happens to a small subset of randomised patients after a trial has ended is invariably
limited by the self-selected nature of the population involved and the limited duration of follow-up.
The limitations of subgroup analyses in trials are well known.354
Relation to overall programme
Limited benefits of intensive management
Our analysis of baseline predictors suggested that some patients are unlikely to benefit from current
intensive management, in particular those with a BMI > 30 kg/m2. It is likely that other approaches are
needed in these patients. The negative impact of obesity has been identified with many RA patients,
but may not be extend across all biologic agents.355,356
Duration of benefits
Intensive management is unlikely to have a permanent effect in RA. Six months after stopping
treatment, many patients who had benefited from intensive management were beginning to show
features of returning disease activity and higher levels of fatigue. When intensive management is
successful, it is likely that ongoing similar treatment is required in the longer term.
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Stability of disease control and impact
on disability
The research in this section focused on understanding disease course and progression and thepatterns of RA-specific physical disability over time in patients receiving intensive management in
‘real-world’ clinical settings. It was intended to place treat-to-target strategies into a broader context.
Aims
The research had three inter-related aims around defining the inter-relationships between disease
activity states, remissions and erosive damage. They were assessed using data from 152 patients in the
REMIRA (Remissions in Rheumatoid Arthritis) study.314,357
Transitions over time
We went beyond investigating solely the state of remission and evaluated transitions between
different disease activity states defined by the DAS28-ESR.
Disability over time
We described and characterised functional disability over time (using the HAQ) with a specific focus on
the impact of erosive disease at baseline and the impact of time-varying disease activity on transitions
between HAQ states.
Erosive damage




The REMIRA study recruited 152 adults with RA undergoing a treat-to-target management strategy
for 12 months. Inclusion criteria comprised disease duration of ≤ 10 years, receiving stable doses of
conventional DMARDs or biologics for > 6 months and DAS28-ESR scores of ≤ 3.2 for 1 month or
longer before recruitment. Details of these patients are shown in Appendix 1, Table 30.
Assessments
Baseline data were collected on demographics, disease duration and current treatment. Three-monthly
assessments comprised DAS28-ESR and its components (i.e. 28 tender joint count, 28 swollen joint
count, patient global assessment and ESR), CRP levels, HAQ, EQ-5D, Functional Assessment of Chronic
Illness Therapy – Fatigue (FACIT-F) for recording self-reported fatigue, and the Medical Outcomes
Study SF-36 and its physical and mental subscales (PCS and MCS).358–362
Posterioanterior radiographs of hands and feet at baseline and 12 months were used to define damage
by radiographic erosions and damage progression by new erosions or worsening of existing erosions
over 12 months.
Definition of disease states
Disease activity states were defined based on DAS28-ESR using the internationally agreed definition363
of a DAS28-ESR score of < 2.6 to indicate clinical remission, a DAS28-ESR score of 2.6–3.1 to indicate
low disease activity, a DAS28-ESR score of 3.2–5.1 to indicate moderate disease activity and a
DAS28-ESR score > 5.1 to indicate high disease activity.
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Functional disability states were defined using the HAQ disability index categorised into four
categories, (1) HAQ = 0, (2) HAQ = 0.1–0.49, (3) HAQ = 0.50–1.49 and (4) HAQ = 1.50–3.00,
representing no functional disability, mild disability, moderate disability and severe disability,
respectively. HAQ scores < 0.50 represent few difficulties (if any) in performing daily activities and
scores > 1.50 reflect considerable difficulties or assistance required in performing daily activities.364–367
Statistical methods
For modelling disease activity and functional disability over time, a multistate modelling approach368
based on Markov processes was adopted, as our interest lay in characterising the evolution of these
disease processes as they transition between clinically meaningful disease states. In addition, multistate
models naturally handle staged data where patients are under only intermittent observations. They allow
the estimation of rates of transitions between the various states of disease activity or functional
disability and easily incorporate the effects of covariates (both time-independent and time-dependent)
on transition rates. Here, correlation among states of a patient at different assessments are directly
modelled through the Markov assumption that the future evolution of the patient’s disease process
depends only on his/her current disease state and not on his/her previous disease history.
For the disease activity process, we consider the three-state multistate model shown in Figure 21a,
where direct transitions (forward and backwards) are allowed between adjacent states (i.e. between
remission and low disease activity or between low disease activity and moderate to high disease
activity). Direct transitions between remission and moderate to high disease activity are not allowed,
although, as we model the disease activity process in continuous time, this simplifying assumption is
not restrictive.
For modelling physical functional disability, we adopt a four-state multistate model, as shown in Figure 21b,
where, again, direct transitions are allowed only between adjacent states (i.e. between no disability






















FIGURE 21 Multistate diagrams for (a) disease activity states and (b) disability states.
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We examined the separate (univariate) and joint (multivariate) effects of select demographic and clinical
variables on the transition rates in the models for both disease activity and disability. These covariates
were incorporated into the models through the proportional hazards assumption. The variables
considered were sex, age, ethnicity, erosive disease and treatment all at baseline, disease duration and
either the HAQ score or DAS28-ESR score updated at each visit when considering either the disease
activity multistate models or the disability multistate models, respectively. Damage progression was




Over 85% of the cohort had low levels of disease activity or were in clinical remission at entry. None
of the patients had high baseline levels of disease activity. Approximately 50% of the cohort had low
levels or no disability at baseline. Erosive disease was observed to be present in 40% of the study
sample (n = 67). Most patients were receiving stable doses of methotrexate for over 6 months prior to
entry. Fifty-three per cent of patients were on two or more RA medications at baseline.
Characterisation of disease activity states over time
Figure 22a displays the longitudinal profiles of disease activity states for the 150 patients with at least


























HAQ 0 to ≤ 0.5
HAQ 0.5 to ≤ 1.5

















FIGURE 22 Longitudinal profiles of disease activity and disability over five visits. (a) Disease activity states; and
(b) disability states. NA, not applicable.
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recorded at all five visits and 44 (46%) of those were observed to have sustained remission (i.e.
observed in remission at all five visits). Table 19 summarises the numbers and types of transitions in
disease activity states that were observed over the 12-month follow-up period. Seventy-two patients
were not observed to have made any transitions out of their initial state. Twenty-eight patients were
observed to have made one transition (16 patients were observed to have deteriorated and 12 patients
to have improved). Fifty patients were observed to have made two or more transitions, with the majority
(92%) of patients observed to have a fluctuating course of both deteriorations and improvements.
On fitting the three-state multistate model (see Figure 21a) with no covariates to the disease activity
states, we estimated that there would be 7.28 (95% CI 5.22 to 10.16) transitions per 100 person-
months from the remission state to the low disease activity state, 36.81 (95% CI 26.30 to 51.51)
transitions per 100 person-months from low disease activity back to remission, and 32.21 (95% CI
20.39 to 50.86) and 24.22 (95% CI 15.26 to 38.51) transitions per 100 person-months from low disease
activity to moderate/high disease activity and moderate/high back to low disease activity, respectively.
Based on these transition rates, we estimate that the mean time spent in the three states of remission,
low disease activity and moderate to high disease activity before exiting are 13.74 (95% CI 9.85 to
19.17) months, 1.45 (95% CI 1.08 to 1.94) months and 4.12 (95% CI 2.60 to 6.55) months, respectively.
Therefore, on average, once a person enters the remission states they spend over 12 months in this
state before transitioning out under a treat-to-target management strategy. In contrast, a person spends
very little time continuously in either the low or moderate/high disease activity states before exiting.
TABLE 19 Frequencies and types of disease activity transitions by initial disease activity state
Number of transitions Type of transition
State at time of first observed disease activity
state assessment
1 (n= 99) 2 (n= 33) 3 (n= 18)
No transitions (n = 72) 68 0 4
One transition (n = 28) Deterioration (n= 16)
State 1→ 2 6 NA NA
State 1→ 3 4 NA NA
State 2→ 3 NA 6 NA
Improvement (n= 12)
State 2→ 1 NA 7 NA
State 3→ 1 NA NA 4
State 3→ 2 NA NA 1
Two or more transitions (n = 50) Steady observed deterioration (n = 4)
State 1→ 2→ 3 4 NA NA
Steady observed improvement (n = 0)
State 3→ 2→ 1 NA NA 0
Fluctuating course both deterioration and improvement (n= 46)
State 1←→ 2 10 9 NA
State 1←→ 3 4 NA 1
State 2←→ 3 NA 2 6
State 1←→ 2, 1←→ 3, 2←→ 3 3 9 2
NA, not applicable.
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The results in Table 20 show the final multivariate multistate model when covariates are explored on
various transition rates. We find that males have a higher transition rate out of low disease activity
to moderate/high disease activity states than females. The rate of transition to remission (from low
disease activity) is 3.2 (95% CI 1.2 to 6.6) times faster for males than for females, and a 1-unit increase
in HAQ increases by 2.9-fold (95% CI 1.8- to 4.7-fold) the rate of transitioning out of remission.
Characterisation of functional disability over time
Figure 22b displays the longitudinal paths of disability states of the same 150 patients. The numbers
of patients observed in the no disability, mild, moderate and severe disability states at first observed
HAQ assessment were 64, 26, 49 and 11, respectively. Ninety-eight patients were observed to have
HAQ measured at all five time points. Of these 98 patients, 23 (23.5%) remained disability free over all
their visits (compared with 46.3% of patients who had five visits with DAS28-ESR measured being in
sustained remission). Table 21 summarises the transition patterns in disability states that were observed
over the 12-month follow-up period. Just under half of the 150 patients (n = 73) were observed to have
not made any transitions out of their initial state. Twenty-five patients were observed to have made one
transition (14 patients were observed to have deteriorated and 11 patients to have improved). Fifty-two
patients were observed to have made two or more transitions and all but one patient were observed to
have a fluctuating course of both deteriorations and improvements.
The results in Table 22 of fitting the final multivariate four-state multistate model provided evidence
for the effects of disease duration, ethnicity and disease activity on transitions between various
disability states. More precisely, we found that a 1-year increase in disease duration reduces the rates
of transitioning both in and out of the no disability state by 0.8. The rate of transition to moderate
disability from mild disability state increased 1.17-fold (95% CI 1.03 to 1.33) for every additional year
of disease. Patients who were white had a slower rate of transitioning in and out of the no-disability
state than non-white patients, and a 1-unit increase in DAS28-ESR score increased the transition rate
from moderate to severe levels by around twofold (95% CI 1.24-fold to 3.92-fold). No evidence of
effects of erosive disease and exposure to treatments at entry on the various transitions between
disability states was found.
Damage progression
At 1-year follow-up, 71 of the 82 (86.6%) patients observed not to have erosive disease at baseline
remained damage free and four patients were observed to have progressed. For the 67 patients with
baseline erosive disease, 46 (68.7%) were observed not to have progressed further and 16 were
observed to have further progression. There was clear statistical evidence, as expected, that the
1-year damage progression rate was higher in those patients with baseline erosive disease than in
those without (p = 0.002).
The final multivariate logistic regression model investigating baseline predictors of 1-year damage
progression identified ethnicity, disease activity and erosive disease at baseline as potentially important
factors (Table 23). Patients who were white were found to have higher odds of damage progression
(OR 9.47, 95% CI 1.11 to 80.47; p = 0.04) than non-white patients, patients with a higher DAS28-ESR
score at baseline were more likely to progress than those with lower scores (OR 2.1, 95% CI 1.04 to
TABLE 20 Multivariate three-state multistate model for disease activity
Variable
Deterioration, relative risk (95% CI) Improvement, relative risk (95% CI)
1→ 2 2→ 3 2→ 1 3→ 2
Sex: male vs. female 1 2.80 (1.19 to 6.62) 3.18 (1.48 to 8.82) 1
HAQ at previous visit 2.89 (1.79 to 4.65) 1 1 1
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2.12 for a 1-unit higher DAS28-ESR score) and RA patients with erosive disease present at baseline
were also at greater risk of progression (OR 7.3, 95% 2.08 to 25.59). No statistical evidence was found
for an effect of physical functional disability on damage progression (p = 0.225) after accounting for
ethnicity, disease activity and erosive disease at baseline.
TABLE 21 Frequencies and types of disability transitions stratified by initial disability state
Number of transitions Type of transition
State at time of first observed disability
assessment
1 (N= 64) 2 (N= 26) 3 (N= 49) 4 (N= 11)
No transitions (n = 73) 33 9 26 5
One transition (n = 25) Deterioration (n = 14)
State 1→ 2 10 NA NA NA
State 1→ 3 1 NA NA NA
State 2→ 3 NA 2 NA NA
State 3→ 4 NA NA 1 NA
Improvement (n = 11)
State 2→ 1 NA 4 NA NA
State 3→ 1 NA NA 1 NA
State 3→ 2 NA NA 4 NA
State 4→ 3 NA NA NA 2
Two or more transitions
(n= 52)
Steady observed deterioration (n = 0)
Steady observed improvement (n= 1)
State 3→ 2→ 1 NA NA 1 NA
Fluctuating course both deterioration and improvement (n = 51)
State 1←→ 2 15 4 NA NA
State 1←→ 3 1 NA 0 NA
State 2←→ 3 NA 6 10 NA
State 3←→ 4 NA NA 4 4
State 1←→ 2, 1←→ 3, 2←→ 3, 3←→ 4 4 1 2 0
NA, not applicable.
TABLE 22 Multivariate four-state multistate model for disability
Variable
Deterioration, relative risk (95% CI) Improvement, relative risk (95% CI)
1→ 2 2→ 3 3→ 4 2→ 1 3→ 2 4→ 3
Disease duration
at previous visit
0.82 (0.71 to 0.94) 1.17 (1.03 to 1.33) 1 0.81 (0.67 to 0.97) 1 1
Ethnicity: white
vs. rest
0.20 (0.07 to 0.52) 1 1 0.26 (0.09 to 0.71) 1 1
DAS28-ESR at
previous visit
1.30 (0.91 to 1.86) 1 2.20 (1.24 to 3.92) 1 1 1
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There is no ideal definition of clinical remission. Even sustained clinical remission may not represent an
underlying state of true biological remission. Although 44 patients in the REMIRA cohort had sustained
remission over the 12 months, 5 of the 44 (11%) patients had damage progression after 1 year. Clinical
remission may overlook subclinical synovitis and, consequently, true remission might be better characterised
molecularly using laboratory markers.
Refractory disease
We found that 18 patients in the REMIRA cohort had moderate to high disease activity states at their
last visit without ever showing any clinically meaningful improvement in their disease activity. These
patients may represent a refractory group of patients who do not respond well to current therapies.
However, our data also suggest that, once remission is achieved, patients under a treat-to-target
strategy will tend to stay in remission for > 1 year, on average, before exiting this state of clinical
disease quiescence.
Relation to overall programme
Variability of remission
In the REMIRA cohort of 152 RA patients, we observed various patterns of disease activity and
physical functional disability over 12 months. Forty-four patients were observed in sustained remission
over all visits, whereas 23 patients were observed to be disability free at all visits and 14 patients were
observed to have been both in sustained remission and disability free. Sizeable proportions of patients
were observed to have a fluctuating disease course (30.7%, n = 46) and to have fluctuating levels of
functional impairment (34%, n = 51). These fluctuating patterns may reflect the difficulty in controlling
patients’ disease, even under a treat-to-target strategy.
Factors influencing transitions between disease states
We found that sex and levels of functional disability had an impact on the rate of transitions between
disease activity states. In particular, males tended to have a higher rate of transitions out of low
disease activity to moderate disease activity than females, although higher levels of disability increased
the rate of transitioning out of the remission state. We also found that higher levels of disease activity
increased the rate of transitioning from moderate to severe levels of disability and that ethnicity and
disease duration also influenced the transition rates between disability states, in particular transitions
in and out of the mild disability state.
Factors influencing erosive progression
As expected, the 1-year damage progression rate was higher in those patients with erosions at baseline.
Ethnicity and disease activity at baseline were identified as possible predictors of damage progression.
No evidence was found for functional disability as a predictor of 1-year damage progression in RA
patients undergoing a treat-to-target strategy.
TABLE 23 Multivariate logistic regression model for 1-year damage progression
Variable OR 95% CI p-value
Ethnicity: white vs. rest 9.47 1.11 to 80.47 0.040
DAS28-ESR at baseline 2.07 1.04 to 4.12 0.039
Erosive at baseline: yes vs. no 7.30 2.08 to 25.59 0.002
HAQ at baseline 0.48 0.14 to 1.69 0.225
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Patients’ and practitioners’ views
The research in this section evaluated patients’ and practitioners’ views on intensive management andconsidered additional points of relevance to patients. This part of the research had considerable PPI.
Aims
This section mainly focused on patients’ and practitioners’ views about intensive management, but it
also took into account patients’ broad-based perspectives about their care. Both parts of the research
have been published.369,370
Patients’ and practitioners’ perspectives about the TITRATE trial
We explored patients’ and practitioners’ views on the feasibility and acceptability of intensive
management and their experience of receiving and providing intensive management. There is
considerable evidence that patients’ perspectives are important in trying to manage their long-term
disorders, such as RA.271,371–374
Broad-based perspectives
Patients discussed many aspects of their care during the TITRATE intensive management sessions,
including emotional distress and treatment of pain and fatigue using self-management approaches.
Practitioners provided emotional and self-management support to patients who learnt strategies to
better manage symptoms. A study outside the TITRATE trial found that one other factor patients
considered important was foot care; however, the TITRATE trial did not directly address this. There is
substantial evidence that foot problems are particularly challenging in RA.375–378 Two expert patients
therefore led a survey of patients and clinic staff about foot care in RA.
Methods
Qualitative study to assess TITRATE trial management
Patients were recruited from the trial sites with no additional patient participant criteria to those of
the trial. Fifteen patients (12 females and three males aged from 35 to 70 years) from 10 different
clinics participated. Details of these patients are shown in Appendix 1, Table 33. Practitioners were
those trained to deliver the TITRATE intensive management intervention who had delivered at least six
sessions with the same patient. Sixteen practitioners (13 research nurses and three specialist nurses)
from 13 rheumatology centres participated. Individual interviews were conducted with all patients and
13 practitioners. Eight interviews were face to face and 20 were via telephone. One focus group was
held with three practitioners.
Separate semistructured topic guides were developed for patient and rheumatology practitioner
participants. Initial topic guides were based on the research questions, constituent components
of the intensive management intervention, and previous qualitative studies (e.g. Schoo et al.379).
The semistructured topic guides were discussed with the multidisciplinary research team and a
departmental patient expert, who provided feedback on the suitability and relevance of the questions.
Following the first two interviews, some small changes were made to the topic guides. These were
based on how participants responded to the questions and the flow of the questions during the
interviews. Further details are given in Appendix 3.
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Foot health
A mixed-methods approach collected qualitative data from two focus groups of nine RA patients380 and
quantitative data from 13 rheumatology team members from one site. The data were collected in a
survey that had been piloted and assessed by two external clinicians and departmental patient experts
living with RA for face and content validity using average congruence.381 Further details of these
patients and clinicians are given in Appendix 1.
Key findings
Patients’ and practitioners’ perspectives
Assessments covered monthly appointments, the therapeutic relationship with the practitioner,
increased medication, the patient handbook and shared treatment planning (Table 24).
Patient and practitioner data were analysed separately. Data were analysed using thematic analysis285
and iterative categorisation.382 Iterative categorisation generates a clear audit trail with the data
analysis, closely linked to the raw data, and involves four stages: (1) familiarisation through the reading
of transcripts, (2) line-by-line coding to organise the data in preparation for analysis, (3) descriptive
analysis that identifies themes and (4) interpretive analysis that explores patterns, inconsistencies and
relates findings to existing knowledge.
Monthly appointments were acceptable to patients and practitioners. The benefits included (1) regular
reviews of medication and (2) practitioners establishing close relationships with patients. Practitioners
felt ‘fairly confident’ using MI techniques.




Monthly appointments acceptable With working full time as well and having to go up
there [clinic appointments], it was difficult, because in
work I had to work my breaks to be able to make
those appointments. So there was difficulty in getting
there [clinic appointments], but I wanted to go
Access to services/consultant We had a lady who was going on holiday and she had
really bad side effects from methotrexate, so she just
came in a few days before her holiday and we
converted the methotrexate to subcut [subcutaneous].
A doctor saw her within an hour of her ringing on the
telephone, so you wouldn’t normally get that
Monthly appointments beneficial If they decided that I needed a change in medication
or increased the medication [. . .] they [practitioners]
were closely monitoring it [patient’s response to
medication]. It’s like fine-tuning an engine really. That’s
how I equate with it [process of medication titration]
Intensive management preferable to
standard care
If you’ve got a clinic of seven [patients booked], you’ve
got to churn them through [. . .] the nurse being a
pastoral carer has gone. We’re basically following up
and checking their disease activity scores and things
like that now [. . .] Whilst you get that pastoral care
with the TITRATE and they [patients] see it [pastoral
care], they love it
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Practitioners ‘fairly’ confident using MI
techniques
I think that they [the sessions] become easier as the
sessions develop. I think just that first two or three
[sessions] when you don’t really know each other and
you’re trying to encourage that – to encourage the
conversation more than just a yes or a no, it’s
quite difficult
Patients and practitioners worked on
goals together
It’s looking at the bigger picture of what else you can
do. It might be that the pain has flared up because
they’re [patient] sitting in a chair all day. Or is their
mood affected because they’re isolated at home
because they’re not able to get out and about?
Importance of continuity of care After a while once I got to know them [practitioners]
we got on a lot better. I was less embarrassed
I suppose is the word or maybe less reserved. I was
able to talk to them [practitioners] about anything
really. I suppose it’s building up trust isn’t it?
Provision of helpful information You know I’m just feeling pretty good, because my
nurse helped me to understand my illness and she
explained clearly how it [the medication] works, what




Improvement in RA symptoms I’ve had arthritis for 34, 35 years [. . .] and only just
recently I feel that it’s [RA] finally been controlled [. . .]
I’ve got stiff swollen joints that have been damaged,
they’ll never be repaired I know that, but the fact that
I’m not having flare after flare after flare, which I was
having that’s a great relief to me
Side effects of medication At first, I found it very hard, because I was just taking
medicines and medicines. I had a few little side-effects –
upset stomach and feeling a bit down and drowsy.
But overall when I got through the first few weeks, fine
Treatment algorithm easy for
practitioners to use
The rest of the intensive management stuff I’m
absolutely happy with. It’s the changes in medication,
where I have to rely on other people, to do
prescriptions and things like that that I think held
me back
Patient handbook Views on the content of the handbook Oh yeah [. . .] it [handbook] was very informative you
know, like loads of information and lots of help.
A lot of it [content of the handbook] wasn’t relevant
to me
I do refer patients back to the information in the
handbook when they’re, for example, struggling with
fatigue or exercise [. . .] I’ve also given the handbook
out or I’ve shown other nurses the handbook because
it’s a great resource
We’ve got those that want to read everything and then
you get those that don’t want to know anything, just
give me a new tablet and I’ll start it
Introductory use of the handbook I can’t say I used it [handbook] often, but I did use it
[. . .] I did use it to begin with more than I did at
the end
continued
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Therapeutic relationships with practitioners were important. Commonly reported goals included weight
loss and exercise, closely followed by the management of fatigue, pain and regulation of sleep patterns.
Patients described how they identified these areas with practitioners who ‘helped to organise them’
and ‘gently encouraged them’ to make changes. Practitioners’ monitoring and progress at subsequent
intensive management sessions was considered helpful. Learning to pace was the most commonly
reported self-management technique patients and practitioners worked on together, followed by
gaining control over pain and fatigue.
Most patients said that their practitioner helped them to learn about their RA condition. Knowledge
about RA and its treatments and what to expect from these is something patients found valuable.
Areas mentioned specifically by patients included fatigue, pain and medication management.
Practitioners appreciated the option to offer biologics to patients with moderate RA. Most patients
found that the optimised medication following monthly joint assessment helpful and side effects were
generally resolved. Practitioners described the treatment algorithm as clear and easy to use. Nurses
were able to seek advice from consultants about treatment changes.
The use of the patient handbook and shared treatment plans varied substantially. Practitioners
described two categories of patients. Some patients would read the handbook carefully and bring the
resource to the sessions and others did not show much interest in the material and did not use it.
Patients’ and clinicians’ views on foot health care for rheumatoid arthritis
A patients’ focus group highlighted the need for foot health information, the absence of regular
assessment of feet in routine consultations and the importance of accessing podiatry services. The
clinician survey showed that 69–85% of clinicians provided patients with foot health information
(Figure 23). The feet were examined in only 47% of routine consultations. Clinicians often failed to
examine feet routinely because foot examinations are not included in the DAS28-ESR score and foot
examination takes additional clinic time. Although 31% of clinicians referred patients to podiatry when RA
was diagnosed, none referred patients for periodic podiatry reviews. Over half of clinicians believed that
patients self-reported their foot problems. Only 62% of clinicians felt fully competent examining feet.




Views on the shared treatment
planning
It was good – it [shared treatment plan] facilitated a
good getting to know you session with the guy
[practitioner] that I was doing it [completing the
shared treatment plan] with. It [the process of
completion] was useful for me to sit down and put it
[previous medication, medication preferences] in black
and white. I suppose it [the process of completion] was
good for him to find out where my head was at
Yes [. . .] I have found that [the shared treatment plan]
useful but [. . .] I’ll be honest I haven’t really referred
back to it very often. I don’t know if that’s just a fault
of mine or whether it’s because the sessions have
taken their own path
Reproduced with permission from Prothero et al.370 This is an Open Access article distributed in accordance with the
terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and
build upon this work, for commercial use, provided the original work is properly cited. See: https://creativecommons.org/
licenses/by/4.0/. The table includes minor additions and formatting changes to the original table.
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The qualitative data from the focus groups were analysed using inductive thematic analysis within a
realist paradigm, whereby analysis was driven by patients’ accounts of their experiences, meaning and
reality. Codes were generated by the first author and validated by a second author to negate potential
patient bias. Themes and subthemes were identified by looking for recurring patterns in the data before
finalisation of the themes by two authors. To enhance the validity of the findings, the simple counting
method was applied, as well as providing accounts from all participants.
The survey was piloted and assessed for face and content validity using average congruence from two
clinicians (external to the clinic) and our departmental patient experts (those living with RA).381,383–385
Limitations
There were two main limitations of the studies in this section. First, there is inevitable uncertainty
about the extent to which our findings are generalisable. Second, there is doubt whether or not the
TITRATE trial covered all the areas that are crucial for patients.
Generalisability of patients’ and practitioners’ perspectives
Both practitioners and patients volunteered to take part in the interviews. It is possible that those who
engaged more with the delivery or receipt of the intensive management intervention may have been
more eager to participate. As patients in the qualitative study were largely elderly, retired and white,
they were not fully representative of the RA population.
The assessment of foot health had to use a non-validated questionnaire and obtained retrospective
views from clinicians because no questionnaire was available for this purpose. These methodological
problems may have resulted in recall bias386 and reduced the generalisability of the findings. The
perspectives of clinical staff were also restricted to clinicians practising in a single specialist unit.
What was missing from the TITRATE trial?
We do not know the extent to which the management approach in the TITRATE trial addressed all
problems experienced by patients. We have highlighted the omission of foot care. Other issues that





















Information on how RA affects feet
Foot care advice
Footwear advice




FIGURE 23 Information about feet provided by clinicians to RA patients. Adapted with permission from de Souza et al.369
This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0)
license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the
original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The figure includes minor additions and
formatting changes to the original figure.
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Relation to overall programme
The most important finding is that intensive management is feasible in RA. The other relevant findings
were that practitioners want to implement lifestyle modification in routine practice and that clinicians
must not overlook foot care in RA.
Intensive management is feasible
We found that intensive management was acceptable to patients, whose feedback was positive.
These findings reflect experience of patients in other comparable intensive treatment situations.270,387,388
Patient participants found that increasing their medication was generally helpful. They also found that
seeing the same practitioner at monthly intensive management sessions and the treatment support they
provided were beneficial. Feedback from practitioners also showed that intensive management was
feasible and that they could be trained to deliver it. Overall, these positive perspectives mirror the
positive findings in the TITRATE trial.
Including lifestyle modification in routine care
Practitioners would like the opportunity to address lifestyle factors with patients in routine
appointments. There is a strong case to examine the most practical and cost-effective way to train
practitioners to adopt this approach in routine care settings. There is considerable support for such
approaches in other settings.344,389–392
Overlooking feet
Clinicians need to take into account foot symptoms when managing patients and avoid what has
been termed ‘DAS blindness’369 (i.e. when consultations focus on components of the DAS28-ESR).
Rheumatology clinic staff may need training in foot examination. Podiatry input should be part of the
standard multidisciplinary care provided in RA, which was overlooked in the TITRATE trial, especially in
view of the substantial evidence underlying the importance of foot care in RA.393–398
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Implementing intensive management
The research in this section considered issues relevant for implementing intensive management inroutine clinical practice. This part of the research also had considerable PPI.
Aims
The research aims in this section span different aspects of delivering intensive management, including
popular perceptions of RA and its care. We assessed the fidelity of delivering the intervention,
evaluated the roles of specialist nurses and other practitioners who delivered intensive management
and carried out a patient-led thematic analysis of language used about RA in UK national newspapers.
One part of the research has already been published.399
Fidelity of intervention delivery
Intervention fidelity can lead to greater confidence in results, supports research dissemination and is of
particular relevance with complex interventions.400–405 Our aim was to assess delivery of the treatment
support by studying 10% of all recorded TITRATE intensive management sessions.
Nurses and other practitioners giving intensive management
The work of rheumatology nurses to deliver intensive management raises several issues. These include
the published evidence for the impact of nurses in the management of RA assessed by a systematic
review, the number of rheumatology nurses involved in rheumatology identified in national surveys,
and the experience and background of nurses and other practitioners who delivered intensive
management in the TITRATE trial.
Rheumatoid arthritis portrayal by UK national newspapers
An important source of knowledge, beliefs and attitudes about illness is the mass media.406 Research
has established the often negative and emotive language utilised by journalists to report on long-term
physical and psychological illnesses. Attempts to increase the use of intensive management in RA
nationally are likely to be influenced by opinions outside the immediate specialist area, including its
representation in the media.247 We therefore examined how RA is portrayed in the UK popular press.
Methods
Fidelity of intervention delivery
Intensive management consultations were audio-recorded by rheumatology practitioners with patients’
consent. A 10% sample of all recorded consultations were assessed (this comprised 126 sessions).
Fidelity assessment was conducted within a team of four researchers. Establishing inter-rater reliability
was undertaken between July 2015 and February 2016. Rating of the treatment support delivery
commenced in March 2016 and continued for 1 year.
Systematic review of nurses contributions
We searched MEDLINE using the terms ‘nursing’ and ‘rheumatoid arthritis’. The search was limited
to English publications from January 2000 to August 2018. Further details are given in Report
Supplementary Material 1 and 2, including a PRISMA flow diagram (see Report Supplementary Material 1,
Figure 7), the studies included (see Report Supplementary Material 1, Table 9) and study quality
(see Report Supplementary Material 1, Tables 10–13).
DOI: 10.3310/pgfar09080 Programme Grants for Applied Research 2021 Vol. 9 No. 8
Copyright © 2021 Scott et al. This work was produced by Scott et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social
Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution,
reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/. For attribution the
title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
83
National data about nurse numbers
Data about rheumatology nurse numbers were obtained from surveys by the National Audit Office407
and National Clinical Audits.408
Nurses and other practitioners involved in the TITRATE trial
The TITRATE team collected data about the professional backgrounds, experience and titles of all
clinicians who delivered the intensive management during the 12-month trial.
Portrayal in newspapers
The study was patient led with the support by a social scientist. The LexisNexis® [RELX (UK) Ltd,
London, UK] online repository of print media was searched for articles from July 2011 to July 2016
that included RA in the headline and/or lead paragraph of 15 UK national non-specialist newspapers.
Resultant articles were uploaded to NVivo (QSR International, Warrington, UK) and a realist
perspective aided thematic analysis.409 Further details are given in Report Supplementary Material 1,
Tables 14 and 15.
Key findings
Fidelity of intervention delivery
Seven assessments were undertaken to assess whether or not the technique was demonstrated (Table 25).
Agreement of agenda between patient and nurse, the patient talking more than 60% of the time and the
use of importance and confidence rulers were evidenced in only a minority of participants’ consultations.
Those techniques that were clearly more instinctive, or easier for the intensive management nurses to
learn and incorporate, were providing solicited information only, demonstrating listening skills and asking
open questions.





Discuss and agree the agenda together with the patient 53 (42)
Assess confidence/importance of changing behaviour using ruler/scale 19 (15)
Provide unsolicited advice and/or information < 50% of time 83 (66)
Provide information when solicited > 80% of the time 92 (73)
Use at least three open-ended questions 75 (60)
Allow the patient to talk > 60% of consultation 44 (35)
Summarise what the patient said on at least two occasions 75 (60)
Graded questions
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Affirm the patient’s strengths, abilities or effort in any area by saying
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Seven questions had graded answers indicating the degree to which a technique was used. These are
shown in Table 25. Between 52% and 73% of assessed consultations did not demonstrate MI skill
levels beyond grade 2 on the 0–4 scale. A high level of MI technique use was observed in 5–12% of
consultations. The technique that nurses demonstrated most often at moderate or high fidelity levels
was affirming the patient’s strengths and abilities [in 58 consultations (46%)]. Evoking and reinforcing
change talk and identifying one main problem area were observed at moderate or high fidelity skill
levels in 34 (27%) and 32 (25%) consultations, respectively. Conversely, exploring reasons for and
against behaviour change and helping the patient identify barriers to and facilitators of behaviour
change were observed at moderate and high fidelity in only 16 (13%) consultations.
Specialist nurses and other practitioners giving intensive management
Systematic review
We identified 655 publications and included 19 papers reporting on eight trials410–417 (1974 patients),
seven qualitative studies388,418–423 (242 patients) and four observational studies424–427 (1234 patients).
The main findings are summarised in Table 26. The trials were undertaken in a range of settings and
used both superiority and non-inferiority designs. Overall, they provided strong evidence that patients
whose follow-up was primarily managed by specialist nurses achieved similar clinical outcomes to those
who were managed by doctors. Several trials showed that nurses were also able to enhance patient
satisfaction and self-efficacy. The qualitative studies showed that nurses are able to increase patients’
knowledge of RA and promote self-management for patients. The observational studies, which had
case–control and cohort designs, also showed that nurses provided effective and acceptable care.
Overall, these studies provided strongly positive evidence in support of nurses playing key roles in the
follow-up management of RA patients.
National data about nurse numbers
The 2009 National Audit Office report407 identified 377 rheumatology nurses and the 2016 Healthcare
Quality Improvement Partnership report408 identified 355 nurses (in addition, there were 0.85/100,000
consultant rheumatologists and 0.64/100,000 rheumatology nurses).
Nurses and other practitioners involved in the TITRATE trial
From 2014 to 2017, TITRATE trial training was given to 100 clinicians from 39 NHS trusts (42 sites).
Eighty-six participants were female, 14 were male and their mean age was 48 (range 28–72) years.
The rheumatology experience of the participants varied, with a mean duration of 5 (range 0–30) years
(59 participants had ≤ 4 years of experience) (Figure 24). The professional backgrounds of participants
also varied: 85 participants were nurses, eight participants were other health professionals, six participants
had medical backgrounds in non-consultant posts and one participant was an occupational therapist.
There were marked differences in how the clinicians described their roles (Figure 25). Nurses were
called rheumatology nurse, rheumatology nurse specialist, rheumatology clinical nurse specialist and
rheumatology nurse practitioner. There were also considerable variations in their seniority, ranging from
band 5 nurses to a modern matron.
Portrayal by UK national newspapers
The LexisNexis search produced 413 newspaper articles, 147 of which met the inclusion criteria.
Some newspapers published many articles on RA and others published few or none. Three themes
were identified in the thematic analysis that conveyed how UK national newspapers used language
to report on RA. These themes comprised (1) language used to describe RA, (2) language used
to refer to those who live with RA and (3) language used to report on potential new treatments
for RA.
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TABLE 26 Systematic review: main findings in trials, qualitative studies and observational studies of specialist nurses
Publication Year Patients (n) Conclusion
Trials
Tijhuis et al.417 2002 210 Nurse specialists achieve similar outcome in comparison to
other approaches
Hill et al.411 2003 80 Clinical outcomes similar, but patient satisfaction greater with
nurse care
Ryan et al.416 2006 71 Nurses improve patients’ perceived ability to cope with
arthritis
Koksvik et al.412 2013 68 Nurses increase satisfaction with care without loss of efficacy
Larsson et al.413 2014 107 Stable patients on biologics monitored in nurse-led clinics have
similar outcomes
Primdahl et al.415 2014 287 Stable patients receiving biologics in nurse-led clinics have
comparable clinical outcomes and enhanced self-efficacy and
satisfaction
Ndosi et al.414 2014 181 Nurse-led care gave similar clinical outcomes and higher
general satisfaction scores
Dougados et al.410 2015 970 Nurse-led programme gave short-term benefits on comorbidity
management
Qualitative studies
Temmink et al.423 2000 128 Patients are positive about quality and continuity of care.
Some limitations in continuity of care
Long et al.421 2002 16 Nurses contribute to assessment, integrating therapy and
emotional support
Arvidsson et al.418 2006 16 Nurses provide holistic assessments, co-ordinated care and
provide insight
Primdahl et al.422 2011 33 Nursing consultations are less factual and less authoritarian
than medical consultations
Bala et al.419 2012 18 Nurses give familial atmosphere, empathy, knowledge,
accessibility and continuity
Larsson et al.420 2012 13 Nurses enhance security, familiarity and participation
van Eijk-Hustings et al.388 2013 18 Nurses provide education, self-management and emotional
support, and help organise care
Observational studies
Esselens et al.424 2009 191 Programmed care achieved better clinical outcomes and
general health
Watts et al.427 2015 349 Minimal differences in clinical outcomes between community
and hospital follow-up
Solomon et al.426 2015 301 Fewer patients seeing nurses/physician assistants had high
disease activities
Muñoz-Fernández et al.425 2016 393 Nurse-led clinics achieved better global assessments and less
disability
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In describing RA, ‘attack’ was the most cited term and was more likely to be used in the tabloid or
middle market press than in the broadsheets. ‘Painful’, ‘crippling’, ‘agony’ and ‘incurable’ were also
commonly used terms.
In describing people with RA, the term ‘sufferers’ had the most number of references across the entire
data set of newspaper articles, and it was more likely to be found in the tabloid/middle market press
than in broadsheets. ‘Patients’, ‘people’ and ‘victims’ were also commonly used terms.
The final theme, the way potential new drugs or medical technologies for RA are reported, showed
that journalists often used the language of ‘hope’ to frame the discussion of potential treatments.
‘Hope’ was mainly used in the tabloid and middle market newspapers. Other terms included
‘breakthrough’, ‘ground-breaking’, ‘cure’ and even ‘miracle’ on one occasion.
Overall, newspaper articles drew on negative and emotionally laden language to convey the experience
of RA. This approach was more apparent in the tabloid or middle market newspapers than in
broadsheets. Neutral terms, such as ‘people’ and ‘individuals’, were used to describe those living with
RA. However, they were often viewed by the popular press in a passive sense as ‘sufferers’ or ‘victims’.
The media’s application of language in the context of potential new medical technologies or drugs for
RA overwhelmingly stressed their positive effects. This is despite the fact that much of the scientific
research highlighted in the printed press over the 5-year time frame of this study was still in
development and often untested in humans.
Limitations
The research in this section of the report was more diverse as there are a broad range of issues that
may influence implementation. Two main limitations need consideration: (1) the nature of intensive
management and (2) the variable nature of specialist rheumatology teams.
Nature of intensive management
The treatment strategy in the TITRATE trial involved both increasing the intensity of treatment with
DMARDs and biologics and supporting patients to manage their disease. Although some health-care
practitioners may be most successful in increasing treatment, others may be most successful in
providing supportive care. Not all practitioners may excel at all the different aspects of intensive
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FIGURE 24 Rheumatology experience of TITRATE trial participants.
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FIGURE 25 Nurses and health-care professionals in training programme. SpN, specialist nurse; SpR, specialist registrar;
ST3, year 3 of specialty training.
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Variable rheumatology teams
There is extensive variation in the nature of specialist rheumatology teams across England. Some have
large teams of nurses and other health-care practitioners. Others have very few staff. There is also
extensive variation in the nature and experience of nurses. This variability makes it particularly difficult
to assess what is available and what can be delivered locally.
Relation to overall programme
The research in this section provides some insights into some of the challenges that are likely to arise
when implementing intensive management for patients using the type of approaches taken in the
TITRATE trial. A key problem is the variability in expertise and training of specialist nurses and other
allied health-care professionals. Many rheumatology nurses have relatively limited experience and they
need more education and support. Another separate problem is the constant negative perspectives
about RA in the mainstream media, which are likely to prove a disincentive for patients and clinicians.
Complexity of intervention
The fidelity assessments showed that nurses and health-care practitioners followed some but not all
the approaches they were taught to use in the TITRATE trial. Training staff in the MI techniques
followed in the TITRATE trial will require both time and commitment from their units.
Limited experience of specialist nurses
Most nurses delivering intensive management in the TITRATE trial had been involved in rheumatology
for < 5 years. Whatever the benefits of using nurses to deliver specialist care, this level of experience
of specialist nurses creates complexities in the delivery of expert care. Consultant rheumatologists, by
comparison, have far more experience in the field. The challenges in training and supporting specialist
nurses and other non-medical health-care professionals managing RA patients are widely understood.428,429
Negative perspectives about rheumatoid arthritis
Media views about RA are not crucial for changing the way care is delivered. However, a persistent
negative message about the disease as ‘crippling’ and patients being portrayed as ‘sufferers’ and
‘passive victims’430 is unhelpful in the promotion of intensive management approaches.
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Our research covered many aspects of the intensive management of patients with moderately active
RA. Several main conclusions dominate our findings about intensive management: (1) it increases
remissions in active RA; (2) it is effective and safe in moderate RA; and (3) it is practical in routine care
settings, although, in the short term, within-trial costs and benefits are unlikely to be cost-effective
at the threshold ranges typically used by UK decision-makers (i.e. £20,000–30,000/QALY). This final
section places the TITRATE trial findings into perspective. Three published reviews undertaken for the
programme helped frame our conclusions.431–433
Intensive management in active rheumatoid arthritis
There is substantial evidence from previous trials that intensive management increases remissions in
patients with active RA. There is no particular reason from the perspective of efficacy to favour one
type of intensive management strategy over another. However, based on custom and practice and
health economic considerations, there is a case to start with combinations of conventional DMARDs.
This perspective is not universally shared. There is marked international variation in conventional
DMARD use,48 and some groups report low persistence rates with combinations of conventional
DMARDs compared with biologic combinations.46,47,434
Intensive management in moderately active rheumatoid arthritis
The TITRATE trial showed that intensive management increases remissions in patients with moderate
RA without increasing harms. The positive findings in the main trial were supported by the associated
qualitative study of patients’ and clinicians’ views.
Using intensive management in routine care
The intensive management approach used in the TITRATE trial is acceptable to patients and clinical
staff and is generalisable across English rheumatology clinics. Although it can be delivered in routine
care, current NHS staff are working at full capacity, and implementing it nationally would have
resource implications. There are unresolved uncertainties about how best to standardise nurse-
delivered intensive management strategies in routine clinical settings. In addition, the way intensive
management was used in the TITRATE trial primarily reflected clinicians’ perspectives. Patients may
have somewhat different views on how it should best be used.
Other important findings
Intensive management, however, does not benefit all RA patients with established moderate disease.
Previous trials and the findings in the TITRATE trial indicate that it usually benefits no more than half
of RA patients. Ongoing active RA has negative clinical and social impacts on patients.435,436 There is
also uncertainty about the extent to which it provides care that is considered cost-effective within
current perspectives on WTP thresholds in general437–439 and how this translates to RA.29,440,441
Remission is the key target of intensive management. Although DAS28-ESR remissions have many
complexities, they appear to be a reasonable and efficient target. When patients achieve DAS28-ESR
remissions for more than a single occasion, they usually continue to have reasonably well-controlled
RA for some considerable time.
The routine management of RA is continually evolving. Over the last two decades patients have received
more intensive management and their disease activity levels have decreased. Current management
resembles many components of the approach used in the TITRATE trial, although it neither achieves the
same intensity of drug treatment nor receives the same extent of supportive care from specialist nurses.
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Implications for practice
Intensive management for patients with moderate rheumatoid arthritis
The positive findings from the TITRATE trial and associated research suggest that it is timely to
manage some patients with moderate RA intensively. This approach is in line with the national and
international guidance.
Biologics in moderate rheumatoid arthritis
The intensive management used in the TITRATE trial involved giving some patients biologics in line
with current specialist guidance but outside what is currently agreed in NICE Technology Appraisal
guidance for these drugs. This is an area of substantial change, as the introduction of biosimilars is
currently reducing the acquisition costs of these drugs.442–444 The TITRATE trial provides information to
inform future national work in this field. It found that only a minority of patients needed these drugs
over and above those meeting current guidance, which are both supportive of extending biologic use
in this way. At the same time, there was no evidence in the TITRATE trial that biologics specifically
contributed to the benefits of intensive management, and many patients who achieved remissions did
not receive biologic drugs. Against this background, we appreciate that many elements are involved in
developing national guidance and the findings from the TITRATE trial are only one factor to take into
account. There is also a need to consider, in more detail, the cost-effectiveness of such an approach, as
the TITRATE trial did not consider all aspects of the economic issues involved. Decisions about using
relatively high-cost interventions for long-term disabling disorders like RA create complex ethics issues
and it is important to take broad-based perspectives on the benefits not only to patients but also to
society as a whole. Such considerations, although important, fall outside what conclusions can be
reasonably be drawn by us as researchers in the field.
Regular assessments by nurses
Nurses and other health-care professionals played crucial roles in delivering intensive management
in the TITRATE trial. A simplified version of the TITRATE training programme will be available for
specialist units that wish to use it. A range of health-care professionals can deliver such care, and it may
be possible to use telephone and digital interactions rather that needing all patients to attend clinics in
person. Since our research was completed, the coronavirus pandemic changed the way clinical practice
is delivered in England. Telephone and digital consultations have been widely adopted, and their impact
on our findings needs careful consideration. Patient perceptions about the way their RA is assessed
and managed are likely to be of particular relevance when refining how care is delivered. It may also
be possible to assess patients at intervals other than monthly. Each specialist unit must decide how to
deliver regular assessments by nurses and other staff based on national and international guidelines and
a range of different sources of evidence, including studies such as the TITRATE trial. Not all patients
require identical follow-up arrangements, and care needs to be individualised. There is also a case for
undertaking further developmental work to further rationalise how intensive management is delivered.
Simplifying the delivery of intensive management approaches will reduce their costs.
Recommendations for future research (in priority order)
Impact of potential predictive factors outcome
The TITRATE trial showed that patients with a high BMI were unlikely to respond to intensive
management, although whether the effect was due to obesity itself or reflective of a range of
underlying associations is unknown There is a growing body of evidence from observational studies
that a high BMI is associated with persisting active disease and poor outcomes.355,445–447 The reasons
for these associations and the implications for management need further investigation. However, such
research needs to take into account a range of genetic, educational, behavioural and environmental
risk factors, rather than focusing entirely on BMI. It is also likely that social factors will be of crucial
importance in predicting responses, although this was not specifically addressed in our research.
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Patients from socioeconomically deprived backgrounds and those from some ethnic minorities may be
more likely to have poor outcomes.
Broadening the approaches to minimising disability
Achieving remission reduced disability in the TITRATE trial, but many patients continued to have
considerable disability. There was also evidence that high initial disability levels reduce response to
intensive management and that, although disease activity levels have declined over the last two
decades, there is less evidence that disability has also reduced. These various findings suggest that
disability needs to be reduced in different ways over and above minimising disease activity levels.
The best way to achieve this goal needs further research. Non-drug approaches, which were not part
of the TITRATE trial, may be relevant.448–450
Part of broadening approaches to minimising disability includes reconsidering how disease activity is
assessed. Although we found that intensive management reduced disease activity in moderate RA, it
did not have any impact on ESR or CRP levels. It is possible that alternative blood tests may be more
appropriate in patients with moderate RA, and further work may help identify which, if any, of these
provide useful data when monitoring treatment responses and how they can be used in conjunction
with clinical data.451–454 It is also possible that other approaches to assessing disease activity may be
more informative (e.g. using patient self-assessments in association with digital consultations).
Explore the long-term cost-effectiveness of intensive management for patients with
moderate rheumatoid arthritis
The clinical findings in the TITRATE trial strongly support using intensive management approaches for
patients with moderately active established RA. In contrast, the economic analysis suggested that its
costs fell above the thresholds usually accepted as affordable by the NHS. However, these economic
assessments were restricted to the 12-month follow-up period in the trial. They did not take into
account the benefits of improved earlier treatment and potentially reduced biologic drug use over
the longer term. Extrapolation of the costs and benefits of the intervention could be carried out in a
decision-analytic model to produce a lifetime estimate of expected costs and QALYs. One important
issue is estimating the impact of the future treatment pathway for the patient populations once a
switch from intensive DMARD therapy has occurred. This will include the costs of biologics if patients
progress to severe RA and the time to loss of efficacy (which could be estimated from survival analysis
of the within-trial data).
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Patient and public involvement
Background
This section is based on the GRIPP2 (Guidance for Reporting Involvement of Patients and the Public 2)
recommendations. To appreciate the way in which patients were involved a brief background about
arrangements in the host institution is likely to be helpful. In 2005, King’s College Hospital (London, UK),
Department of Rheumatology, which hosted the TITRATE programme, implemented a strategy to
embed PPI in research, teaching and health service delivery. This PPI strategy was led by Heidi Lempp
(a TITRATE investigator).
The department established a PPI group comprising six patients and one carer. All members were
provided with honorary contracts with King’s College London. One patient currently had a contract
with King’s College Hospital NHS Foundation Trust (London, UK) to advise clinic staff on outpatient
service delivery improvement.
Our commitment to PPI led to the setting up of patient education evenings, which have been running
since 2014. These sessions take place in collaboration with clinic staff, patients and academic staff
and are based on topics suggested by patients/carers. These sessions have been very successful, with
several requests for their continuation. The annual patient education event takes place during the
summer months (as requested by patients) and are held during early evening, starting at 5.30 p.m.
The presenters are patients and clinicians from King’s College Hospital or invited external speakers.
The number of attendees is gradually growing (now up to 30–40 people) and the feedback has been
mostly positive (average 9/10, very good/excellent). The topics covered in 2017 included the following:
l emotional support as part of a comprehensive rheumatology outpatient service: findings from an
interview study with patients
l adjusting to and living well with a long-term condition
l Garment+ – redesigning clothing with patients for people
l my home is my castle – but the drawbridge is up – accessible housing when living with long-term
rheumatological conditions
l an overview of fatigue in patients with long-term musculoskeletal conditions
l evidence-based self-management of fatigue and emotional well-being in long-term
musculoskeletal conditions.
Aims for involving patients and the public in the TITRATE programme
Patients made key contributions to many aspects of the TITRATE programme and were involved in all
aspects of its design, delivery and plans for future implementation of its findings.
The three main aims for PPI were to (1) help design a care pathway for delivering intensive
management in a way that patients found acceptable; (2) assess the impact of receiving intensive
management and (3) consider the issues involved in implementing the findings of the programme.
Patients were also encouraged to extend the work on the programme into areas they considered of
particular relevant.
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Methods for involving patients and the public
The local arrangements for PPI within the host department were supplemented by additional support
for the TITRATE programme in two ways. First, the key patient organisation in England for people
with RA – the NRAS – was involved. The chief executive of NRAS was one of the co-applicants on the
TITRATE programme. During the research programme, the NRAS website provided information about
the TITRATE trial, which had been approved by the Research Ethics Committee. Second, two other
co-applicants in the TITRATE programme were also patients (one had no professional background in
medicine and the other was both a patient and a former GP). These various arrangements enabled us
to achieve a high level of involvement of patients and the public in the TITRATE programme.
One part of the TITRATE programme, workstream A, focused on developing care that is ‘best for
patients’. This aspect of the research was the main focus for PPI. The workstream had three themes:
(1) equipping patients for intensive treatment, (2) understanding patients’ views on intensive treatment
and (3) implementing intensive treatment approaches in routine clinical care.
Outcomes from involving patients and the public
Equipping patients for intensive treatment
The patient handbook was developed with substantial PPI. First, it was supported by one focus group
that involved six patients who live with RA from a single NHS hospital trust. Second, individual
feedback was received from one departmental patient expert in close collaboration with two RA
charities (the NRAS and Arthritis Research UK). Shared treatment plans, which are an associated part
of the research, were developed with help from five patients and one carer from one hospital trust.
The developmental work for the patients’ handbook and shared treatment plans has been described in
one paper, which was published in 2017.268 Two patients who were involved developing the handbook
co-authored this publication.
Patients’ views on intensive treatment
Patients’ views on intensive treatment in the TITRATE programme before the trial commenced were
evaluated through focus groups and one-to-one interviews with nine patients and five carers, and
an additional two patients whose first language was not English. These patients and careers were
from three different hospital trusts. The findings from the focus groups were published in 2016.269
One patient co-authored this publication.
In 2017, the main focus has been an evaluation of the views of nurses and patients about their
participation in the trial. Louise Prothero interviewed 13 MI practitioners from 20 different centres
and a similar number of patients who participated in the active arm of the trial. The interview schedule
for the patients was developed from the literature and in collaboration with one of our departmental
expert patients so that the content of the questions were relevant and comprehensible to the
participants. The research findings were published in 2019.370
Input to research questions
The topic guide for the patient interviews was reviewed by a patient. Changes were made to key
questions to make them more positive and understandable to patients.
Planning implementation
Four service users attended a planning meeting for implementing nurse training, together with 15 staff
from national charities, health professionals and academic and clinic staff. The service users contributed
substantially, based on their experiences attending nurse-led clinics. One author, a service user, agreed
to co-author the report underpinning this initiative.
PATIENT AND PUBLIC INVOLVEMENT
NIHR Journals Library www.journalslibrary.nihr.ac.uk
96
Foot health
A mixed-methods approach collected qualitative data from two focus groups of RA patients and
quantitative data from rheumatology team members. The data were collected in a survey that had
been piloted and assessed for face and content validity, using average congruence, by two external
clinicians and departmental patient experts living with RA.
Rheumatoid arthritis portrayal by UK national newspapers
The mass media are an important source of knowledge, beliefs and attitudes about illness. A research
team of academic staff and patients examined how RA is portrayed in the UK popular press. This was
considered an important factor in influencing uptake of intensive management in routine clinical practice.
Outcomes
Supporting ongoing research
The workstream A team met 6-monthly to inform all co-applicants of the TITRATE programme about
the progress of the research, including publications.
Qualitative studies
Several aspects of the research involved qualitative studies to evaluate patients’ perspectives about
their management and preferred options for taking drugs and other treatments. These studies involved
patients in both their designs and in their analysis. Without patient involvement, they would not have
been possible.
Designing successful intensive management
The TITRATE programme centred on the trial of intensive management. There are two key challenges
to overcome when asking patients with moderately active RA to participate in a treatment strategy
based on intensive management. First, the treatments have to be effective. Second, patients have to be
prepared to take them. The first part of the programme focused on making certain that care was given
in a way that patients found acceptable in the context of treating them intensively. Patient involvement
in this part of the research was crucial to the success of the programme. As intensive management was
taken by patients and they achieved more remissions as a consequence, it is reasonable to conclude
that this crucial aspect of patient involvement was successful.
Placing the research in context
Studies of foot health and representation of RA in newspapers were suggested by patients. They helped
place the research into context relevant for implementation.
Advice on progress of research
Patients contributed to both the Trial Steering Committee and the Programme Steering Committee.
This involvement has proved useful in assessing the progress of the research and in planning how to
develop the programme over time. In particular, it was helpful in assessing what is reasonable for
patients to be asked to do in respect of the trial and other studies, and also what questions were most
relevant to patients.
Publications and dissemination
Patients were involved as co-authors of many TITRATE trial publications and conference presentations.
They are also co-authoring the final report.
DOI: 10.3310/pgfar09080 Programme Grants for Applied Research 2021 Vol. 9 No. 8
Copyright © 2021 Scott et al. This work was produced by Scott et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social
Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution,
reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/. For attribution the
title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
97
Discussion
We did not encounter major difficulties involving patients and the public in the TITRATE trial. This
reflects the long-standing commitment of the host department to have PPI in its research portfolio.
We have established a reliable and enthusiastic team of expert patients and charity involvement in
workstream A of the programme. This involved keeping patient research partners informed, and in
engaging them by detailed forward planning and advanced agreement in what was expected in relation
to meeting deadlines for our research outputs.
Clinical research involves diverse teams. Patients were involved in some parts of the research more
than others. For example, they were heavily involved in the qualitative studies but had limited roles in
the systematic reviews or secondary analyses of published trials. However, this issue applies to all
members of the research team, all of whom had roles that were restricted to only some aspects of the
overall programme.
A particularly important issue influencing the potential future implementation of the research findings
is that a substantial body of patients and key patient groups have seen all the results and have
reflected and commented on them. This involvement makes it unlikely for the TITRATE trial to receive
future negative criticism from patient groups that it is not relevant for them, which has occurred in
some related clinical areas.
Reflections
There have been several challenges involving patients. One was recruiting patients and carers for focus
groups, which has sometimes been difficult. Suitable patients must be identified by clinical teams that
may not be familiar with focus group research. It can also be complex identifying times suitable for a
range of patients and carers to meet, as all have other daily commitments that are unique and variable.
These problems are not unique to the TITRATE trial. In particular, it is difficult to engage younger
patients in work or those with family responsibilities and patients from black and ethnic communities.
A second challenge has been obtaining continuity of patient involvement in the various committees
related to the TITRATE trial (e.g. the Trial Steering Committee). These meetings, which are held
intermittently over several years, are relatively long and involve detailed technical discussions.
Therefore, it has been difficult arranging for patients to attend all meetings, although all such meetings
have involved patients. Although there are benefits from involving different patients who can provide
different insights and opinions, there are advantages in having continuity of involvement. This issue,
also not unique to the TITRATE trial, has no simple solution.
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Data-sharing statement
All data requests should be submitted to the corresponding author for consideration. Access to
anonymised data may be granted following review.
Patient data
This work uses data provided by patients and collected by the NHS as part of their care and support.
Using patient data is vital to improve health and care for everyone. There is huge potential to
make better use of information from people’s patient records, to understand more about disease,
develop new treatments, monitor safety, and plan NHS services. Patient data should be kept safe
and secure, to protect everyone’s privacy, and it’s important that there are safeguards to make
sure that it is stored and used responsibly. Everyone should be able to find out about how patient
data are used. #datasaveslives You can find out more about the background to this citation here:
https://understandingpatientdata.org.uk/data-citation.
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Appendix 1 Baseline data in clinical studies
Studies of changes in disease activity
Data were collected at four time points from patients attending rheumatology departments at King’s
College Hospital and University Hospital Lewisham (London, UK) in 1996–97 to 2013–14. All of the
patients had a consultant diagnosis of RA. The first three cohorts were surveys of consecutive patients
seen in routine care settings.70–72 Data for the fourth cohort were extracted from routinely captured
clinic attendance electronic patient records. The cohorts ranged from 189 to 520 patients. A total of
1324 patients were studied. The groups had similar demographic features (Table 27). The patients in
these cohorts and in most of the other observational studies had established RA, which means that
they had already been treated by a rheumatologist and that they did not yet have end-stage disease.
The concept of established RA has been explained in detail by Conaghan et al.455
Longitudinal observational study
Most RA patients attending the Guy’s and St Thomas’ NHS Trust RA Centre were included.53 They had
clinical diagnoses of RA made by experienced rheumatologists. They were seen regularly for routine
care and each visit involved a clinical review and assessment of key clinical outcomes. Management
followed the treat-to-target approach, with an aim of reaching DAS28-ESR remission. The patients
were analysed in two ways: (1) all patients in whom data were available and (2) patients who were
followed for ≥ 3 years. Details of these patient groups are shown in Table 28.
Early Rheumatoid Arthritis Network
We studied 155 patients in the observational cohort –ERAN – who had completed 12 months’ follow-up
and who had clinical data collected at 0, 6 and 12 months. These patients had mean age of
56 (SD 14) years and 101 (65%) were women. Their disease durations < 12 months.
TABLE 27 Patients in four cross-sectional studies of disease activity
Characteristic
Time point
1996–97 (N= 189) 2001–3 (N= 310) 2009–10 (N= 304) 2013–14 (N= 520)
Female, n (%) 140 (74) 237 (76) 244 (80) 413 (79)
Age (years), mean (SD) 59 (14) 60 (13) 59 (15) 58 (15)
Disease duration (years),
median (IQR)
8 (13) 9 (10) 10 (9) 10 (9)





≤ 3 years (N= 752)
Patients followed for
> 3 years (N= 941)
Female, n (%) 1262 (75) 579 (77) 683 (73)
Age (years), mean (SD) 55 (16) 55 (15) 55 (14.7)
Disease duration (years), mean (SD) 11 (10) 10 (10) 10 (9.7)
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Observational studies of limitations of DAS28-ESR
We undertook secondary analyses of three observational data sets that enrolled 1374 RA patients.
The observational data sets involved 747 European white patients (enrolled in previous observational
studies72,221) and 197 black African/Caribbean British patients (enrolled in one previous observational
study223) who were seen in rheumatology clinics in England. A total of 430 Arab patients (enrolled in
one previous observational study222) were seen in rheumatology clinics in Saudi Arabia. Details of these
patients are summarised in Table 29.
Stability of disease control in the REMIRA cohort
We studied the 152 RA patients who entered the REMIRA observational cohort study.357,456 These
patients were undergoing a treat-to-target management strategy for 12 months, had disease durations
of ≤ 10 years, were receiving stable doses of conventional DMARDs or biologic DMARDs for > 6 months
and had DAS28-ESR scores of ≤ 3.2 for 1 month or longer prior to entry. Details of these patients are
shown in Table 30. Two-thirds of the cohort were females and three-quarters were white. The mean age
at entry was 57 (SD 14) years. The mean duration of RA from diagnosis until entry was 50 (SD 32) months.
Over 85% of the cohort had low levels of disease activity or were in clinical remission at entry. None of the
patients had high baseline levels of disease activity. Approximately 50% of the cohort had low levels or no
disability at baseline. Erosive disease was observed to be present in 44% of the study sample (67 patients),
and the majority of patients were receiving stable doses of methotrexate for over 6 months prior to entry.
Fifty-three per cent of patients were on two or more RA medications at baseline.
TABLE 29 Patients in three cross-sectional studies of limitations DAS28-ESR
Characteristic European (N= 747)
Black African/Caribbean
British (N= 197) Arab (N= 430)
Female, n (%) 422 (57) 163 (83) 364 (85)
Age (years), mean (SD) 62 (13) 56 (15) 46 (13)
Disease duration (years), mean (SD) 12 (11) 11 (10) 6 (6)
Methotrexate, n (%) 417 (56) 116 (58) 201 (47)
Other DMARDs, n (%) 159 (21) 117 (59) 282 (66)
Biologics, n (%) 45 (6) 36 (18) 4 (1)
TABLE 30 Baseline features of 152 RA patients in the REMIRA cohort
Baseline feature Category Mean/number
Demographic
Age (years), mean (SD) 57 (14)
Disease duration (months), mean (SD) 50 (32)
Female, % 66
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TABLE 30 Baseline features of 152 RA patients in the REMIRA cohort (continued )
Baseline feature Category Mean/number
Clinical assessment
Tender joint count for 28 joints, mean (SD) 0.6 (1.6)
Swollen joint count for 28 joints, mean (SD) 1.0 (1.8)
Patient global (0- to 100-mmVAS), mean (SD) 23 (20)
ESR (mm), mean (SD) 9.8 (8.4)
CRP (mg/l), mean (SD) 6.1 (4.0)
DAS28-ESR, mean (SD) 2.1 (0.9)
DAS28-CRP, mean (SD) 2.4 (0.6)
Disease activity states, % DAS28-ESR < 2.6 64
DAS28-ESR= 2.6–3.2 22
DAS28-ESR > 32–5.1 12
DAS28-ESR > 5.1 0
Missing 2
HAQ, mean (SD) 0.51 (0.60)
HAQ states, % HAQ = 0 42
HAQ 0.1–0.49 17
HAQ 0.5–1.49 33
HAQ = 1.5–3.00 7
Missing 1
EQ-5D, mean (SD) 0.75 (0.22)
FACIT-F, mean (SD) 39 (10)
Fatigue (0- to 100-mm VAS), mean (SD) 34 (23)
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The CARDERA trial73 randomised 467 patients with early active RA to receive 2 years of intensive
combination treatment with methotrexate, ciclosporin and/or corticosteroids compared with
methotrexate monotherapy. We evaluated the 379 completers in this trial.
TACIT trial
The TACIT trial74 randomised 205 established, active RA patients to receive 1 year of intensive
DMARD therapy or TNFis. We evaluated the 146 completers in this trial.
OPTTIRA trial
The Optimizing Treatment with Tumour Necrosis Factor Inhibitors In Rheumatoid Arthritis (OPTTIRA)
trial randomised 103 established RA patients receiving etanercept or adalimumab and a DMARD with
DAS28 score < 3.2 for > 3 months who remained on their current biologic or had their treatment
tapered over 6–12 months.224 We evaluated the 97 patients treated in this trial.
Details of the patients in these trials are summarised in Table 31.
Qualitative research
Patients’ and carers’ views and expectations
Purposive sampling was used to recruit nine patients and five carers (Table 32) from four rheumatology
clinics across three London hospital NHS trusts. The sample size was based on previous published
qualitative studies. Patients were eligible for inclusion if they had moderate disease activity (i.e. a
DAS28 score of 3.2–5.1), had received at least one DMARD for a minimum of 6 months and were
currently receiving at least one DMARD. Carers were carers of eligible patients. Participants were
approached by a designated member of the clinical team at each site.
The patients in this and other qualitative studies had comparable ages, sexes and ethnicities to the
patients in observational studies and the trial.
Patients’ and practitioners’ views of intensive treatment
This qualitative study was nested within the TITRATE trial. Patient and practitioners were recruited from
the 39 trial sites. There were no additional patient participant inclusion or exclusion criteria to those of
the trial. Practitioners were those trained to deliver the intensive management intervention in trial sites,
provided that they had delivered at least six intensive management sessions with the same patient.
TABLE 31 Patients evaluated in three randomised trials
Characteristic
Trial
CARDERA73 (N= 379) TACIT74 (N= 192) OPTTIRA224 (N= 97)
Female, n (%) 259 (68) 144 (75) 72 (74)
Age (years), mean (SD) 54 (12) 57 (12) 57 (11)
Disease duration (years), mean (SD) 0.5 (0.5) 8 (9) 13 (9)
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During their first intensive management session, practitioners provided each patient with information
about a ‘substudy’, which included an optional semistructured interview. The invitation letter requested
that patients who chose to participate in the substudy should complete the consent form and return
it directly to the researcher. Fifteen patients from 10 rheumatology clinics consented to participate
(Table 33). Sixteen practitioners (13 research nurses and three specialist nurses) from 13 rheumatology
clinics consented to participate.
Patients’ views on foot health care for rheumatoid arthritis
A mixed-methods approach was adopted, collecting qualitative focus group-based data from patients
with RA, followed by quantitative survey-based data from clinicians.
TABLE 32 Sociodemographic features of patients and carers in qualitative study
Sociodemographic feature Patients Carers
Sex Six women and three men Two women and three men
Age range (years) 46–69 26–73
Self-defined ethnicity Unknown, n = 1 British Indian, n = 1
White European, n= 1 Black British, n = 1
Turkish Cypriot, n = 1 White British, n= 3
White British, n= 6
Employment status Full time, n= 1 Full time, n= 2
Not currently working, n = 5 Retired, n = 3
Retired, n = 3
TABLE 33 Features of patients in qualitative substudy from the TITRATE trial
Number Sex Age (years) Self-reported ethnicity Site
1 Female 65 White British A
2 Female 64 White British A
3 Female 56 White British A
4 Male 70 White British B
5 Female 69 White British B
6 Female 54 White B
7 Female 62 White British C
8 Male 35 White European C
9 Female 70 White British D
10 Female 56 White British E
11 Female 67 White British F
12 Male 43 White European G
13 Female 66 White British H
14 Female 58 White British I
15 Female 35 White British J
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Focus group participants were recruited by health-care staff from one tertiary rheumatology outpatient
clinic in London. Inclusion criteria were adults with established RA who were able to read, speak and
understand English. Collective views were gathered via two focus groups, which generated rich data
about the experiences and beliefs of participants. They were facilitated by one investigator who was
also a patient with established RA. An anonymous online survey allowed clinicians to provide easy
completion in minimal time and a higher response rate. It comprised 11 items in six themes: (1) provision
of foot health information, (2) frequency of foot examination, (3) reasons for choosing whether or not
to examine feet, (4) clinician beliefs, (5) podiatry referral and (6) clinician training. All clinicians from
the outpatient clinic were invited, via e-mail, by a rheumatology consultant to fill out the survey online,
with one reminder sent 2 weeks later.
APPENDIX 1
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Appendix 2 Clinical assessments
Demographic, diagnostic and treatment information
Demographic information
Data were collected on age, sex, ethnicity and disease duration.
Diagnostic information
Evidence for the diagnosis of RA was assessed using 1987 ACR criteria and 2010 EULAR/ACR criteria
or consultant-made diagnoses, depending on the study and setting.
Treatment information
Current treatments, including conventional DMARDs, biologics and steroids, were recorded, depending
on the study and setting.
Disease activity assessments
Joint counts
l Swollen and tender joint counts for 28 joints.433
l Swollen and tender joint counts for 66 and 68 joints.433
Global assessments
l Patients’ global assessment on 100-mm VAS.457
l Assessors’ global assessment on 100-mm VAS.457
Other clinical assessments
l Pain on 100-mm VAS.458
l Fatigue on 100-mm VAS.459
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Remission criteria
l DAS28-ESR score of < 2.6.464
l DAS28-CRP.312





l Low disease activity (i.e. DAS28-ESR score of 2.6–3.2).
l Moderate disease activity (i.e. DAS28-ESR score of 3.2–5.1).





l Plain radiographs of the hands and feet read by a modified Larsen’s score.316
Quality of Life
l EQ-5D-3L and EQ-5D-5L scores.226
Patient acceptability
l Medication Adherence Rating Scale.465
Economic assessments
l CSRI.466
Lifestyle, mood and health beliefs
l Lifestyle factors (e.g. alcohol consumption and tobacco smoking).
l Mood and anxiety: PHQ-9467 and GAD-7.468
l Health beliefs/illness perceptions: BMQ469 and Brief Illness Perceptions Questionnaire.470
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Appendix 3 Analytic methods
Observational studies and secondary analyses of trials
Cross-sectional studies of changes in disease activity and disability
Data management and analyses used Stata. Age, disease duration, disease activity assessments and
other outcomes were described using means and SDs or medians and IQRs for non-normal data.
DAS28 category proportions were given as raw figures and percentages. Spearman’s correlations
were used to assess relationship between the DAS28 and HAQ.
Longitudinal study of changes in disease activity and disability
Data management and analyses used Stata. Descriptive analyses used numbers of patients and
percentages and mean scores with SDs or 95% CIs. We used mixed models to examine the changes
in DAS28 and its components over time. We also used trend analysis to take into account repeated
measures from the same patient. Subgroups were compared by chi-squared analyses or by one-way
analysis of variance.
Clinical studies giving evidence for treating moderately active rheumatoid arthritis
intensively
Data management and analyses used IBM SPSS Statistics (version 25; IBM Corporation, Armonk,
NY, USA). Descriptive analyses used numbers of patients and percentages and mean scores with SDs
or 95% CIs. Subgroups were compared by chi-squared analyses.
Treatment targets: DAS28-ESR and disability
Data management and analyses using IBM SPSS (version 23). Descriptive analyses used numbers of
patients and percentages and mean scores with SDs or 95% CIs. We evaluated the sensitivity and
specificity of point and sustained DAS28-ESR scores of < 2.6 and ≤ 3.2 at identifying patients with
and without low HAQ scores and normal EQ-5D scores at the cohort end points.
Treatment targets: optimal responses in DAS28-ESR scores
Data management and analyses used IBM SPSS Statistics (version 22). Descriptive statistics described
means, standard error and CIs. We studied patients with all data available at the trial end points.
We divided patients into EULAR non-responders, moderate responders and good responders. We
compared changes in HAQ and EQ-5D scores between good and moderate EULAR responders for each
trial using the independent-samples t-test. We also subdivided moderate and good EULAR responders
by their final DAS28 scores. In addition, we used the previous NICE criterion for remaining on treatment
(i.e. a change in DAS28 score of > 1.2) to categorise patients, replicating EULAR response criteria by
dividing patients into those who also achieved DAS28 low disease activity scores at the trial end point
and those who did not. Finally, we assessed the numbers of patients who achieved different levels of
improvement in HAQ and EQ-5D scores in both trials in relation to moderate and good EULAR responses.
Treatment targets: limitations of DAS28-ESR and alternative assessments
Data management and analyses used IBM SPSS Statistics (version 25). Disease activity assessments
and other outcomes were described using means and SDs or medians and IQRs for non-normal data.
We used the formula for calculating DAS28-ESR to assess the relative contributions of different
components to overall scores. We took a similar approach to CDAI and RAPID3 scores. Spearman’s
correlations were used to assess relationship between the quality of life and different components of
DAS28-ESR and other disease activity scores.
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Treatment targets: DAS28-ESR components and health-related quality of life
Analyses were performed in R (V.3.1.3; The R Foundation for Statistical Computing, Vienna, Austria).
Treatment effects were evaluated using linear regression models, including the 6-month changes
in each SF-36 domain and summary score as the response variable. An unadjusted model included
treatment as the explanatory variable (active vs. placebo corticosteroids in the CARDERA trial73 and
TNFi vs. conventional DMARD therapy in the TACIT trial74). An adjusted model included treatment,
baseline SF-36 domain/summary score, age, sex and disease duration as explanatory variables. The
mean SF-36 domain scores at the final time point in the CARDERA trial73 and the TACIT trial74 were
plotted on spydergrams stratified by (1) DAS28-ESR activity category [i.e. remission (DAS28-ESR
score of < 2.6), low disease activity (DAS28-ESR score of ≥ 2.6 to < 3.2), moderate disease activity
(DAS28-ESR score of 3.2–5.1) and high disease activity (DAS28-ESR score of > 5.1)]; and (2) remission
compared with non-remission according to each DAS28 component (i.e. tender joint count of ≤ 1,
swollen joint count of ≤ 1, patient global assessment of disease activity on a 100-mm VAS of ≤ 10 and
ESR ≤ 20 mm/hour). These component cut-off points represent the preliminary ACR/EULAR Boolean-
based definition of RA remission for clinical trials. As CRP data were not available, a normal ESR level
was considered indicative of acute-phase response remission.
To minimise type I error from multiple testing (four DAS28 components and eight health domains),
associations between DAS28-ESR components and PCS and MCS were tested. Linear regression
models used final time point PCS and MCS scores as response variables, and swollen joint count,
tender joint count, ESR and patient global assessment as explanatory variables, adjusted for covariates
(treatment, age, sex and disease duration). Model 1 tested each DAS28-ESR component separately.
Model 2 included all DAS28-ESR components as explanatory variables. To ensure that multicollinearity
between DAS28-ESR components was not an issue in model 2, variance inflation factors were
calculated for each predictor. The variance inflation factor was < 2 for all explanatory variables.
Standardised β-values were calculated, enabling direct comparison of effect sizes of each DAS28-ESR
component on PCS and MCS. In the CARDERA trial,73 missing data had been imputed at all time points
using last observation carried forward (LOCF) analysis. Missing data were imputed in 19% of patients
at 24 months. An observed case analysis had excluded a significant impact of the LOCF assumption on
the study end points, which included PCS and MCS scores. For consistency across studies, we imputed
missing TACIT trial74 data using LOCF (undertaken at 6 months in five and 18 patients for SF-36
domain scores and DAS28-ESR components, respectively, and at 12 months in 15 and 16 patients for
SF-36 domain scores and DAS28-ESR components, respectively). We undertook an additional analysis
using non-imputed TACIT trial74 data to ensure that our findings were not biased by LOCF imputation.
Age- and sex-matched US normative scores were generated for CARDERA trial73 and TACIT trial74
protocol populations using data published in SF-36 manuals and updates. It was not possible to use UK
age- and sex-matched norms, as these data are not publicly available, although existing studies have
highlighted similarities in mean SF-36 domain scores between UK and US populations.
Predictive factors: simple four-point scores
Data management and analyses used IBM SPSS Statistics (version 17). Persistent disease activity was
defined as a DAS28 score of > 3.2 at both 6- and 12-month visits. Predictors of persistent disease
activity in the ERAN patients were assessed using logistic multiple regression and expressed as ORs
with 95% CIs. The baseline explanatory variables considered were sex, tender joint count, swollen joint
count, ESR, DAS28 and HAQ. As DAS28 was strongly associated with all other variables, it was not included
in the model. Chi-squared tests compared the proportion of patients with low disease activity scores.
Predictive factors: high baseline Health Assessment Questionnaire as outcome predictor
Data management and analyses used IBM SPSS Statistics (version 25). Disease activity assessments
and other outcomes were described using means and SDs or medians and IQRs for non-normal data.
Groups were compared using Fisher’s exact test for categorical data and Student’s unpaired t-test for
continuous data.
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Predictive factors: anxiety and depression
Multilevel models were used pooling across the CARDERA trial73 2-year treatment arms. This approach
was taken to account for both missing outcome data and variations between and within patients over
the course of the study. The models used Stata. There were two multilevel linear models for continuous
outcomes. First, unadjusted models assessed only depression/anxiety status. Second, adjusted models
included age, sex, disease duration, time, baseline level of physical health, the type of treatment
received and rheumatoid factor status. Further details of the methods are given in Matcham et al.207
Qualitative research and other patient-focused activities
Patient expectations of intensive management
Semistructured topic guides were developed based on the discussions with multidisciplinary research
team and three ‘patient experts’ who provided feedback on its suitability and relevance. Two separate
focus groups were held for patients (n = 3) and for carers (n = 4). Semistructured interviews were
also conducted with six patients and one carer, which included face-to-face and telephone interviews.
Non-English-speaking patients (n = 2) were interviewed with the assistance of a translator. All audio-
recorded focus groups and interviews were conducted by one researcher who was not involved in
the direct care of any of the participants. On average, the focus groups lasted 1 hour and interviews
20 minutes. They took place between April and July 2014. Audio-recordings were transcribed verbatim
and transcripts analysed using a framework analysis approach. A second rater (HL) appraised the
emergent themes from the transcripts and consensus between both researchers was reached. To improve
the validity of the data, the researcher referred back to the original transcripts throughout the analysis,
including deviant accounts.
Developing patient handbook
The development of the patient handbook took place between May 2013 and April 2014 and involved
five stages (Figure 26).
Stage 1
Researchers collated information about RA
Stage 2
Workshop with six RA patients; received feedback
on draft handbook
Stage 3
Feedback incorporated into a revised version
Stage 4
Patient testimonies added and feedback received
from six RA patients plus one additional RA patient
Stage 5
Final approval from all seven RA patients
FIGURE 26 Development of handbook based on the plan–do–study–act framework.
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Two researchers collected information, including current treatments for RA, intensive management in
the TITRATE trial and managing life with RA. The information was gathered from evidence-based sources,
for example publications and current clinical guidelines, expert medical and allied health practitioners,
and online from national charities (e.g. NRAS and Arthritis Research UK). It was then collated by one
of the researchers into a draft handbook across nine chapters. One patient workshop was organised at
an inner-city NHS foundation trust in June 2013. The workshop did not require ethics approval as its
purpose was categorised as service development. The inclusion criteria comprised adults aged > 18 years
with a confirmed diagnosis of RA, who were able to understand and communicate sufficiently in English to
participate. All patients who agreed to take part were sent a participant information sheet describing
the purpose of the workshop and its planned procedure. A week prior to the workshop, patients were
sent a copy of the draft handbook. They were asked to read and consider the content and layout of the
handbook and encouraged to make notes of any initial thoughts or feedback for the meeting.
The researchers who collected the information co-facilitated the workshop, which was conducted in a
private room. Participants were asked to sign a written consent form before the start of the workshop.
The consent form informed participants that taking part was voluntary and withdrawal from the
workshop would not affect the care they receive from the outpatient clinic. It also stated that the workshop
was being audio-recorded and anonymised quotations from the recording would be used in the future.
The workshop began with a brief presentation and explanation about the purpose of the handbook within
the context of the TITRATE trial. The draft handbook chapters were used to structure the remainder of the
workshop. Taking each chapter in turn, the group was invited to provide feedback on all aspects of the draft
document. There was a specific focus on the chapters about ‘intensive treatment for RA’ and ‘psychosocial
support’ because these are key aspects of the intensive management intervention. The lead author took
field notes during the workshop. The audio-recording was transcribed verbatim and the transcript and notes
from the workshop analysed, applying thematic content analysis. This involved ‘identifying, analysing, and
reporting patterns (themes) within data’. The researcher referred back to the original transcript throughout
the analysis to confirm that participants’ accounts were presented accurately.
Using the audio-recording and notes written during the workshop, feedback from participants relating
to the content and layout was incorporated into a revised version of the handbook. Following participants’
suggestions, selected anonymous testimonies that were expressed during the workshop were included
to add context and personalise the content of the handbook. A further round of comments was then
arranged for all workshop participants and an additional patient who was unable to attend the
workshop. Participants were sent the revised version of the handbook via e-mail and asked to make any
additional comments and send them to the researchers. A final version of the handbook was sent to all
who contributed to the development for approval prior to printing.
Patients’ and practitioners’ views of intensive treatment
Data collection took place between February 2016 and September 2017. The semistructured topic
guides for both groups were developed based on constituent parts of the intensive management
intervention. These were discussed with the multidisciplinary research team and a patient expert
who provided feedback on their suitability and relevance.
Individual interviews were conducted with patients and practitioners both face to face (n = 8) and over
the telephone (n = 20). One group interview was also held with three practitioners. Interviews with
patients were arranged for a date after they had completed all their intensive management sessions in
case the interview influenced their views of the intervention or the trial. No pilot interviews were held;
however, slight adjustments were made to the topic guides following the first two interviews with each
group. The audio-recorded interviews were carried out by the lead author who was not involved in the
care of any of the patients. The interviews with the practitioners were considered service evaluation
and, therefore, ethics approval was not required for these.
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Audio-recordings of the interviews were transcribed verbatim by an external professional transcribing
agency. Both sets of transcripts were analysed using thematic analysis and iterative categorisation
(supported by NVivo). Iterative categorisation generates a clear audit trial with the data analysis, closely
linked to the raw data, and involves four stages: (1) familiarisation through the reading of transcripts,
(2) line-by-line coding to organise the data in preparation for analysis, (3) descriptive analysis that
identifies themes and (4) interpretive analysis that explores patterns, inconsistencies and relates findings
to existing knowledge. To validate the data, a second experienced qualitative researcher cross-referenced
the emergent themes with the lead researcher, and consensus between both researchers was reached.
Systematic reviews
Narrative descriptions
The reviews on RA guidelines, treat to target, psychological interventions (review of reviews), MI and
nurse care in RA did not include any meta-analyses and only narrative descriptions of the findings
were provided.
Meta-analysis of erosive progression
The means and SDs of the Larsen or Sharp–van der Heijde score were recorded at each follow-up
time for each study. In cases where only a median score was obtained, the median and range were
converted into a mean score and SD. To estimate annual rates of change, with standard errors, a linear
regression model was conducted with follow-up year as the independent variable. Baseline scores and
annual progression rates, with standard errors, were transformed into percentage maximum damage
for each scoring method. These transformed scores were assessed using random-effects meta-analysis.
Analysis used Stata (version 13). Further details are given in Carpenter et al.52
To assess the strength of predictive markers, the regression coefficients and ORs with 95% CIs were
collated. Unadjusted effect estimates were sought. Where these were not reported, the adjusted
estimates were used. Random-effects meta-analysis was used for all models because of the likely high
level of heterogeneity between studies. Analysis used Stata (version 13). Significance was assumed at a
p-value < 0.05.
Meta-analysis of remissions with intensive management
Results were analysed using Review Manager 5.3 (The Cochrane Collaboration, The Nordic Cochrane
Centre, Copenhagen, Denmark). The random-effects model, based on the DerSimonian and Laird
method,79 was used to estimate the pooled effect sizes. This gives more equal weighting to studies
of different precision in comparison with a simple inverse variance weighted approach, thereby
accommodating between-study heterogeneity. For all meta-analyses, we performed Cochrane’s
chi-squared test to assess between-study heterogeneity and quantified I2 statistics.80 p-values of
< 0.05 were considered significant.
Some of the randomised controlled trials had more than two treatment arms. When there were two
control groups the results were combined and when there were two or more intensive treatment
groups only those reporting licensed dosage regimens were included.
TITRATE trial details of imputation for primary and secondary outcome
missing observations
Outcomes assessed every 6 months
Multiple imputation using chained equations with PMM using five nearest neighbours was used.
DOI: 10.3310/pgfar09080 Programme Grants for Applied Research 2021 Vol. 9 No. 8
Copyright © 2021 Scott et al. This work was produced by Scott et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social
Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution,
reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/. For attribution the
title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
167
In subjects who had missing outcomes at 6 months, under the monotone assumption, baseline outcomes
and explanatory covariates were used to impute the missing values at 6 months. For patients who had
missing outcomes at 12 months, baseline and 6-month outcomes with explanatory covariates were used
to impute the missing values. If outcome variables were missing at 6 and 12 months, then the outcome
variables at 6 months was imputed first, followed by the outcomes at 12 months.
Number of cycles
The imputation was 20 cycles. At the end of the cycle, one imputed data set was created. The process
was repeated to create 20 imputed data sets. The 20 data sets were combined using Rubin’s rules.471,472
Therefore, the estimates and standard errors presented here are the combined ones.
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Appendix 4 Additional details of the
TITRATE trial
Complete-case/completer analyses
Baseline data and numbers analysed
This analysis evaluated patients in whom all data were present and who also followed the protocol.
It evaluated 258 patients (134 patients received intensive management and 124 patients received
standard care). Demographic and disease assessments were similar in both the groups (Table 34).
The analysis complements the ITT analyses in The TITRATE trial.
Primary outcome
Remissions based on DAS28-ESR score were more frequent with intensive management. Remissions
occurred in 43 of 134 (32%) patients receiving intensive management and in 23 of 124 (19%) patients
receiving standard care, with a highly significant unadjusted OR of 2.07 (95% CI 1.16 to 3.70; p = 0.014).
The adjusted OR was also significantly different, as shown in Table 35.
Other remission criteria and low disease activity at 12 months
Simple Disease Activity Index, DAS28-CRP, CDAI and ACR/EULAR Boolean remissions at 12 months
showed higher achievement of remission with intensive management (21%, 19%, 27% and 20%,
respectively) than standard care (9%, 11%, 14% and 8%, respectively) (Figure 27). Logistic regression
analyses showed that most of these differences were also significant (see Table 35).
TABLE 34 Baseline characteristics and assessments in complete-case analyses
Assessment
Treatment group
Intensive management (N= 134) Standard care (N= 124)
Age (years) 56.5 (11.9) 56.8 (11.8)
Disease duration (years) 6.5 (7.3) 5.1 (5.3)
Female 114 (85%) 99 (80%)
DAS28-ESR 4.3 (0.5) 4.3 (0.5)
DAS28-CRP 4.5 (0.6) 4.6 (0.6)
CDAI 19.8 (6.6) 20.6 (7.0)
SDAI 20.7 (6.3) 21.3 (6.6)
Tender joint counts (68 joints) 12 (9) 14 (9)
Swollen joint counts (66 joints) 6 (5) 6 (4)
ESR (mm/hour) 18 (14) 14 (12)
CRP (mg/l) 9 (12) 7 (7)
Assessor global rating (mm) 40 (22) 39 (18)
Patient global assessment (mm) 44 (19) 48 (22)
Fatigue VAS (mm) 59 (26) 52 (26)
Pain VAS (mm) 41 (23) 43 (23)
HAQ 1.2 (0.7) 1.2 (0.7)
EQ-5D-5L 0.72 (0.16) 0.69 (0.21)
Larsen score 12 (18) 8 (11)
Data are presented as mean (SD) or as n (%).
Reproduced with permission from Scott et al.308 This is an Open Access article distributed in accordance with the terms
of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build
upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/
licenses/by/4.0/. The table includes minor additions and formatting changes to the original table.
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A total of 61 out of 134 (46%) patients receiving intensive management and 39 out of 124 (31%)
patients receiving standard care had low disease activity, as measured using the DAS28-ESR
(unadjusted OR 1.84, 95% CI 1.10 to 3.08; p = 0.020).
Clinical outcomes at 12 months
The mean DAS28-ESR scores were significantly lower (p = 0.002 in unadjusted and p = 0.006 in adjusted
regression analyses) with intensive treatment (see Appendix 5, Table 51). The mean tender and swollen joint
counts and assessor and patient global scores were lower with intensive management (Table 36). These
differences were significant in unadjusted and adjusted linear regression analyses. The mean ESR and CRP
levels were unchanged during the trial, with no significant differences between groups. There were only
small improvements in disability assessed by mean HAQ and quality of life assessed by mean EQ-5D.
Differences between groups were not significant (see Table 36). The mean pain and fatigue scores were
significantly lower with intensive management in unadjusted and adjusted linear regression analyses.
Clinical outcomes over 6 and 12 months
Longitudinal analyses assessed changes over both 6 and 12 months using mixed-effects models (Table 37).
Unadjusted and adjusted analyses showed significant differences between groups for DAS28-ESR, swollen
joint counts for 66 joints and fatigue.





OR (95% CI) p-value OR (95% CI) p-value
DAS28-ESR 2.07 (1.16 to 3.70) 0.014 2.39 (1.27 to 4.49) 0.007
DAS28-CRP 2.73 (1.30 to 5.76) 0.008 2.94 (1.32 to 6.53) 0.008
SDAI 1.89 (0.93 to 3.82) 0.077 1.90 (0.92 to 3.94) 0.082
CDAI 1.97 (0.98 to 3.98) 0.058 2.02 (0.98 to 4.15) 0.056
ACR/EULAR Boolean 2.61 (1.10 to 6.20) 0.030 2.65 (1.08 to 6.48) 0.033
a Adjusted for demographics (i.e. age, sex, ethnicity and disease duration), design factors (i.e. NHS region) and baseline
values. ACR/EULAR Boolean remissions were adjusted only for demographics.
Note





























FIGURE 27 Remissions with intensive treatment and standard care: complete-case analyses.
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TABLE 36 Clinical assessments at 12 months in completers
Assessment









DAS28-ESR 3.4 (1.5) 3.9 (1.4) –0.54 (–0.88 to –0.20) 0.002 –0.49 (–0.83 to –0.14) 0.006
Tender joint counts (68 joints) 7.5 (8.6) 11.1 (9.1) –2.31 (–4.59 to –0.02) 0.048 –2.72 (–4.72 to –0.72) 0.008
Swollen joint counts (66 joints) 3.6 (4.3) 5.3 (6.1) –1.98 (–3.31 to –0.65) 0.004 –1.72 (–2.93 to –0.51) 0.006
ESR (mm/hour) 17 (18) 15 (15) –1.34 (–4.11 to 1.43) 0.342 –1.15 (–3.79 to 1.50) 0.394
CRP (mg/l) 10 (22) 7 (9) 0.64 (–3.19 to 4.47) 0.743 1.47 (–1.83 to 4.78) 0.380
Assessor global rating (mm) 23 (21) 31 (22) –7.48 (–13.78 to –1.18) 0.020 –8.27 (–13.65 to –2.89) 0.003
Patient global assessment (mm) 30 (25) 41 (25) –7.29 (–14.57 to –0.01) 0.050 –10.64 (–16.89 to –4.39) 0.001
Fatigue VAS (mm) 40 (30) 50 (30) –16.84 (–24.19 to –9.50) < 0.001 –14.33 (–20.93 to –7.72) < 0.001
Pain VAS (mm) 28 (25) 38 (29) –7.93 (–15.30 to –0.56) 0.035 –9.76 (–16.28 to –3.24) 0.004
HAQ 1.05 (0.71) 1.13 (0.77) –0.11 (–0.23 to 0.01) 0.083 –0.11 (–0.22 to 0.01) 0.078
EQ-5D-5L 0.76 (0.19) 0.72 (0.22) 0.02 (–0.03 to 0.06) 0.486 0.03 (–0.01 to 0.07) 0.155
a Change from baseline analysed and adjustments made for demographics (i.e. age, sex, ethnicity and disease duration), design factors (i.e. NHS region) and baseline score.
Note




























































































































































































































































































Response predictors and response persistence
Studies of response predictors evaluated the 298 patients in whom 12-month DAS28-ESR and fatigue
measures were present. Studies of response persistence were restricted to the 95 patients who were
assessed at 18 months. Baseline assessments of these patients are shown in Table 38. These analyses
are reported in Response predictors and persistence in the TITRATE trial. Additional baseline assessments
related to ethnicity, smoking and alcohol consumption, psychological assessments and BMI are shown
in Table 39. Changes in disease activity states in these patients at 12 and 18 months are shown in
Table 40 and Figure 28.







DAS28-ESR –0.24 (–0.43 to –0.05) 0.012 0.22 (–0.41 to –0.03) 0.022
Tender joint counts (68 joints) –0.66 (–2.14 to 0.82) 0.384 –0.94 (–2.25 to 0.37) 0.159
Swollen joint counts (66 joints) –1.02 (–1.81 to –0.24) 0.011 –0.89 (–1.58 to –0.20) 0.012
ESR (mm/hour) –0.68 (–2.23 to 0.88) 0.392 –0.53 (–1.96 to 0.90) 0.464
CRP (mg/l) 0.31 (–1.63 to 2.24) 0.756 1.02 (–0.59 to 2.62) 0.215
Assessor global rating (mm) –2.95 (–6.65 to 0.76) 0.119 –3.59 (–6.61 to –0.57) 0.020
Patient global assessment (mm) –3.42 (–7.52 to 0.68) 0.102 –5.45 (–8.92 to -1.98) 0.002
Fatigue VAS (mm) –9.55 (–13.61 to –5.49) < 0.001 –8.05 (–11.71 to –4.39) < 0.001
Pain VAS (mm) –3.37 (–7.77 to 1.02) 0.132 –4.74 (–8.40 to –1.08) 0.011
HAQ –0.04 (–0.11 to 0.03) 0.218 –0.04 (–0.11 to 0.02) 0.211
EQ-5D-5L 0.004 (–0.02 to 0.03) 0.736 0.01 (–0.01 to 0.03) 0.296
a Adjusted for demographics (i.e. age, sex, ethnicity and disease duration), design factors (i.e. NHS region) and
baseline score.
Note
The standard care arm was the reference group.
TABLE 38 Baseline assessments of patients evaluated in the TITRATE trial
Assessment
Treatment group, 12-month
DAS28-ESR and fatigue scores







None/one Two or more
Patients, n 148 150 95 48 47
Age (years), mean (SD) 56.4 (12.2) 56.9 (11.9) 56.4 (11.2) 57.5 (10.2) 55.2 (12.2)
Disease duration (years), mean (SD) 6.5 (7.1) 5.1 (5.3) 6.8 (7.2) 7.0 (7.7) 6.7 (6.8)
Female, n (%) 122 (82) 119 (79) 74 (78) 41 (85) 33 (70)
DAS28-ESR, mean (SD) 4.4 (0.5) 4.3 (0.5) 4.4 (0.5) 4.5 (0.5) 4.3 (0.6)
Pain, mean (SD) 41 (22) 43 (22) 41 (23) 41 (22) 40 (24)
Fatigue, mean (SD) 59 (25) 51 (25) 60 (25) 64 (22) 57 (27)
HAQ, mean (SD) 1.25 (0.66) 1.22 (0.67) 1.30 (0.64) 1.39 (0.60) 1.20 (0.66)
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TABLE 39 Additional baseline characteristics of TITRATE trial patients
Assessment
Treatment group













PHQ-9 score of ≥ 10 60 59
Anxiety
GAD-7 score ≥ 10 33 33
BMI (kg/m2)
< 25 56 55
25–30 56 64
30–35 28 33
> 35 28 14
TABLE 40 Stability of remission and low disease activity at 12 and 18 months after intensive management
12-month state Per cent at 12 months
18-month states
Remission Low Moderate High
Remission 30% 11% 8% 9% 3%
Low 17% 3% 5% 5% 3%
Moderate 42% 11% 9% 15% 8%
High 11% 1% 0% 4% 5%
Note
Data from 95 patients followed for 18 months.
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FIGURE 28 Disease Activity Score for 28 joints based on the ESR in patients receiving intensive management in the
TITRATE trial by remission status. Patients divided into groups of patients who never achieved remission, patients who
had one or more remissions without achieving a final 12-month remission and patients who achieved final 12-month
remission. Means and standard errors shown.
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Appendix 5 Additional tables for health
economic evaluation
This section provides additional tables (Tables 41–54) referenced in the main economic results inHealth economic evaluation of the TITRATE trial.
TABLE 41 Rheumatoid arthritis medications included in the cost calculation for NHS resources
Resource use item Unit cost Pack cost and costing assumptions Source
Methotrexate (oral) 5-mg dose: £0.14 £1.73 for 24 tablets (2.5 mg) BNF 2018327
10-mg dose: £0.95 £47.50 for 100 tablets (10 mg)
Sulfasalazine 500-mg dose: £0.08 £8.43 for 112 tablets (500 mg) BNF 2018327
Leflunomide 10-mg dose: £0.24 £7.08 for 30 tablets (10 mg) BNF 2018327
20-mg dose: £0.24 £7.33 for 30 tablets (20 mg)
Hydroxychloroquine 200-mg dose: £0.09 £5.46 for 60 tablets (200 mg) BNF 2018327
Azathioprine 25-mg dose: £0.06 £1.62 for 28 tablets (25 mg) BNF 2018327
50-mg dose: £0.04 £2.25 for 56 tablets (50 mg)
Penicillamine 250-mg dose: £1.59 £88.77 for 56 tablets (250 mg) BNF 2018327
Gold injections 20-mg dose: £4.56 £45.55 for solution for injection
(20 mg)
BNF 2018327
Folic acid 5-mg dose: £0.02 £0.66 for 28 tablets (5 mg) BNF 2018327
Etanercept 50-mg dose: £169.81 £679.25 for four solutions for
injection (50 mg)
BNF 2018327
Adalimumab 40-mg dose: £352.14 £704.28 for two solutions for
injections (40 mg). We used the
average NHS indicative price because
there was no drug tariff price
BNF 2018327
Rituximab 500-mg dose: £1266.07 £1266.07 for one solution for
injection (500 mg). We used the
average NHS indicative price because
there was no drug tariff price
BNF 2018327
1000-mg dose: £2532.14
Abatacept (subcutaneous) 125-mg dose: £302.40 £1209.60 for four solutions for
injection (125 mg). We used the
average NHS indicative price because
there was no drug tariff price
BNF 2018327
Golimumab 50-mg dose: £762.97 £762.97 for one solution for injection
(50 mg)
BNF 2018327
100-mg dose: £1525.94 £1525.94 for one solution for
injection (100 mg). We used the NHS
indicative price because there was no
drug tariff price
Tocilizumab (subcutaneous) 162-mg dose: £228.28 £913.12 for four solutions for
injections (162 mg)
BNF 2018327
Certolizumab pegol 200-mg dose: £357.50 £715.00 for two solutions for
injections (200 mg). We used the
average NHS indicative price because
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TABLE 41 Rheumatoid arthritis medications included in the cost calculation for NHS resources (continued )
Resource use item Unit cost Pack cost and costing assumptions Source
Methylprednisolone 1-gram dose: £17.30 £17.30 1 g of powder BNF 2018327
120-mg dose: £8.96 £8.96 for one suspension for
injection (120 mg)
80-mg dose: £6.18 £6.18 for one suspension for
injection (80 mg)
40-mg dose: £3.44 £3.44 for one suspension for
injection (40 mg)
4-mg dose: £0.21 £6.19 for 30 tablets (4 mg). We used
the average NHS indicative price
because there was no drug tariff price
Prednisone 1-mg dose: £0.89 £26.70 for 30 tablets (1 mg) BNF 2018327
2-mg dose: £0.89 £26.70 for 30 tablets (2 mg)
5-mg dose: £0.89 £26.70 for 30 tablets (5 mg). We used
the average NHS indicative price
because there was no drug tariff price
Ibuprofen 200-mg dose: £0.04 £0.87 for 24 tablets (200 mg) BNF 2018327
400-mg dose: £0.06 £1.39 for 24 tablets (400 mg)
600-mg dose: £0.05 £3.69 for 84 tablets (600 mg)
Diclofenac 74-mg dose: £0.06 £12.95 for 200 units of mouth wash
(74 mg)
BNF 2018327
Celecoxib 100-mg dose: £0.04 £2.19 for 60 tablets (100 mg) BNF 2018327
200-mg dose: £0.06 £1.88 for 30 tablets (200 mg)
Naproxen 250-mg dose: £0.02 £1.02 for 56 tablets (200 mg) BNF 2018327
500-mg dose: £0.05 £1.41 for 28 tablets (500 mg)
Etodolac 600-mg dose: £0.52 £15.50 for 30 tablets (600 mg) BNF 2018327
Etoricoxib 30-mg dose: £0.50 £13.99 for 28 tablets (30 mg) BNF 2018327
60-mg dose: £0.13 £3.58 for 28 tablets (60 mg)
90-mg dose: £0.15 £4.08 for 28 tablets (90 mg)
Meloxicam 15-mg dose: £0.04 £1.13 for 30 tablets (15 mg) BNF 2018327
Nabumetone 500-mg dose: £0.12 £6.90 for 56 tablets (500 mg) BNF 2018327
Tiaprofenic acid 300-mg dose: £0.24 £14.95 for 56 tablets (300 mg) BNF 2018327
Alendronic acid 70-mg dose: £0.16 £0.64 for 56 tablets (70 mg) BNF 2018327
Risedronate sodium 35-mg dose: £0.22 £0.88 for four tablets (35 mg) BNF 2018327
Zoledronic acid 5-mg dose: £997.22 £997.22 for one solution for infusion
vials (5 mg)
BNF 2018327
Calcium and ergocalciferol 300-mg dose: £0.88 £24.64 for 28 tablets (300 mg) BNF 2018327
Omeprazole 20-mg dose: £0.24 £0.73 for 28 tablets (20 mg) BNF 2018327
40-mg dose: £0.98 £6.84 for seven tablets (40 mg)
Lansoprazole 15-mg dose: £0.03 £0.73 for 28 tablets (15 mg) BNF 2018327
30-mg dose: £0.04 £1.07 for 28 tablets (30 mg)
Ranitidine 150-mg dose: £0.02 0.96 for 60 tablets (150 mg) BNF 2018327
300-mg dose: £0.03 0.95 for 30 tablets (300 mg)
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TABLE 41 Rheumatoid arthritis medications included in the cost calculation for NHS resources (continued )
Resource use item Unit cost Pack cost and costing assumptions Source
Acetaminophen 500-mg dose: £0.02 £0.50 for 32 tablets (500 g) BNF 2018327
1000-mg dose: £0.03
Co-codamol 8-mg dose: £0.03 £0.76 for 100 tablets (8 mg) BNF 2018327
15-mg dose: £0.05 £4.59 for 100 tablets (15 mg)
30-mg dose: £0.03 £3.40 for 100 tablets (30 mg)
Co-dydramol 10-mg dose: £0.02 £0.73 for 30 tablets (10 mg) BNF 2018327
Codeine phosphate 30-mg dose: £0.03 £0.93 for tablets (30 mg) BNF 2018327
60-mg dose: £0.05 £1.45 for tablets (60 mg)
Tramadol hydrochloride 50-mg dose: £0.08 £4.6 for tablets (50 mg) BNF 2018327
100-mg dose: £0.24 £14.47 for tablets (100 mg)
Methylprednisolone acetate 40-mg dose: £3.44 £3.44 for one 40mg/1 ml suspension
for injection
BNF 2018327
80-mg dose: £6.18 £6.18 for one 80mg/1 ml suspension
for injection
125-mg dose: £4.75 £4.75 for one powder and solvent for
solution for injection vial (125 mg).
We used the NHS indicative price
because there was no drug tariff
price
Prednisolone acetate 2.5-mg dose: £0.03 £0.97 for 28 tablets (5 mg) BNF 2018327
5-mg dose: £0.03 £0.96 for 28 tablets (2.5 mg)
20-mg dose: £0.13 We used the NHS indicative price
because there was no drug tariff
price
Triamcinolone acetonide 10-mg dose: £0.89 £4.47 for five suspension for
injection ampoules (10 mg)
BNF 2018327
40-mg dose: £1.49 £7.45 for five suspension for
injection ampoules (40 mg)
Methotrexate (subcutaneous) 7.5-mg dose: £13.37 £13.37 for one solution for injection
(7.5 mg)
BNF 2018327
10-mg dose: £13.77 £13.77 for one solution for injection
(10 mg)
12.5-mg dose: £14.85 £14.85 for one solution for injection
(12.5 mg)
15-mg dose: £14.92 £14.92 for one solution for injection
(15 mg)
17.5-mg dose: £15.75 £15.75 for one solution for injection
(17.5 mg)
22.5-mg dose: £16.61 £16.61 for one solution for injection
(22.5 mg)
25-mg dose: £16.64 £16.64 for one solution for injection
(25 mg)
continued
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TABLE 41 Rheumatoid arthritis medications included in the cost calculation for NHS resources (continued )
Resource use item Unit cost Pack cost and costing assumptions Source
Abatacept (i.v.) 125-mg dose: £302.40 £1209.60 for four solutions for
injection. We used the NHS indicative
price because there was no drug
tariff price
BNF 2018327
Tocilizumab (i.v.) 162-mg dose: £228.28 £913.12 for four solutions for
injection
BNF 2018327
Paracetamol 500-mg dose: £0.01 £0.50 for 100 tablets (500 mg) BNF 2018327
1 g dose: £0.03 £2.50 for 100 tablets (1 g). We used
the NHS indicative price for 1 g
because there was no drug tariff
price
Hydrocortisone 20-mg dose: £2.76 £82.76 for 30 tablets (20 mg) BNF 2018327
Prednisolone 5-mg dose: £0.03 £3.55 for 28 tablets (20 mg) BNF 2018327
10-mg dose: £0.07 £1.90 for 28 tablets (10 mg)
20-mg dose: £0.13 £0.70 for 28 tablets (5 mg)
Predisolone 1-mg dose: £0.02 £0.57 for 29 tablets (1 mg) BNF 2018327
10-mg dose: £0.03 £0.70 for 29 tablets (10 mg)
Pregabaline 300-mg dose: £0.09 £5.08 for 56 tablets (300 mg) BNF 2018327
Amitriptyline 10-mg dose: £0.04 £1.09 for 28 tablets (10 mg) BNF 2018327
25-mg dose: £0.03 £0.85 for 28 tablets (25 mg)
50-mg dose: £0.10 £2.88 for 28 tablets (50 mg)
Vitamin D 400-unit dose: £0.10 £8.42 for 84 capsules (400 units) BNF 2018327
4000-unit dose: £0.08 £6.75 for 84 capsules (4000 units)
Gabapentin 100-mg dose: £0.02 £2.16 for 100 capsules (100 mg) BNF 2018327
i.m. depomedrone 120-mg dose: £8.96 £8.96 for one suspension for
injection vials (120 mg)
BNF 2018327
Kenalog (Bristol Myers
Squibb™, New York, NY, USA)
40-mg dose: £1.49 £7.45 for five suspension for




50-mg dose: £167.88 £671.50 for four solutions for
injection (pre-filled vials). We used
the average NHS indicative price for




Sohn AG & Co. KG, Ingelheim
am Rhein, Germany)
10-mg dose: £0.02 £5.45 for oral solution (10 mg) BNF 2018327
Salbutamol 100 µg: £0.02 £3.31 for 200 units of inhalation
powder (100 µg)
BNF 2018327
Dihydrocodeine 30-mg dose: £0.03 £0.90 for 28 tablets (30 mg) BNF 2018327
Morphine sulphate SR 10-mg dose: £0.09 £5.20 for 60 tablets (10 mg) BNF 2018327
Mycophenolate mofetil 500-mg dose: £0.13 £6.53 for 50 tablets (500 mg) BNF 2018327
Rabeprazole 10-mg dose: £0.04 £1.24 for 28 tablets (10 mg) BNF 2018327
Cetirizine 10-mg dose: £0.03 £0.80 for 30 tablets (10 mg) BNF 2018327
Ibuprofen gel 50-mg dose: £0.02 £1.13 for 50 units of gel (50 mg) BNF 2018327
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TABLE 41 Rheumatoid arthritis medications included in the cost calculation for NHS resources (continued )
Resource use item Unit cost Pack cost and costing assumptions Source
Piroxicam 0.5% gel (Accord-UK
Ltd, Barnstaple, UK)
0.5% dose: £0.03 £1.79 for 60 units of gel (0.5%) BNF 2018327
Fenbid gel 5% (ADVANZ
Pharma, London, UK)
50-mg dose: £0.02 £1.13 for 50 units of gel (5%).
Unit cost based on ibuprofen gel
BNF 2018327
Colecalciferol 800-unit dose: £0.12 £3.6 for 43 tablets (800 units) BNF 2018327
Baricitinib 2-mg dose: £28.77 £805.56 for 28 tablets (2 mg) BNF 2018327
4-mg dose: £28.77 £805.56 for 28 tablets (4 mg)
Fultium D3 400-unit dose: £0.07 £1.85 for 28 tablets (400 units) BNF 2018327
800-unit dose: £0.07 £3.60 for 30 tablets (800 units)
Lidocaine 100-mg dose: £0.44 £4.40 for 10 100-mg ampoules for
injection
BNF 2018327
Buprenorphine patch 10-mg dose: £7.89 £31.55 for four 10 µg/hour. We used
the price for transdermal patches as
buprenorphine patch not listed in the
BNF327
BNF 2018327
Salbutamol 100 µg/dose: £0.02 £3.31 for 200 100 µg/dose of
dry powder
BNF 2018327
Depo-medrone with lidocaine 40-mg dose: £3.89 £38.88 for 10 suspension for
injection vials (40 mg/1 ml)
BNF 2018327
Cyclizine 50-mg dose: £0.07 £7.45 for 100 tablets (50 mg) BNF 2018327
Pregabilin 50-mg dose: £0.07 £6.16 for 84 tablets (50 mg) BNF 2018327
Depo-medrone 80-mg dose: £6.18 £6.18 for one suspension for
injection vials (80 mg/2 ml)
BNF 2018327
120-mg dose: £8.96 £8.96 for one suspension for
injection vials (120 mg/3 ml)
Arcoxia® [Organon Pharma
(UK) Ltd, London, UK]
90-mg dose: £0.15
(120 mg/3 ml)
£4.08 for 28 tablets (90 mg) BNF 2018327
Celebrex® (Upjohn UK Ltd,
Sandwich, UK)




50-mg dose: £0.02 £1.13 for 50 gel tablets (50 mg). We
used the price of ibuprofen tablets as




50-mg dose: £0.26 £7.94 for 30 tablets (50 mg). We used
the price of voltarol tablets as
voltarol is not listed in BNF327
BNF 2018327
Linctus 6.25-mg dose: £0.01 £1.29 for 200 tablets (6.25 mg) BNF 2018327
Hydroxocobalamine 1mg/1 ml dose: £1.44 £7.22 for five solutions for injection
ampoules (1 mg/1 ml)
BNF 2018327
Antifungal cream 0.1% cream dose: £0.19 £2.83 for 0.1% cream. We used the
price of hydrocortisone cream
BNF 2018327
i.m., intramuscular; i.v., intravenous; SR, sustained release.
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TABLE 42 Unit costs for primary care, secondary care, PSS and indirect costs
Practitioner Care sector Unit cost (£) Assumptions Source
GP clinical visit or
telephone conversation
Primary care 37.40 Per patient contact lasting
9.22 minutes. Unit cost includes
carbon emissions (5 kgCO2e) (carbon




GP home visit Primary care 100.88 Assume 15 minutes of GP travel
time per visit. Home visit lasting
10.22 minutes [PSSRU 2018/19
(p. 126)328]. Per minute of patient
contact in PSSRU 2018/19 is £4
(p. 126). Unit cost includes direct care
staff costs and qualification cost 328
PSSRU 2018/19
(p. 127)328
Practice nurse visit or
telephone conversation
Primary care 42 Cost per hour, including qualifications PSSRU 2018/19
(p. 125)328
Physiotherapist home
visit at participants home,
general practice or
elsewhere
Primary care 45.99 NHS band 5 (£34 per working hour).
Assume a visit lasting 1 hour. In
addition, 15 minutes of physiotherapist
travel time per visit and a travel cost of
a 4-mile return journey at the NHS








Primary care 45.99 NHS band 5 (£34 per working hour).
Assume a visit lasting 1 hour. In
addition, 15 minutes of physiotherapist
travel time per visit and a travel cost of
a 4-mile return journey at the NHS
reimbursement rate of 56p per mile
PSSRU 2018/19
(p. 119)328
Clinical visit to the
hospital
Secondary care 105 A visit to the hospital was assumed to
be to see a RA specialist. Cost is




Meals on Wheels PSS 4.40 per
meal





Home help PSS 29.74 Based on the price multipliers for
independent sector home care
provided for social services: £22 per
weekday hour. Assume a visit lasting
1 hour. In addition, 15 minutes of staff
travel time per visit and a travel cost
of a 4-mile return journey at the NHS











self-report to any other
health or social services
(e.g. podiatrist)
NHS or PSS 34.00 NHS band 5 (£34 per working hour).










work due to RA of the
participant or care from
their friends or relatives
Indirect cost 92 per day
and £12.78
per hour
Median full-time weekly earnings is
£460. Median per day: £92 (assuming





NA, not applicable; PSSRU, Personal Social Services Research Unit.
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TABLE 43 The impact of missingness on health economic outcomes




of missing values (SD)
Mean with imputation of
missing values (SD)
Health-related quality of life estimated using van Hout et al.473 mapping
Health utility score at
6 months
24 (7.1) 0.625 (0.212) 0.624 (0.207)
Health utility score at
12 months
29 (8.7) 0.648 (0.210) 0.646 (0.204)
Health-related quality of life estimated using EQ-5D-5L scores
Health utility score at
6 months
24 (7.1) 0.724 (0.203) 0.722 (0.196)
Health utility score at
12 months
29 (8.7) 0.745 (0.201) 0.743 (0.195)
Health-related quality of life estimated using Hernández-Alava and Pudney’s334 mapping based on the EuroQol Group
data set
Health utility score at
6 months
24 (7.1) 0.610 (0.210) 0.609 (0.205)
Health utility score at
12 months
29 (8.7) 0.637 (0.204) 0.635 (0.199)
Health-related quality of life estimated using Hernández-Alava and Pudney’s334 mapping based on FORWARD: National
Databank For Rheumatic Diseases
Health utility score at
6 months
24 (7.1) 0.618 (0.225) 0.616 (0.220)
Health utility score at
12 months
29 (8.7) 0.647 (0.220) 0.645 (0.217)
The number of clinical visits
At 6 months 37 (11) 2.27 (2.69) 2.27 (2.69)
At 12 months 43 (12.8) 2.39 (3.12) 2.39 (3.12)
The number of intensive
management sessions
29 (17.2) 10.03 (2.74) 10.03 (2.74)
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Rheumatology practitioner 1.75 per working
minute




Matron 2.63 per minute of
patient contact
Cost per minute of patient contact is not
available for band 8a (matrons). We estimated
this. We find the multiplier per working hour
between band 8a and band 6, which is £64
(band 8a)/£45 (band 6)= 1.42 and multiply
this by the cost per minute of patient contact





advanced nurse practitioner or
manager
2.22 per minute of
patient contact
Cost per minute of patient contact is not
available for band 7 (senior nurses). We
estimated this. We find the multiplier per
working hour between band 8a and band 6,
which is £54 (band 7)/£45 (band 6) = 1.2 and
multiply this by the cost per minute of
patient contact for a band 6 (£1.85 × 1.22 =
£2.22 per minute of patient contact)
PSSRU 2018/19
(pp. 155–7)328
Specialist nursing staff 1.85 per minute of
patient contact
£111 cost per hour of patient contact PSSRU 2018/19
(pp. 155–7)328
Nurse or research nurse 1.5 per minute of
patient contact
£90 cost per hour of patient contact PSSRU 2018/19
(pp. 155–7)328
PSSRU, Personal Social Services Research Unit.




Probability (%) intensive management is cost-effective vs. standard care from an NHS and social
services cost perspective
Health-related quality
of life estimated using







function derived from the














10,000 0 0 0 0
15,000 0 0 0 0
20,000 2 1 1 1
25,000 7 6 5 3
30,000 17 14 12 7
35,000 29 24 21 15
40,000 40 35 30 23
45,000 52 45 39 31
50,000 61 54 47 39
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TABLE 46 Costs by treatment group
Cost component






Intensive management sessions only NA 1269 (978 to 1560) 0
NHS hospital clinical visits only (includes
intensive management sessions)
628 (552 to 704) 1761 (1454 to 2067) 1132 (p < 0.001)
Biologics costs only (in patients who use
biologics)
4467 (3439 to 5496) 3465 (2870 to 4060) 1003 (p = 0.07)
Biologic costs for all patients randomised to
this arm (includes many patients who do not
move to biologics and, as such, have zero cost)
642 (365 to 919) 949 (665 to 1233) 307 (p = 0.13)
NHS pharmaceutical costs only (includes
biologic costs)
1009 (726 to 1291) 1460 (1172 to 1748) 451 (p = 0.03)
All NHS and PSS costs (includes pharmaceutical
costs)
2258 (1950 to 2565) 3784 (3345 to 4223) 1526 (p < 0.001)
Societal costs (includes all NHS, PSS and
productivity losses)
3678 (2651 to 4705) 4697 (4042 to 5352) 1019 (p = 0.10)
NA, not applicable.
TABLE 47 Health-related quality of life by treatment group
Health-related quality of life






Health-related quality of life estimated using van Hout et al.473 mapping from EQ-5D-5L to EQ-5D-3L scores
EQ-5D-3L index score at baseline 0.59 (0.56 to 0.62) 0.61 (0.58 to 0.64) 0.0160 (p = 0.42)
EQ-5D-3L index score at 6 months 0.60 (0.57 to 0.64) 0.64 (0.61 to 0.67) 0.0375 (p = 0.10)
EQ-5D-3L index score at 12 months 0.62 (0.59 to 0.65) 0.67 (0.64 to 0.70) 0.0478 (p = 0.03)
QALYs 0.61 (0.58 to 0.63) 0.64 (0.62 to 0.67) 0.0264 (p = 0.07)
QALYs with regression adjustment for EQ-5D-3L
score at baseline
0.61 (0.58 to 0.63) 0.64 (0.62 to 0.66) 0.0347 (p = 0.02)
Alternative approaches to estimating health-related quality of life
QALYs estimated using Hernández-Alava and
Pudney’s334 mapping from EQ-5D-5L to EQ-5D-3L
scores derived from the EuroQol Group c data set
and with regression adjustment for EQ-5D-3L
score at baseline
0.59 (0.57 to 0.62) 0.63 (0.61 to 0.65) 0.0323 (p = 0.03)
QALYs estimated using Hernández-Alava and
Pudney’s334 mapping from EQ-5D-5L to EQ-5D-3L
scores derived from FORWARD: National
Databank for Rheumatic Diseases and with
regression adjustment for EQ-5D-3L score
at baseline
0.60 (0.58 to 0.63) 0.63 (0.61 to 0.65) 0.0292 (p = 0.08)
QALYs based on EQ-5D-5L index scores with
regression adjustment for EQ-5D-5L score
at baseline
0.71 (0.69 to 0.73) 0.74 (0.72 to 0.76) 0.0264 (p = 0.07)
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TABLE 48 Logit regression exploring associations of patient characteristics with any improvement in EQ-5D-3L score at
12 months
Variable OR 95% CI p-value
Region of health centre (reference category is London and South East)
South West 0.58 0.32 to 1.06 0.08
Midland 1.44 0.65 to 3.18 0.37
North East 1.17 0.62 to 2.21 0.64
Age (years) 1.00 0.98 to 1.02 0.67
Female (reference category is male) 0.74 0.41 to 1.34 0.32
Ethnicity (reference category is white) 1.89 0.81 to 4.41 0.14
Disease duration (years) 1.00 0.96 to 1.04 0.96
Intervention group (reference category is standard care group) 1.54 0.96 to 2.47 0.07
Patient moved to biologic during the trial 1.21 0.67 to 2.20 0.52
TABLE 49 Ordinary least squares regression exploring associations of patient characteristics with change in EQ-5D-3L
score from baseline to 12 months
Variable Coefficient 95% CI p-value
Region of health centre (reference category is London and South East)
South West –0.030 –0.084 to 0.023 0.27
Midland 0.007 –0.060 to 0.076 0.82
North East 0.008 –0.05 to 0.064 0.79
Age (years) 0.001 –0.001 to 0.003 0.42
Female (reference category is male) –0.051 –0.104 to 0.001 0.06
Ethnicity (reference category is white) 0.011 –0.065 to 0.088 0.78
Disease duration (years) –0.0003 –0.003 to 0.003 0.84
Intervention group (reference category is standard care group) 0.031 –0.011 to 0.072 0.15
Patient moved to biologic during the trial 0.059 0.007 to 0.111 0.03
TABLE 50 Ordinary least squares regression exploring associations of patient characteristics with change in EQ-5D-3L
score from baseline to 12 months in a subgroup of patients with remission at 12 months
Variable Coefficient 95% CI p-value
Region of health centre (reference category is London and South East)
South West –0.002 –0.05 to 0.05 0.93
Midland –0.031 –0.09 to 0.03 0.28
North East –0.001 –0.05 to 0.05 0.98
Age (years) 0.00005 –0.001 to 0.002 0.96
Female (reference category is male) –0.037 –0.08 to 0.008 0.10
Ethnicity (reference category is white) –0.010 –0.09 to 0.07 0.80
Disease duration (years) 0.00003 –0.003 to 0.003 0.96
Intervention group (reference category is standard care group) –0.001 –0.04 to 0.04 0.96
Patient moved to biologic during the trial 0.056 0.011 to 0.10 0.02
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
184




Patients in each group who
switched to biologics, %
For patients without remissiona
Intensive management group 29 17.3
Standard care group 16 9.6
For patients with remissiona
Intensive management group 10 6
Standard care group 5 3
a Remission is defined as a DAS score of < 2.6 at 12 months.
TABLE 52 Total number of hospital visits (including intensive management sessions) by remission status at 12 months
Hospital visits Mean (SD) 95% CI Observations, n
For patients without remissiona
Intensive management group 14.3 (6.1) 13.2 to 15.4 120
Standard care group 5.7 (4.5) 4.9 to 6.4 139
Combined groups 9.7 (6.8) 8.8 to 10.5 259
For patients with remissiona
Intensive management group 14.2 (3.3) 13.3 to 15.2 48
Standard care group 7.4 (5.7) 5.2 to 9.6 28
Combined groups 11.7 (5.4) 10.5 to 12.9 76
a Remission is defined as a DAS score of < 2.6 at 12 months.
TABLE 53 Number of hospital visits (including intensive management sessions) for patients with remission at 6 months
who maintained remission to 12 months
Hospital visits Mean (SD) 95% CI Observations, n
For patients without remissiona
Intensive management group 14.5 (6.2) 13.3 to 15.6 107
Standard care group 5.8 (4.6) 5.0 to 6.6 130
Combined groups 9.7 (6.9) 8.8 to 10.6 237
For patients with remissiona
Intensive management group 14.4 (3.3) 12.9 to 15.8 23
Standard care group 4.7 (4.6) 1.7 to 7.6 12
Combined groups 11.0 (6.0) 8.9 to 13.1 35
a Remission is defined as a DAS score of < 2.6 at 12 months.
TABLE 54 Number of intensive management sessions by remission status at 12 months
Remissiona Mean (SD) 95% CI Observations, n
Patients without remission 9.1 (3.7) 8.4 to 9.8 120
Patients with remission 10.9 (1.5) 10.5 to 11.4 48
a Remission is defined as a DAS score of < 2.6 at 12 months.
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